

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Sunday, 21 October 2018

Satellites
08:30 - 13:00

Dresden & Stuttgart

SA01 Advocates' Pre-Conference Workshop

Hosted by: IRMA, AVAC and others This full day pre-conference workshop will provide an overview of the field and amplify certain topics to contextualize the themes and issues that will be presented at HIVR4P; will connect research and advocacy priorities and explore common goals; and build the capacity of advocates and trial staff to better engage with emerging issues in the field. This workshop is especially designed for advocates, scholarship recipients, new investigators, first time attendees, community liaison officers at trials and other interested stakeholders to what HIVR4P.

Chairs:

Jim Pickett (AIDS Foundation of Chicago, United States)

Satellites
08:45 - 12:00

Estrasburgo

SA02 New Pieces to the HIV-1 Vaccine Puzzle: Germline Targeting Strategies and Immunization Protocols to Elicit Anti-HIV-1 bNAbs

Hosted by: The Rockefeller University It is becoming evident that the design of a vaccine that elicits broadly protective antibodies against HIV-1 will require a meticulous engineering process to generate suitable germline targeting strategies that activate bNAb precursors and subsequently support antibody maturation in germinal centers. Encouraging results were obtained in a bNAb knock-in mouse model in which PGT121-like antibodies were elicited by step-wise immunization. Despite multiple efforts, these results have not been fully reproduced in wild type (wt) animal models with a polyclonal B cell repertoire. One of the hurdles to overcome in wt animals is the activation of bNAb precursors that are present in low frequencies. Recent studies have shown that high-affinity immunogens are necessary to efficiently activate and expand low-frequency bNAb precursors. An additional barrier for vaccine design in a wt system is the polyclonal nature of the antibody response. It is believed that immunogen refinement is necessary in order to focus the antibody response towards neutralizing epitopes and avoid distracting responses to non-neutralizing epitopes that could frustrate bNAb maturation by competition in the germinal centers. In this session, we will present progress achieved in the design of strategies to specifically activate and increase the frequency of bNAb precursors, as well as the results of immunization experiments aiming to elicit anti-HIV-1 bNAbs in wt animal models. 8:45 am Eliciting broadly neutralizing responses to the exposed N- terminal residues of the fusion peptide - Peter Kwong 9:00 am Discussion 9:05 am Induction of glycan-reactive bNAb B cell lineages - Kevin Saunders 9:20 am Discussion 9:25 am Sequential immunization strategies to elicit bNAbs in animal models with a polyclonal B cell repertoire - Amelia Escolano 9:40 am Discussion 9:45 am Design of germline targeting immunogens to elicit antibodies targeting the CD4-binding site and V3-N332 epitopes on Env - Harry Gristick 10:00 am Discussion 10:05 am Dissecting neutralizing antibodies to guide rational HIV vaccine design - Marit van Gils 10:20 am Discussion 10:25 am Nanoparticle-display of native-like envelope trimers - Kwinten Sliepen 10:40 am Discussion 10:45 am Anti-idiotypic antibodies as a strategy to prime bNAb precursors - Andrew McGuire 11:00 am Discussion 11:05 pm Structural basis for germline VRC01 antibody recognition of a glycosylated HIV-1 envelope CD4-binding site - Marie Pancera 11:20 am Discussion 11:25 am HIV-1 MPER Germline Targeting - Torben Schiffner 11:40 am Discussion 11:45 am Sequential Immunization with Different Repaired and Stabilized HIV-1 Envelope Trimers Induces broad Tier2 neutralization in Rabbits - Johannes P.M. Langedijk 11:55 pm Discussion

Chairs:

Amelia Escolano (The Rockefeller University, United States)

Marit van Gils (Amsterdam AMC, University of Amsterdam, Netherlands)

Download Program (PDF)

Satellites
12:30 - 15:30

Estrasburgo

SA03 Progress in Inducing HIV Broad Neutralizing Antibodies

Hosted by: The Scripps Research Institute and Duke University This session will explore the progress made in inducing HIV broad neutralizing antibodies. 12:30 pm Overview of the bnAb Problem- Barton Haynes 12:40 pm V2 apex as a target - Raiees Andrabi 12:55 pm Discussion 1:00 pm Polyclonal Ab response mapping by EM - Andrew Ward 1:15 pm Discussion 1:20 pm Mouse models of bnAb germ line targeting immunogens - Facundo Batista 1:35 pm Discussion 1:40 pm Host control of bnAbs - Todd Bradley 1:55 pm Discussion 2:00 pm Overcoming roadblocks of improbable mutations in bnAb B cell lineages - Kevin Wiehe 2:15 pm Discussion 2:20 pm The impact of antibody isotype on neutralization - Penny Moore 2:35 pm Discussion 2:40pm Structural Diversity of antibody recognition at the V3-glycan epitope - Priyamvada Acharya 2:55 pm Discussion 3:00 pm SHIV infected Rhesus macaques as a model for bnAb development - George Shaw 3:15 pm Discussion 3:20 pm BnAbs - The way forward- Dennis Burton

Chairs:

Dennis Burton (The Scripps Research Institute, United States)
Barton Haynes (Duke University, United States)

Satellites
12:30 - 14:30

Marsella

SA06 Social Sciences in Vaccine Trials: A Booster to Recruit Volunteers

Hosted by: ANRS and Vaccine Research Institute The recruitment of healthy, HIV-seronegative patients to HIV preventive vaccine trials has fluctuated since the early days of their implementation. There are numerous reasons for this, including the normalization of the epidemic, the displacement of HIV community action towards other causes, the transformation of disease management, and the lack of direct benefits. Vaccination is being increasingly rejected. At a time when scientific advances offer hope for the development of preventive HIV vaccine strategies, the recruitment of volunteers to future clinical trials may well become a stumbling block. This symposium aims to highlight the contribution that social science research has made to this complex process by both addressing the particular nature of HIV infection and placing the topic in a more global context of recruitment to preventive vaccine trials. 15 minutes Welcome
François Dabis, Director of the ANRS, France Yves Lévy, Director of VRI and CEO of Inserm, France
5 minutes Recruitment of healthy volunteers for HIV vaccine trials: a stumbling block?
Jean-Daniel Lelièvre, Vaccine Research Institute, France
15 minutes Volunteers/Participants Recruitment/Enrolment in Africa
Morenike Folayan, Obafemi Awolowo University, Nigeria
15 minutes Exceptional Risk: US Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.
Marci Cottingham, University of Amsterdam, The Netherlands
15 minutes Participant Recruitment in an Outbreak Context: The Ebola vaccine trials in Sierra Leone
Luisa Enria, University of Bath, UK
45 minutes General discussion and Round Table:
What Kind of Social Science Research to support Clinicians Issues?
Giulio Maria Corbelli, ECAB/EATG, Italy
Frédéric Le Marcis, ENS Lyon, France
Warren Mitchell, AVAC, USA
Caroline Ollivier-Yaniv, Université Paris-Est Créteil, France
10 minutes Conclusion
Guillaume Lachenal and Jean-Daniel Lelièvre
A snack will be served to all participants after the Symposium from 14:30 to 15:00

Chairs:

Guillaume Lachenal (Université Paris-Diderot, France)
Jean-Daniel Lelièvre (Vaccine Research Institute/VRI, Hôpital Henri Mondor, France)

Welcome

François Dabis (ANRS, France)

12:30 - 12:45

Download Program (PDF)

Recruitment of healthy volunteers for HIV vaccine trials: a stumbling block?	12:45 - 12:50
Jean-Daniel Lelièvre (Vaccine Research Institute/VRI, Hôpital Henri Mondor, France)	
Volunteers/Participants Recruitment/Enrolment in Africa	12:50 - 13:05
Morenike Ukpong-Folayan (Obafemi Awolowo University, Nigeria)	
Exceptional Risk: US Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials	13:05 - 13:20
Marci Cottingham (University of Amsterdam, Netherlands)	
Participant Recruitment in an Outbreak Context: The Ebola vaccine trials in Sierra Leone	13:20 - 13:35
Luisa Enria (University of Bath, United Kingdom)	
General discussion and Round Table: What Kind of Social Science Research to support Clinicians Issues?	13:35 - 14:20
Giulio Maria Corbelli (ECAB/EATG, Italy) Frédéric Le Marcis (ENS Lyon, France) Mitchell Warren (AVAC, United States) Caroline Ollivier-Yaniv (University Paris-Est, France)	
Conclusion	14:20 - 14:30
Guillaume Lachenal (Université Paris-Diderot, France) Jean-Daniel Lelièvre (Vaccine Research Institute/VRI, Hôpital Henri Mondor, France)	

Satellites
14:00 - 17:00

Burdeos

SA05 Planning for Success: Next Steps for Dapivirine Ring

Hosted by: OPTIONS and IPM Researchers, implementers, advocates, policy makers and dapivirine ring users will share research and experience to refine and coalesce on practical next steps for introduction.

Chairs:

Elizabeth Gardiner (AVAC, United States)
Nadia Sutton (Johnson & Johnson, Global Public Health, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
15:00 - 18:00

Marsella

SA07 Engagement of African MSM in HIV Prevention Research: Effective Recruitment and Retention

Hosted by: International AIDS Vaccine Initiative (IAVI) and the US Military HIV Research Program (MHRP) The purpose of this meeting is to convene researchers and other stakeholders to discuss how African MSM can be successfully engaged in planned HIV biomedical prevention trials, discuss various recruitment and retention strategies from Africa and develop best practices and tools to inform future research in Africa and other regions.

- Overview: HIV Prevalence, HIV Incidence, and Retention from Key African Studies of MSM – Joshua Kimani, University of Manitoba Kenya office •Plenary: Including African MSM in HIV biomedical prevention research – opportunities, challenges – Anatoli Kamali, IAVI •Lessons learned in recruitment and retention of African MSM
- Frederick Otieno, Nyanza Reproductive Health Society •Elizabeth Wahome, KEMRI •Zahra Parker, Research Manager, U.S. Military HIV Research Program-Nigeria •Hannah Kibuuka, Research Physician, Makerere University Walter Reed Project •Victor Akelo, KEMRI/CDC Senior Research Officer, Kisumu, Kenya •Travis Sanchez, Emory University
- Strategic community engagement
- Sylvia Adebajo, Population Council, Nigeria •Jeffrey Walimbwa, ISHTAR, Kenya
- Moderated Panel Q & A Discussion •Closing remarks – Merlin Robb, U.S. Military HIV Research Program

Chairs:

Kenneth H. Mayer (Fenway Health, United States)
Sylvia Adebajo (Population Council, Nigeria)

Satellites
16:00 - 18:00

Estrasburgo

SA04 State of the Art of HIV bnAbs for Prevention of HIV Infection

Hosted by: HIV Vaccine Trials Network and HIV Prevention Trials Network In April 2016, the HIV Vaccine Trials Network (HVTN) and the HIV Prevention Trials Network (HPTN) launched the precedent-setting AMP studies to determine if the broadly neutralizing antibody called VRC01 can prevent HIV infection in people. Broadly neutralizing antibodies (bnAbs) can be detected in an estimated 25% of persons with untreated HIV infection. Attracting the most attention are bnAbs with the greatest breadth — those that demonstrate the ability to neutralize the largest number of HIV strains — or those that have the greatest potency. Such bnAbs offer considerable opportunities for treatment and prevention of HIV infection. This session will have some of the major figures in the field cover current topics on the discovery and clinical development of bnAbs to prevent HIV infection.

Chairs:

Larry Corey (Fred Hutchinson Cancer Research Center, United States)
Myron Cohen (University of North Carolina, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Monday, 22 October 2018

Satellites
08:30 - 11:30

Bristol

SA16 Current State of Play: PrEP Implementation Update and Challenges

Hosted by: ICAP at Columbia University, World Health Organization (WHO), AVAC, CHAI and HIV Prevention Trials Network (HPTN) For more details, please click on this link: <https://ghve.box.com/s/vngwv4hrihncgt3vvz7uc3qzll1fgfrd> This session will provide participants with an update on where we are with PrEP and future products, current understanding of the different approaches to oral PrEP implementation in low- and middle-income countries, the challenges faced and solutions found in efforts to scale-up programs. Panel discussions will elicit the perspectives from key experts and include debate on current controversies when considering and prioritizing PrEP implementation.

Chairs:

Wafaa El-Sadr (Mailman School of Public Health, Columbia University, United States)
Rachel Baggaley (World Health Organization, Switzerland)
Mitchell Warren (AVAC, United States)

Satellites
08:30 - 11:30

Oxford

SA18 A Treasure Trove of Clinical Specimens and Data: Mining Research Opportunities with the HIV Vaccine Trials Network (HVTN)

Hosted by: HIV Vaccine Trials Network (HVTN) The HVTN has conducted more than 75 clinical trials across four continents, evaluating the safety, tolerability and immunogenicity of numerous study products, delivery methods and regimens. During the conducting of all HVTN studies, participant data and specimens are collected at multiple time points to evaluate immunogenicity and generate data across several cellular and humoral research platforms. In addition, extra samples are collected and stored for use in other studies potentially related to vaccinology, immunology and HIV. The HVTN maintains comprehensive metadata for all specimens, and has collected more than one million pages of case report form data from study participants to date. The HVTN is committed to making the specimens and data collected in HVTN studies available to investigators around the world to foster the development of diverse, hypothesis-driven research projects to advance HIV vaccine science. This session will provide a brief overview of the types of specimens, data and resources available to investigators to formulate research hypotheses, as well as steps to approach collaborating with the HVTN. This overview will be followed by a showcase of several, ongoing research projects initiated by investigators in collaboration with the HVTN and utilizing HVTN specimens and/or data.

Chairs:

James Kublin (Fred Hutchinson Cancer Research Center, United States)
Ashley Clayton

Download Program (PDF)

Satellites
08:30 - 11:30

Dresden & Stuttgart

SA08 Catalyzing Translational Research to Advance HIV Vaccine and Immune-based Cure Research in Africa: Cross-cutting Translational Research and Capacity Strengthening in Africa

Hosted by: IAVI and University of KwaZulu Natal This satellite will showcase early and mid-level career African scientists supported by a 15-year IAVI-led USAID-funded capacity program and from the SANTHE consortium, part of the DELTAS Africa Initiative, an independent funding scheme of the African Academy of Sciences' (AAS's) Alliance for Accelerating Excellence in Science in Africa (AESA). This satellite workshop will aim to provide evidence of the impact that these investments have created in translational biomedical research in Africa. This session will also host a moderated panel discussion by African investigators to share personal career pathways, experiences and perspectives on how research capacity and research outputs could be further strengthened and improved on the continent.

Chairs:

Daniel Ochiel (IAVI, Kenya)
Thumbi Ndung'u (University of KwaZulu-Natal, South Africa)

Satellites
08:30 - 11:30

Estrasburgo

SA10 Immunological Mechanisms of Inducing HIV Immunity in Infants

Hosted by: Division of AIDS, NIAID, NIH The session aims to better understand: (i) how the unique tolerogenic nature of the human fetal immune system and developing immune-tolerance in infants provide a unique setting for B-cell maturation pathways and development of early and broad immunity to HIV; and (ii) how to prioritize HIV candidate vaccines and target populations for assessment of infant HIV immunization.

Chairs:

Mary Marovich (Division of AIDS, NIAID, NIH, United States)
Sallie Permar (Duke University Medical Center)
Anjali Singh (Division of AIDS, NIAID, NIH)

Satellites
08:30 - 11:30

Burdeos

SA12 Voices in the Long-acting PrEP Movement: Fostering Dialog Between End-users and Product Developers During the Product Development Process

Hosted by: RTI International, Desmond Tutu HIV Research Foundation, AVAC and IAVI This satellite session aims to demonstrate and discuss strategies to foster open and iterative dialog between end-users and product developers of long-acting HIV prevention products. The objective of hosting this satellite is directly in line with the theme of this year's HIVR4P Conference, From Research to Impact. Satellite presenters, those working both in product development and those interfacing with target populations of young women in Southern Africa, aim to achieve synergistic solutions for the development of long-acting HIV PrEP products that are safe, effective, acceptable and appropriate for their target end-users, a goal that will ultimately achieve the greatest public health impact.

Chairs:

Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)
Mitchell Warren (AVAC, United States)

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
08:30 - 11:30

Marsella

SA14 GPP@10 -- Setting New Standards for Clinical Trial Engagement Globally

Hosted by: AVAC, Amsterdam Institute for Global Health and Infectious Diseases Through presentations and moderated discussions, the session will articulate evolved the Good Participatory Practices (GPP) after 10 years of implementation, debate challenges and questions around GPP, and explore consensus on GPP as a standard in clinical trials.

Chairs:

Stacey Hannah (AVAC, United States)
Catherine Hankins (Amsterdam Institute for Global Health and Development, Netherlands)

Satellites
11:30 - 15:00

Burdeos

SA13 It Only Hurts a Little: Long-acting Injectables for HIV Prevention and Treatment

Hosted by: Center for HIV Identification, Prevention, and Treatment Services and the Center for AIDS Research at the University of California, Los Angeles, HIV Prevention Trials Network and the AIDS Clinical Trials Group For more information on the program, please visit: <http://chipts.ucla.edu/features/upcoming-hiv-r4p-satellite-session-on-long-acting-injectables-for-hiv-prevention-and-treatment/> To RSVP to the satellite session, please visit: goo.gl/RQYe1u Ongoing clinical trials of long-acting injectable antiretroviral medications are being studied currently as both HIV prevention and maintenance of virologic suppression in HIV treatment. If safe and effective, long-acting agents have the potential to significantly impact the HIV epidemic by eliminating the requirement for daily oral dosing of antiretrovirals. This may have significant benefits for individuals living with or at risk for HIV, particularly among those who also have co-morbidities that complicate daily routinization of medication dosing, such as mental health and substance use disorders. Such individuals also commonly face structural issues, including housing instability and food insecurity, which can interfere with their capacity for daily oral medication adherence and persistence. With the first regulatory approvals of long-acting injectable antiretrovirals imminent, this interactive satellite session aims to facilitate efforts to mobilize, prepare and plan for culturally responsive, equitable and sustainable scale-up of long-acting injectable prevention and treatment agents for key populations in high-, middle- and low-income countries. The session will engage multidisciplinary stakeholders, including academic experts, policy researchers and civic society members, in a dialogue to articulate the challenges for implementation and uptake and, in particular, how acceptability and/or barriers may differ from those applicable to daily oral tablet formulations. The session will convene two moderated panels to discuss clinical, behavioral, policy and community considerations associated with the implementation of long-acting injectable antiretrovirals for prevention and treatment in the context of different international resource settings and key populations (for example, MSM, transgender women, pregnant and parenting cisgender women, youth).

Chairs:

Steven Shoptaw (UCLA Medical Center, Santa Monica, United States)
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)

Lunch and Registration	11:30 - 12:00
Welcome	12:00 - 12:10
Opening Remarks	12:10 - 12:20
Steven Shoptaw (UCLA Medical Center, Santa Monica, United States)	

Download Program (PDF)

Panel 1: Preparing for Long Acting Injectable for Prevention	12:20 - 13:30
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States) Beatriz Grinsztejn (Fundação Oswaldo Cruz, Brazil) Nyaradzo Mgodi (University of Zimbabwe Collaborative Research Program, Zimbabwe) Le Minh Giang (Hanoi Medical University, Viet Nam) Mitchell Warren (AVAC, United States)	
Break	13:30 - 13:40
Panel 2: Preparing for Long Acting Injectable for Treatment	13:40 - 14:50
Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa) Santiago Moreno (University of Alcalá de Henares, Spain) Omar Sued (Fundacion Huesped, Argentina) Ntando Yola (Desmond Tutu HIV Foundation, South Africa)	
Closing Remarks	14:50 - 15:00
Adjourn	

Satellites
12:00 - 15:00

Bristol

SA17 Love, Power and PrEP: Addressing Relationship Dynamics and Intimate Partner Violence to Promote Successful HIV Prevention for Women and Girls

Hosted by: FHI 360, RTI International, Population Council and Wits Reproductive Health and HIV Institute For more details, please click on this link: <https://mailchi.mp/3af389e4ecc5/reminder-love-power-prep-r4p-satellite-session-325431> To successfully empower women and girls to protect themselves against HIV, researchers, policy makers, funders, advocates and programmers need a nuanced understanding of how relationship dynamics affect HIV prevention and interventions that jointly address these issues. This satellite session will summarize the state of the evidence on the effect of gender inequality on the HIV risk of women and girls and their use of HIV prevention methods, including pre-exposure prophylaxis (PrEP). New evidence will be presented from adolescent girls, young women, key populations and male partners in Kenya, Ghana and Tanzania on their HIV prevention needs and preferences, including their views on PrEP and how intimate partner violence (IPV) could affect PrEP access and use. A panel of experts will present new evidence from clinic- and community-based interventions (CHARISMA, EMPOWER and Project SOAR) implemented in South Africa and Tanzania, jointly addressing relationship dynamics, IPV, HIV prevention and PrEP.

Chairs:

Kawango Agot (Impact Research & Development Organization, Kenya)
Jared Baeten (University of Washington, United States)

Download Program (PDF)

Satellites
12:00 - 15:00

Oxford

SA19 Whose Desire? Whose Choice? A Debate on the Future of HIV Prevention

Hosted by: AVAC and IRMA Lively, moderated discussion and debate featuring speakers from funding agencies, research networks and sites, product developers and the advocacy community. Panelists will unpack the evolving HIV prevention research priorities and product development agendas, and share thoughts on what is necessary to develop prevention products that people desire and what we mean by giving people "choices."

Chairs:

Mitchell Warren (AVAC, United States)
Helen Rees (Wits Reproductive Health and HIV Institute, South Africa)

Satellites
12:00 - 15:00

Dresden & Stuttgart

SA09 Fc-mediated Antibody Functions Impacting HIV Prevention

Hosted by: NIH/NIAID/Division of AIDS Objectives for the Meeting •To review NHP and clinical data on Fc-mediated functions in the context of HIV/SIV infection and vaccine design. •To further discuss the biological relevance and limitations of different assays for measuring Fc-mediated functions. •To provide insights into immunogen design to maximize the induction of antibodies with Fc-mediated functions. Fc-mediated antibody functions, including antibody-dependent cell cytotoxicity (ADCC), are potential mechanisms that the immune system can resource to prevent the establishment of HIV infection by eliminating HIV and/or HIV-infected cells. This session will bring together investigators to review NHP and clinical data on Fc-mediated antibody functions in the context of HIV/SIV infection and vaccine design, to discuss the biological relevance and limitations of different assays and to provide insights into immunogen design strategies to maximize the induction of antibodies with Fc-mediated functions that could impact HIV infection and persistence.

Chairs:

Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)
Stephen Kent (University of Melbourne, Australia)

Welcome and Opening Remarks	12:00 - 12:05
Mary Marovich (Division of AIDS, NIAID, NIH, United States)	
Higher Antibody Fc Effector Functions Significantly Impact HIV-1 Infection Risk in a Human Efficacy Trial	12:05 - 12:20
Georgia Tomaras (Duke University, United States)	
Epitopes For C1/C2 ADCC Antibodies Induced in HIV Infection and in Response to the RV144 and RV305 Vaccine Trials	12:20 - 12:35
Marzena Pazgier (Institute of Human Virology of University of Maryland, United States)	
Impact of HIV-1 Env Conformation on ADCC	12:35 - 12:50
Andres Finzi (CRCHUM / Université de Montréal, Canada)	
Knowns and Unknowns: Antibody Fc-Mediated Anti-Viral Activity in Passive and Active Immunization	12:50 - 13:05
Ann Hessel (Oregon Health and Science University, United States)	
Role of Non-Neutralizing Effector Mechanisms in Sterilizing Immunity Conferred by Passive Immunization in NHPs	13:05 - 13:15
Klaus Überla (Universitätsklinikum Erlangen, Germany)	

Download Program (PDF)

PGT121 Sterilely Protects Macaques from Vaginal Challenge with SHIVSF163P3 in an FcγR- Independent Manner	13:15 - 13:25
David Beauparlant (The Scripps Research Institute, USA, United States)	
The Link Between Fc Effector Function and Neutralization	13:25 - 13:35
Simone Irene Richardson (Centre for HIV & STIs, National Institute for Communicable Diseases, South Africa)	
The immunomodulatory role of serum IgA upon Fc effector functions	13:35 - 13:50
Amy Chung (Australia)	
Time-dependent susceptibility of HIV-1-infected cells to ADCC	13:50 - 13:55
Wen Shi Lee (University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Australia)	
Contribution of Fc-Mediated Antibody Activities to HIV Control	13:55 - 14:00
Jéromine Klingler (UMR S_1109, France)	
High Rate of anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy Volunteers	14:00 - 14:05
Frank Msafiri (Muhimbili University of Health and Allied Sciences, Tanzania, United Republic of)	
Circulating levels of HIV-1-specific IgG differentially affect antibody-dependent cellular cytotoxic and phagocytic responses in HIV-1 infected individuals.	14:05 - 14:10
Ntando G. Phaahla (National Institute for Communicable Diseases of the National Health Laboratory Service, Center for HIV and STIs, South Africa)	
Good things come in threes: mAb combinations for killing infected cells	14:10 - 14:15
Marina Tuyishime (Duke University Medical Center, United States)	
Discussion moderated by Dr. Moog and Dr. Kent	14:15 - 15:00

Satellites
12:00 - 15:00

Estrasburgo

SA11 Accelerating a Labor of Love: Time to Transform HIV Prevention for Pregnant and Breastfeeding Women

Hosted by: Jhpiego, MTN, PHASES, AVAC A growing body evidence supports the need to expand biomedical HIV prevention options during pregnancy and breastfeeding, periods known to have increased risk for HIV acquisition for both women and their infants. While the large majority of biomedical HIV prevention trials have excluded pregnant and breastfeeding women, this trend is starting to change. HIV pre-exposure prophylaxis (PrEP) programs are starting to serve pregnant and breastfeeding women, and the conversation around equitable access for these populations is evolving. The proposed session would highlight the growing body of evidence, action, advocacy, and ethics around increasing access for pregnant and breastfeeding women to safe and effective biomedical HIV prevention options.

Chairs:

Sharon Hillier (University of Pittsburgh, United States)
Kelly Curran

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Satellites
12:00 - 15:00

Marsella

SA15 Human Centric Vaccine Discovery

Hosted by: EAVI2020 To view the agenda, please click on this link:
<https://ghve.box.com/s/suoa2aow4o4qpsvvgbdcry0u8neo5uev> For more details, please click on this link:
<https://ghve.box.com/s/9b8uki8p4ep8veinb3notr8tjbyqtgoz> This session will highlight the importance of discovery-phase clinical vaccine trials.

Chairs:

Robin Shattock (Imperial College, United Kingdom)

Opening Plenary
16:00 - 18:00

Auditorium

PL01 Planning for Success (and the Challenges Ahead)

Plenary 1 opens HIVR4P 2018 with a broad statement of our goals, a look at the major challenges facing the field as we convene and a tribute to some of the researchers and advocates who are taking it forward and keeping us focused.

Chairs:

Jose Alcamí (Instituto de Salud Carlos III, Spain)
Susan Buchbinder (San Francisco Department of Public Health, United States)
Mike Chirenje (University of Zimbabwe, Zimbabwe)
Georgia Tomaras (Duke University, United States)

	Welcome to HIVR4P 2018	16:00 - 16:10
	Jose Alcamí (Instituto de Salud Carlos III, Spain)	
	Desmond Tutu Award for HIV Prevention and Human Rights	16:10 - 16:17
	Georgia Tomaras (Duke University, United States)	
PL01.01	HIV Vaccines: Where Are We and What Next?	16:17 - 16:47
	Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)	
PL01.02	Novel Trial Designs for a Complex Environment	16:47 - 17:17
	Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom)	
PL01.03	Ending the HIV/AIDS Pandemic: The Critical Role of HIV Prevention Science	17:17 - 17:47
	Anthony Fauci (National Institute of Allergy and Infectious Diseases, NIH, United States)	
	The Omololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy	17:47 - 17:55
	Manju Chatani-Gada (AVAC, United States)	
	HIVR4P 2018 Scholars	17:55 - 18:00
	Mike Chirenje (University of Zimbabwe, Zimbabwe)	

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Welcome Reception
18:00 - 20:00

Atrium Bar and England-France Gallery

Welcome Reception

Download Program (PDF)

Tuesday, 23 October 2018

Plenary
08:30 - 10:00

Auditorium

PL02 What Happens First: Understanding Susceptibility, Transmission and Early Infection

Plenary 2 dives deep into some of the most fundamental and challenging questions about the earliest moments of infection, when HIV enters the complex mucosal microenvironment, and how untangling the mysteries of susceptibility and infection can lead to smarter, more targeted prevention approaches.

Chairs:

Felipe Garcia (IDIBAPS, Spain)

Julie McElrath (Fred Hutchinson Cancer Research Center, United States)

PL02.01	Visualizing HIV Transmission and Prevention Thomas Hope (Northwestern University, United States)	08:30 - 09:00
PL02.02	First Responders: What Early Infection Teaches About Prevention and Functional Cure Strategies Thumbi Ndung'u (University of KwaZulu-Natal, South Africa)	09:00 - 09:30
PL02.03	Untangling Hormonal Impacts on the Vaginal Microbiome and HIV Acquisition Risk Sharon Achilles (University of Pittsburgh, United States)	09:30 - 10:00

Oral
10:30 - 12:00

Londres

OA01 Location, Location, Location: Mucosal Mediators of Risk

Chairs:

Doug Kwon (Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital and Harvard Medical School, United States)

Lindi Masson (University of Cape Town, South Africa)

OA01.01	Role of Epithelial Cells and Fibroblasts From the Female Reproductive Tract in TFV and TAF Protection of CD4+ T Cells from HIV Infection Charles Wira (Geisel School of Medicine at Dartmouth, United States)	10:30 - 10:45
OA01.02	Optical Tissue Imaging and Spectroscopic Measurement of Spatiotemporal Tenofovir Distribution, Partitioning and Diffusivity in Vaginal and Rectal Mucosa Oranat Chuchuen (Khon Kaen University, Faculty of Engineering, Thailand)	10:45 - 11:00
OA01.03	Transplanted Human Vaginal Microbiomes Alter HIV-1 Infection and Tenofovir Efficacy in Colonized Vaginal Epithelial Multilayer Cultures Richard Pyles (University of Texas Medical Branch, United States)	11:00 - 11:15
OA01.06	Reducing Inflammation as a Novel HIV Prevention Approach: Aspirin Reduces Inflammation and HIV Target Cells at the Female Genital Tract Keith R Fowke (University of Manitoba, Canada)	11:15 - 11:30

Download Program (PDF)

OA01.05	Hormonal Contraception Induced Changes to the Female Genital Microbiota in South African Adolescents: A Randomized, Crossover Trial Christina Balle (University of Cape Town, Institute of Infectious Disease and Molecular Medicine & Division of Immunology, South Africa)	11:30 - 11:45
OA01.04	Impact of Vaginal Bacteria Communities on Antiretroviral-based PrEP Drug Metabolism Ryan Cheu (University of Washington, United States)	11:45 - 12:00

Oral
10:30 - 12:00

Bristol

OA02 Immunity in Human Vaccine Trials

Chairs:

Laura Richert (Vaccine Research Institute/VRI, France)
Gabriella Scarlatti (San Raffaele Scientific Institute, Italy)

OA02.01	T-cell and Transcriptomic Responses to Prime-boost Strategies of 3 HIV Vaccines (MVA HIV-B; LIPO-5; GTU-MultiHIV B) - ANRS/INSERM VRI01 Trial Jean-Daniel Lelièvre (Vaccine Research Institute/VRI, Hôpital Henri Mondor, France)	10:30 - 10:45
OA02.02	Safety and Immunogenicity of a pDNA Clade B Env Prime, rVSV Clade C Env Boost HIV-1 Vaccination Regimen in a Phase 1 Clinical Trial Gregory Wilson (Vanderbilt University Medical Center, United States)	10:45 - 11:00
OA02.03	V1V2 IgG and Antibody Fc Effector Functions in a Subtype C ALVAC-HIV and Bivalent Subtype C gp120/MF59 HIV-1 Vaccine Trial in South Africa Xiaoying Shen (Duke Human Vaccine Institute, United States)	11:00 - 11:15
OA02.04LB	DNA-prime Induces Higher Magnitude Humoral Responses Than ALVAC-prime in HIV Vaccine Regimens With the Same Protein Boost Zoe Moodie (Fred Hutchinson Cancer Research Center, United States)	11:15 - 11:30
OA02.05LB	Vaccine-induced Gene Signature Correlates With Protection Against Acquisition in Three Independent Vaccine Efficacy Trials Including RV144 Rasmi Thomas (US Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, United States)	11:30 - 11:45
OA02.06LB	Primary Analysis of TRAVERSE: A Phase 1/2a Study to Assess Safety/Tolerability and Immunogenicity of 2 Different Prime/Boost HIV Vaccine Regimens Daniel J. Stieh (Janssen Vaccines & Prevention B.V., Netherlands)	11:45 - 12:00

Oral
10:30 - 12:00

Oxford

OA03 Structure and Maturation of bNAbs

Chairs:

Alejandro Balazs (Ragon Institute of MGH, MIT and Harvard, United States)
Mary Marovich (Division of AIDS, NIAID, NIH, United States)

Download Program (PDF)

OA03.01	Induction and Maturation of HIV-1 Fusion Peptide-directed Broadly Neutralizing Antibodies in Rhesus Macaques by Vaccination Peter D. Kwong (Vaccine Research Center, United States)	10:30 - 10:45
OA03.02	Identification of Near Pan-neutralizing Antibodies Against HIV-1 by Deconvolution of Plasma Humoral Responses Mohammad Sajadi (Institute of Human Virology, School of Medicine, University of Maryland, United States)	10:45 - 11:00
OA03.03	Structural Basis for Germline VRC01 Antibody Recognition of a Glycosylated HIV-1 Envelope CD4-binding Site Marie Pancera (Fred Hutchinson Cancer Research Center, United States)	11:00 - 11:15
OA03.04	Fast and Focused Maturation of VH1-2-restricted HIV-env CD4-binding Site Targeting bNAbs Elise Landais (International AIDS Vaccine Initiative (IAVI), United States)	11:15 - 11:30
OA03.05	Somatic hypermutation to counter a rare viral immunotype drove off-track antibodies in the CAP256-VRC26 V2-directed bNAb lineage David Sacks (National Institute for Communicable Diseases, National Health Laboratory Service, South Africa)	11:30 - 11:45
OA03.06	New SHIV Models of bNAb Elicitation and Env-Ab Coevolution Hui Li (University of Pennsylvania, United States)	11:45 - 12:00

Oral
10:30 - 12:00

Marsella, Burdeos & Estrasburgo

OA04 Entry Into the PrEP Continuum

Chairs:

Sybil Hosek (Stroger Hospital of Cook County, United States)
Rupa Patel (Washington University in St. Louis, United States)

OA04.01	Tracking Global Oral PrEP Provision: The Who, What, Where of Oral PrEP Laura Fitch (AVAC, United States)	10:30 - 10:45
OA04.02	Sexual Health Goal Congruence and PrEP Adoption Among Gay and Bisexual Men in Primary Partnerships Kristi Gamarel (University of Michigan School of Public Health, United States)	10:45 - 11:00
OA04.03	Characterization of Early Adopters in a National Oral Pre-exposure Prophylaxis (PrEP) Scale-up Program in Kenya Daniel Were (Jhpiego, Kenya)	11:00 - 11:15
OA04.04	"So That I Don't Get Infected Even If I Have Sex With Someone Who Is Positive:" Factors Influencing PrEP Uptake Among Young Women in Kenya Nicholas Thuo (Partners in Health Research and Development, Kenya)	11:15 - 11:30
OA04.05	HIV-related Risks and Interest in Pre-exposure Prophylaxis (PrEP) Among Transgender Respondents of the Community-based Survey Flash! PrEP in Europe Rosemary M. Delabre (Coalition PLUS, Community-based Research Laboratory, France)	11:30 - 11:45

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

OA04.06	Substantial Gaps in the PrEP Continuum Among Transwomen Compared With MSM in San Francisco Albert Liu (San Francisco Department of Public Health, United States)	11:45 - 12:00
----------------	--	----------------------

Meet the Experts Lunch
12:00 - 13:00

Toulouse & Lyon

ME01 Meet the Experts Lunch

Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges, and HIV-affected communities.

Chairs:

Sharon Achilles (University of Pittsburgh, United States)
Eric Arts (University of Western Ontario, Canada)
Emily Bass (AVAC, United States)
Linda-Gail Bekker (Desmond Tutu HIV Centre, University of Cape Town, South Africa)
Marta Boffito (Chelsea and Westminster NHS Trust, United Kingdom)
Zhiwei Chen (The University of Hong Kong AIDS Institute, China)
Charles Dobard (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States)
Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)
Andrew Harman (The Westmead Institute, University of Sydney, Australia)
Walid Heneine (CDC, United States)
Thomas Hope (Northwestern University, United States)
Luciana Kamel (Fiocruz, Brazil)
Sheena McCormack (MRC Clinical Trials Unit at UCL, United Kingdom)
Lynn Morris (National Institute for Communicable Diseases of the NHLS, South Africa)
Irene Mukui (National AIDS & STI Control Program, Kenya)
Jeffrey Murray (FDA, United States)
Thumbi Ndung'u (University of KwaZulu-Natal, South Africa)
Manish Sagar (Boston University, United States)
Kevin Saunders (Duke Human Vaccine Institute, United States)
William Schief (The Scripps Research Institute and IAVI, United States)
Alexandra Schuetz (MHRP Thailand, Thailand)
Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)
Eloisa Yuste (Instituto de Salud Carlos III, Spain)

Meet the Experts Lunch

12:00 - 13:00

Oral
13:00 - 14:30

Londres

OA05 If I Choose, Will I Use? Products, People and Preferences

Chairs:

Mary Aikenhead (Bill and Melinda Gates Foundation, United States)
Mina Hosseinipour (University of North Carolina at Chapel Hill, Malawi)

OA05.01	Acceptability of Long-acting Injectable Cabotegravir (CAB LA) in HIV-uninfected Individuals: HPTN 077 Elizabeth (Betsy) Tolley (FHI 360, United States)	13:00 - 13:15
----------------	---	----------------------

Download Program (PDF)

OA05.02	Partners, Peers and Rumours as Influencers of Use and Attitudes Towards the Dapivirine Vaginal Ring: Qualitative Data From The Ring Study (IPM 027) Cecilia Milford (MatCH Research Unit (MRU), University of the Witwatersrand, South Africa)	13:15 - 13:30
OA05.03	Testing Objective Markers of Placebo Vaginal Product Adherence in the Field Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)	13:30 - 13:45
OA05.04	Preference and Choice of Four Vaginal HIV Prevention Placebo Dosage Forms Among Young African Women: Results of the Quatro Randomized Crossover Trial Elizabeth Montgomery (RTI International, United States)	13:45 - 14:00
OA05.05	Attribute Preferences for Long-acting Pre-exposure Prophylaxis (PrEP): Results of a Discrete Choice Experiment With South African Youth Alexandra Minnis (RTI International, United States)	14:00 - 14:15
OA05.06LB	UChoose: An Adolescent Study of HIV Prevention Choice in Cape Town, South Africa Katherine Gill (Desmond Tutu HIV Foundation, South Africa)	14:15 - 14:30

Oral
13:00 - 14:30

Bristol

OA06 Mucosal Models of Prevention

Chairs:

Carolina Herrera (Imperial College London, United Kingdom)
Thandi Onami (Bill & Melinda Gates Foundation, United States)

OA06.01	Combination of MUC5AC and MUC2 Enhances Antibody Neutralization Potency Against HIV-1 Infection Arangassery Rosemary Bastian (Northwestern University, United States)	13:00 - 13:15
OA06.02	Neutrophil Extracellular Traps Represent a Novel Mechanism for HIV Prevention in the Female Genital Tract Marta Rodriguez-Garcia (Geisel School of Medicine at Dartmouth, United States)	13:15 - 13:30
OA06.03	Select V2 Loop Antibodies Inhibit gp120 Binding to Integrin $\alpha_4\beta_7$ Sakaorat Lertjuthaporn (Faculty of Medicine Siriraj Hospital, Thailand)	13:30 - 13:45
OA06.04	Investigating the Interactions Between HIV and a New Epithelial Target Cell in Human Genital Tissue Jake Rhodes (Westmead Institute for Medical Research, Australia)	13:45 - 14:00
OA06.05	Live Imaging of HIV-1 Transfer Across T-cell Virological Synapse to Epithelial Cells That Promotes Stromal Macrophage Infection Morgane Bomsel (Institut Cochin CNRS UMR8104, France)	14:00 - 14:15
OA06.06	Fcα-receptor I Expression by Stratified Squamous Epithelia: Implications for IgA-associated Immune Function in the Human Lower Genital Tract Kadryn Kadasia (Boston University School of Medicine, United States)	14:15 - 14:30

Download Program (PDF)

Oral
13:00 - 14:30

Oxford

OA07 Understanding Protection Against HIV From the T Cell Perspective

Chairs:

Marcus Altfeld (Heinrich Pette Institute, Germany)
Richard Koup (Vaccine Research Center, United States)

OA07.01	Increased Breadth of T-cell Responses After Mosaic HIV Vaccination in Humans (HVTN 106)	13:00 - 13:15
	Nicole Frahm (Fred Hutchinson Cancer Research Center, United States)	
OA07.02	Gag and Env Conserved Element DNA Vaccines Elicit Cytotoxic Responses Targeting Subdominant Epitopes Able to Recognize Infected Cells in Macaques	13:15 - 13:30
	Barbara K. Felber (National Cancer Institute at Frederick, United States)	
OA07.03	Utilizing Computational Machine Learning Tools to Understand Immunogenic Breadth of HIV in the Context of a CD8 T-cell Mediated HIV Response	13:30 - 13:45
	Jonathan Hare (International AIDS Vaccine Initiative (IAVI), United Kingdom)	
OA07.04	Structure-based Network Analysis of HIV-1 Defines Protective CD8+ T Cell Epitopes Across Diverse HLA: Implications for Global Immunogen Design	13:45 - 14:00
	Gaurav Gaiha (Ragon Institute of MGH, MIT & Harvard, United States)	
OA07.05	CD8+ T Cells Do Not Control SIV Replication During ART or Viral Relapse After ART Withdrawal	14:00 - 14:15
	Afam Okoye (Oregon Health & Science University, United States)	
OA07.06	CD8 T Cells Responding to Adapted Epitopes Are Enriched in Chronic HIV Infection and Induce Dendritic Cell Maturation with Enhanced CD4 Infection	14:15 - 14:30
	Kai Qin (University of Alabama at Birmingham, United States)	

Oral
13:00 - 14:30

Marsella, Burdeos & Estrasburgo

OA08 bNAbs for Prevention

Chairs:

Boris Juelg (Ragon Institute of MGH, MIT and Harvard, United States)
Alexandra Trkola (University of Zurich, Switzerland)

OA08.01	Combination of HIV-1 Antibodies 3BNC117 and 10-1074 Delays Viral Rebound During Treatment Interruption	13:00 - 13:15
	Pilar Mendoza (Rockefeller University, United States)	
OA08.02	SHIV162P3 Transmission by Semen Leukocytes Is Efficiently Inhibited by a Combination of Broad Neutralizing Antibodies	13:15 - 13:30
	Karunasinee Suphaphiphat (CEA, France)	
OA08.03	Broadly Neutralizing Antibodies Provide Potent Dose-dependent Protection to Rhesus Macaques Against Mucosal SHIV Challenge	13:30 - 13:45
	Amarendra Pegu (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States)	

Download Program (PDF)

OA08.04	VRC01 Pharmacokinetics at Mucosal Sites in HIV-infected and Healthy Adults Madhu SP Prabhakaran (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, United States)	13:45 - 14:00
OA08.05	Safety and Pharmacokinetics of Multiple Doses of a Potent Anti-HIV Monoclonal Antibody, VRC01, in HIV-exposed Newborns Coleen Cunningham (Duke, United States)	14:00 - 14:15
OA08.06	Imaging the Distribution of I.V.-injected VRC01 and VRC01-LS in the In Vivo Rhesus Macaque Model Ann M. Carias (Northwestern University, United States)	14:15 - 14:30

Symposium
15:00 - 16:30

Londres

SY01 We Want bNAbs: Passively Infused and Induced by Vaccines

This session will look at state-of-the-art passive infusion designs, including optimal combinations to achieve maximum breadth, coverage, potency and durability. In addition, multiple vaccine concepts designed to induce bNAbs will be presented, from the stage of basic concept up to the clinical trials pipeline.

Chairs:

Marina Caskey (The Rockefeller University, United States)
Quentin Sattentau (Sir William Dunn School of Pathology, United Kingdom)

SY01.01	Engineered Tandem Bispecific Neutralising Antibody for HIV-1 Prevention and Immunotherapy Zhiwei Chen (The University of Hong Kong AIDS Institute, China)	15:00 - 15:18
SY01.02	Antibody Mediated Protection (AMP): Where Are We? Which Antibodies to Use and How Will We Know If It's Working? Lynn Morris (National Institute for Communicable Diseases of the NHLS, South Africa)	15:18 - 15:36
SY01.03	Generation of Immunogens Based on HIV-1 Envelopes From Patients With Broadly Neutralizing Responses Within the First 6 Months of Infection Eloisa Yuste (Instituto de Salud Carlos III, Spain)	15:36 - 15:54
SY01.04	HIV-1 Vaccine Design for the Elicitation of V3-glycan Broadly Neutralizing Antibodies Kevin Saunders (Duke Human Vaccine Institute, United States)	15:54 - 16:12
SY01.05	Progress in Germline-targeting Vaccine Design for HIV William Schief (The Scripps Research Institute and IAVI, United States)	16:12 - 16:30

Download Program (PDF)

Symposium
15:00 - 16:30

Bristol

SY02 Early Invaders: Establishment of HIV Infection

This session addresses virus-host interaction at the mucosal border where transmission occurs and where cells involved in early immune responses are both viral targets and defense mechanisms.

Chairs:

Cecilia Cabrera (IrsiCaixa AIDS Research Institute, Spain)
Penny Moore (University of the Witwatersrand, South Africa)

SY02.01	Selection of Transmitted Founder Viruses During Sexual HIV-1 Acquisition	15:00 - 15:22
	Manish Sagar (Boston University, United States)	
SY02.02	Identification of a New HIV Transmitting Target Cell in Human Genital Tissue	15:22 - 15:44
	Andrew Harman (The Westmead Institute, University of Sydney, Australia)	
SY02.03	Characteristics Leading to HIV Trapping in the Female Genital Tract and Systemic Primary Infection During Transmission	15:44 - 16:06
	Eric Arts (University of Western Ontario, Canada)	
SY02.04	Mucosal Immunology in the Context of Acute HIV Infection and HIV Remission Studies	16:06 - 16:28
	Alexandra Schuetz (MHRP Thailand, Thailand)	

Symposium
15:00 - 16:30

Oxford

SY03 Beyond Placebo: Designing and Implementing Next Generation HIV Prevention Trials

This session will explore challenges in designing and conducting the next generation of HIV prevention trials. Topics discussed will include regulatory perspectives, novel trial designs, ethical considerations in provision of standard of prevention, and active community engagement in the design and successful implementation of complex trials in an era of proven HIV prevention tools (including voluntary medical male circumcision and oral PrEP).

Chairs:

Peter Godfrey-Faussett (UNAIDS, Switzerland)
Catherine Hankins (Amsterdam Institute for Global Health and Development, Netherlands)

SY03.01	Regulatory Perspectives for Streamlining HIV Prevention Trials	15:00 - 15:18
	Jeffrey Murray (FDA, United States)	
SY03.02	Novel Trial Design in the Era of Successful HIV Prevention Interventions	15:18 - 15:36
	Deborah Donnell (Fred Hutchinson Cancer Research Center, United States)	
SY03.03	The Landscape is Changing... [It's] Quite a Complicated Issue" : Perspectives on the Standard of Prevention in South African HIV Vaccine Trials	15:36 - 15:54
	Zaynab Essack (Human Sciences Research Council, South Africa)	
SY03.04A	Strengthen Community Expertise on the Important Aspects of Clinical Trial Design	15:54 - 16:03
	Luciana Kamel (Fiocruz, Brazil)	

Download Program (PDF)

SY03.04B	Community Engagement in the Design and Implementation of HIV Prevention Trials: Uganda Virus Research Institute-International AIDS Vaccine Initiative	16:03 - 16:12
	Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)	
	Discussion	16:12 - 16:30

Symposium
15:00 - 16:30

Marsella, Burdeos & Estrasburgo

SY04 ARVs for Prevention: Extrapolating from Data to Clinical Practice

Data on mechanisms for PrEP efficacy are somewhat limited, and interpretation varies in creating policy about timing of starting and stopping PrEP for protection. This session will explore the PK, PD and clinical trials, and discuss implications of what is currently known for developing policy on PrEP.

Chairs:

Lara Coelho (Instituto de Pesquisa Clínica Evandro Chagas, Fundação Oswaldo Cruz, Brazil)
Clemensia Nakabiito (MUJHU Research Collaboration, Uganda)

SY04.01	Pharmacokinetics of PrEP Agents: Where Do Drugs Go? How Long Do They Last?	15:00 - 15:22
	Marta Boffito (Chelsea and Westminster NHS Trust, United Kingdom)	
SY04.02	Lessons Learned from Pre-clinical Animal Models on Pharmacokinetics and Pharmacodynamics of ARVs for PrEP	15:22 - 15:44
	Charles Dobard (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States)	
SY04.03	Understanding PrEP Effectiveness in Different Populations in the Context of Public Health Programs	15:44 - 16:06
	Irene Mukui (National AIDS & STI Control Program, Kenya)	
SY04.04	The PrEP Paradigm for Prevention, Advocacy and Implementation in sub-Saharan Africa: Strong Starts, Short Cuts, and the Use (and Abuse?) of Data	16:06 - 16:28
	Emily Bass (AVAC, United States)	

Poster Discussion
16:45 - 17:30

Londres

PD01 Revealing Targets for Prevention and Cure

Chairs:

Damian Purcell (Doherty Institute, University of Melbourne, Australia)
Jesus Salazar-Gonzalez (Mrc/uvri And Lshtm Uganda Research Unit, Uganda)

PD01.01	V3 Reactive, Broadly Neutralizing DARPins Reveal Efficiently Targetable V3 Exposure During Entry and Provide Insight on Native HIV-1 Env Stability	16:45 - 16:54
	Matthias Glögl (University of Zurich, Switzerland)	

Download Program (PDF)

PD01.02	Memory CD4+CD45RO+SAMHD1low Cells Exhibit Distinct Genes Profile and Contain the Highest Level of HIV-1 DNA With Segregated HIV-1 Populations Lylia Hani (INSERM, U955, Equipe 16, France)	16:54 - 17:03
PD01.03	Killing a Moving Target: ADCC Against HIV-1-infected Cells in the Process of CD4-downregulation Wen Shi Lee (University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Australia)	17:03 - 17:12
PD01.04	Transmitted/Founder Virus-like Variants Are Archived in the Reservoir Kelsie Brooks (Emory University, United States)	17:12 - 17:21

Poster Discussion
16:45 - 17:30

Bristol

PD02 MEN-ding the Gaps

Chairs:

Kennedy Mupeli (Center for Youth of Hope (CEYHO), Botswana)
Michelle Rodolph (WHO, Switzerland)

PD02.01	"If She Tests Negative, It Means I Am Also Negative": Men's Construction of HIV Testing in South Africa Oluwafemi Adebo (Africa Health Research Institute, South Africa)	16:45 - 16:54
PD02.02	Awareness, Willingness and Barriers to HIV Self-testing (HIVST) Among Men Who Have Sex With Men (MSM) in Brazil: A Cross-sectional Online Study Thiago Silva Torres (Fundação Oswaldo Cruz, Brazil)	16:54 - 17:03
PD02.03	Increased Trust and Reduced Blaming Characterize Age-disparate Heterosexual Relationships in KwaZulu-Natal, South Africa Alastair van Heerden (Human Sciences Research Council, South Africa)	17:03 - 17:12
PD02.04	Profile of the Uncircumcised Zambian Male After Seven Years of Circumcision Programs for HIV Prevention Omega Chituwo (Centers for Disease Control and Prevention, Zambia)	17:12 - 17:21
PD02.05LB	Reaching Men and Under Tested Populations in South Africa Using the STAR Wits RHI HIV Self-screening Test Kits Distribution Models Mohammed Majam (University of the Witwatersrand, South Africa)	17:21 - 17:30

Poster Discussion
16:45 - 17:30

Oxford

PD03 Insights From Vaccines for Improved Breadth, Potency and Durability

Chairs:

Anatoli Kamali (International AIDS Vaccine Initiative, Kenya)
Hanneke Schuitemaker (Janssen Vaccine and Prevention, Netherlands)

PD03.01	Impact of Vaccine Regimen on Vaccine-induced Antibody Durability Kelly Seaton (Duke Human Vaccine Institute, United States)	16:45 - 16:54
----------------	---	----------------------

Download Program (PDF)

PD03.02	Delayed and Repetitive Boosting of RV144 Vaccinees Improves Antiviral Immunity Associated With Correlates of HIV-1 Infection Risk	16:54 - 17:03
	La Tonya Williams (Duke University/Duke Human Vaccine Institute, United States)	
PD03.03	AIDSVAX (R) B/E gp120 Late Boost Increases HIV-1 Neutralizing Antibodies to the Highest Levels in RV144/RV305 Participants Boosted With ALVAC-HIV Alone	17:03 - 17:12
	Lindsay Wiczorek (U.S. Military HIV Research Program, United States)	
PD03.04	Elicitation of Fusion Peptide-directed Neutralizing Activity Through Three Distinct Vaccination Regimens in Rhesus Macaques	17:12 - 17:21
	Alexander J. Jafari (Vaccine Research Center (VRC), National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH), United States)	
PD03.05LB	Increase in Env-specific Binding Antibody and CD4+ T Cell-responses After Month 30 Boost of gp120/MF59 Delivered Alone or With ALVAC-HIV	17:21 - 17:30
	Kristen Cohen (Fred Hutchinson Cancer Research Center, United States)	

Poster Discussion
16:45 - 17:30

Marsella, Burdeos & Estrasburgo

PD04 PrEP: Doing It Right at Delivery

Chairs:

Joshua Kimani (University of Nairobi, Kenya)
Benny Kottiri (USAID, United States)

PD04.01	Unmet PrEP Demand and Factors Associated With PrEP Interest Among Men Who Have Sex With Men in the United States	16:45 - 16:54
	Hyman Scott (San Francisco Department of Public Health, United States)	
PD04.03	Towards the Development of a Behaviorally Congruent HIV-prevention Rectal Microbicide Douche - The DREAM Study	16:54 - 17:03
	Alex Carballo-Diéguez (Columbia University, HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, United States)	
PD04.04	"What About the Boys?" Community Perceptions of Girl-centered HIV Programming in Nairobi Informal Settlements: Experiences From DREAMS Implementation	17:03 - 17:12
	Jane Osindo (Africa Population and Health Research Center, Kenya)	
PD04.05	Experiences of Accessing PrEP in Public HIV Clinics: A Case of Kenyan HIV-uninfected People in Serodiscordant Relationships	17:12 - 17:21
	Fernandos Ongolly (Kenya Medical Research Institute, Kenya)	

Poster Discussion
16:45 - 17:30

Dresden & Stuttgart

PD05 Microbiome: When Microorganisms and the Immune System Meet

Chairs:

Sinaye Ngcapu (Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa)
Sergio Serrano-Villar (Hospital Universitario Ramón y Cajal, Spain)

Download Program (PDF)

PD05.01	Bacterial Vaginosis Is Associated With Elevated Genital Inflammation and Cellular Activation in Young African Women at High Risk for HIV infection Smritee Dabee (University of Cape Town, South Africa)	16:45 - 16:54
PD05.02	Immunoregulatory Properties of Clinical Lactobacillus Isolates From South African Women at High Risk of HIV Acquisition Monalisa T. Manhanzva (University of Cape Town, Institute of Infectious Diseases and Molecular Medicine (IDM), South Africa)	16:54 - 17:03
PD05.03	Chlamydia Infection Skews Mucosal CD4+ T-helper Subsets in the Genital Tract of HIV-uninfected At-risk Women Seth Bloom (Massachusetts General Hospital, United States)	17:03 - 17:12
PD05.04	Exosomal Proteomics Offers a Biological Basis for Increased Susceptibility to HIV in Trichomonas Vaginalis Infection Yashini Govender (Brigham & Women's Hospital, Harvard Medical School, United States)	17:12 - 17:21
PD05.05LB	Human Gut Microbiota Are Associated With HIV-reactive Immunoglobulin at Baseline and Following HIV Vaccination James Kublin (Fred Hutchinson Cancer Research Center, United States)	17:21 - 17:30

Poster
17:30 - 19:30

Poster Hall

P01 Antibody Functions (Neutralizing and Non-neutralizing)

P01.03	Prevalence of Broadly Neutralizing Antibody Responses in HIV-1-infected Injecting Drug Users Marit van Gils (Amsterdam AMC, University of Amsterdam, Netherlands)	
P01.05	Elicitation of Moderate Neutralization Response Associated With Polyclonal Antibodies Among HIV-1 Subtype C Infected Individuals From Southern India Paneerselvam Nandagopal (YRG Center for AIDS Research and Education, India)	
P01.07	Germline-targeting and Reverse Engineering to Elicit CH235.12 Lineage bNAbs Shay Behrens (Duke University Medical Center, United States)	
P01.09	Association of Circulatory Tfh-like Cells With Neutralizing Antibody Responses Among Chronic HIV-1 Subtype C Infected LTNP and Progressors Chinnambedu Ravichandran Swathirajan (Y.R. Gaitonde Centre for AIDS Research and Education, India)	
P01.11	Immune Responses in HIV-1 Cross-infection and Epidemiologically Linked Superinfection Ralf Duerr (New York University - School of Medicine, United States)	
P01.13	Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA With or Without CN54rgp140/GLA-AF in Healthy Tanzanian and Mozambican Volunteers Frank Msafiri (Muhimbili University of Health and Allied Sciences, Tanzania, United Republic of)	
P01.15	HIV Infection Leads to the Development of Neutralization-interfering Antibodies that Hamper the Function of Neutralizing Antibodies Maria Luisa Rodriguez de la Concepción (IrsiCaixa AIDS Research Institute, Spain)	
P01.17	HIV-1 Subtype G Variants Have Similar Sensitivity to Broadly Neutralizing Monoclonal Antibodies, but Sensitivity to Inhibitors of Viral Entry Varies Essomba René Ghislain (Catholic University of Central Africa, Cameroon)	

Download Program (PDF)

- P01.19 Monitoring the Sensitivity to Broadly Neutralizing Antibodies of Early (T/F) HIV-1 Variants of Clade CRF02_AG**
Karl Stefic (Université de Tours, France)
- P01.21 Inhibition of Robust Antibody-dependent Cellular Cytotoxicity in Elite Controllers by Elevated HIV-1 Specific gp120 Antibodies**
Ntando G. Phaahla (National Institute for Communicable Diseases of the National Health Laboratory Service, Center for HIV and STIs, South Africa)
- P01.23 A Novel Anti-CD4-binding Site Broadly Neutralizing Monoclonal Single Chain Variable Fragment (scFv) From HIV-1 Clade-C Chronically Infected Children**
Sanjeev Kumar (All India Institute of Medical Sciences (AIIMS), India)
- P01.25 Recognition and Elimination of HIV-1-infected Cells by ADCC-mediating mAbs for Prevention and Treatment of HIV-1 Infection**
Marina Tuyishime (Duke University Medical Center, United States)
- P01.27 Prolonged Intervals Between Boosts Induces High Magnitude Transient V2-specific Functional Antibodies That Inhibit the Binding of V2 to $\alpha 4\beta 7$ Integrin**
Kristina Peachman (U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States)
- P01.29 Divergent Members of a HIV-1 Broadly Neutralizing Antibody Lineage That Share a Common Mode of Recognition Within the N332-glycan Supersite**
Dale Kitchin (National Institute for Communicable Diseases of the National Health Laboratory Service, Center for HIV and STIs, South Africa)
- P01.31 Bridging Vaccine-induced Antibody Responses in Rabbit and Rhesus Macaque Animal Models**
Justin Pollara (Duke University School of Medicine, United States)
- P01.33 HIV-1 Env Trimers Eliciting Antibody With Neutralising and Cellular-dependent Functions in Vaccinated Cows**
Damian Purcell (Doherty Institute, University of Melbourne, Australia)
- P01.37LB A Newly Developed B Cell Immunoglobulin Phenotyping Panel to Facilitate More Efficient HIV-1 Antibody Discovery**
Rosemarie Mason (Vaccine Research Center, NIAID, NIH, United States)

Poster
17:30 - 19:30

Poster Hall

P02 Antiretroviral Resistance and Impact on Prevention

- P02.01 HIV-positive Sex Workers' Economic Empowerment to Achieve 90-90-90**
Simon Mwangi (Bar Hostess Empowerment and Support Program, Kenya)
- P02.03 Ultra-deep Sequencing for HIV-1 Minority Drug Resistance Testing Has a Limited Impact on Virological Outcomes**
Bin Su (Beijing You'an Hospital, Capital Medical University, China)
- P02.05 Machine Learning-based Classifier Predicts Clinical HIV-1 Isolate Neutralization Susceptibility to Neutralizing Antibodies With High Accuracy**
Chen-Hsiang Shen (Vaccine Research Center, NIAID, NIH, United States)

Download Program (PDF)

Poster
17:30 - 19:30

Poster Hall

P04 Cellular Immunity

- P04.01 Genetic Variation in CD101 Alters Immune Signatures and Risk of HIV Acquisition**
Jairam Lingappa (University of Washington, United States)
- P04.03 Efficacy of Novel Broadly Bispecific CAR-T Against HIV-1 Infection in Humanized Mice**
Xilin Wu (Nanjing University, China)
- P04.05 Anatomic Site of Origin Affects the Immune-cell Composition of Bone Marrow in Rhesus Macaques**
Thomas Musich (AFRIMS, Thailand)
- P04.07 Broad Recognition of Circulating HIV-1 by HIV-1-specific CTLs With Strong Ability to Suppress HIV-1 Replication**
Nozomi Kuse (Kumamoto University, Japan)
- P04.09 Control of HIV-1 by CD8+ T Cells Specific for Epitopes of Conserved Mosaic Vaccine Immunogens**
Hayato Murakoshi (Center for AIDS Research, Kumamoto University, Japan)
- P04.11 Identification of HIV-1 Epitopes Presented by the Protective HLA-C*12:02 Allele Using Mass Spectrometry Analysis of Single-allele Transfectants**
Takayuki Chikata (Kumamoto University, Japan)
- P04.13 Vaccine-encoded Adapted Epitopes Infrequently Induce CD8 T Cell Responses**
Sushma Boppana (University of Alabama at Birmingham, United States)
- P04.15 Evaluating the Role of Early HIV-1 Specific T-follicular Helper and B Cells on the Subsequent Antibody Function in HIV-1 Infection**
Ian Oyaro (KEMRI-Wellcome Trust Research Programme, Kenya)
- P04.17 Correlating HIV RNA Levels, Viral Replicative Capacity and Immune Control Within an Assay to Measure CD8 T Cell Mediated HIV-1 Inhibition In Vitro**
Catherine Kibirige (Imperial College London, United Kingdom)
- P04.19 Low HIV-specific CD8+ T-cell Cytotoxic Capacity in Ad5/HIV Vaccinees Is Associated With Impaired Degranulation of Functionally Intact Lytic Proteins**
Stephen Migueles (National Institutes of Health, United States)

Poster
17:30 - 19:30

Poster Hall

P03 Behavioral and Social Science Research

- P03.01 Concordance in Reporting of Sexual Risk Behaviors in the HIV Sero Discordant Couples From Central Region, Uganda**
Charles Brown (Makerere University, Infectious Diseases Institute, Uganda)
- P03.03 Behavioral and Social Science Research Supporting Clinical Trials With Broadly Neutralizing Antibodies Against HIV**
Yumeng Wu (The Rockefeller University, United States)

Download Program (PDF)

- P03.05 Integrating Syndemic and Resiliency Approaches to Assessing YMSM's Engagement in Transactional Sex**
Steven Meanley (University of Pennsylvania School of Nursing, United States)
- P03.07 Psychological and Behavioural Within-participant Predictors of Adherence to Oral HIV Pre-exposure Prophylaxis (PrEP)**
Nneka Nwokolo (Chelsea & Westminster Hospital, United Kingdom)
- P03.09 Perceptions of PrEP and HIV Risk in Adolescent Girls and Young Women Declining PrEP Uptake From a Community Mobile Clinic in Cape Town, South Africa**
Elzette Rousseau-Jemwa (Desmond Tutu HIV Foundation, South Africa)
- P03.11 Site Approaches to Working With Participant Concerns Regarding Hair Collection: Kampala Site Experience With Women in MTN025/HOPE**
Joselyne Nabisere (Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Uganda)
- P03.13 Does the Use of the Dapivirine Vaginal Ring Result in Change in Risk Sexual Behavior?**
Sylvia Kusemererwa (MRC/UVRI Uganda Research Unit on AIDS, Uganda)
- P03.15 Intimate Partner Violence and Engagement in the HIV Care Continuum Among Women in sub-Saharan Africa: A Prospective Cohort Study**
Sarah T. Roberts (RTI International, United States)
- P03.17 Knowledge and Awareness of Acute HIV Infection Among Patients of Primary Care Clinics in High HIV Prevalence Neighborhoods of New York City**
Javier Lopez-Rios (HIV Center for Clinical and Behavioral Studies, United States)
- P03.19 HIV Risk and PrEP Beliefs Among Young Kenyan Women**
Maria Pyra (University of Washington, United States)
- P03.21 Risk Perceptions Before and After Initiating PrEP Among Young Women in Kenya: A Qualitative Study**
Kenneth Ngure (School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Kenya)
- P03.23 Focusing on the Positive to Stay Negative: Oral Pre-exposure Prophylaxis (PrEP) Uptake, HIV Risk and Vulnerability Among South African Young Women**
Shannon O'Rourke (RTI International, United States)
- P03.25 Factors Influencing Antiretroviral Therapy Adherence: Voices of Adolescents in Kenya**
Millicent Kiruki (LVCT Health, Kenya)
- P03.27 Formative Research to Inform Development of PrEP Services for Chinese MSM**
Kathrine Meyers (Aaron Diamond AIDS Research Center, United States)
- P03.29 HIV Seroadaptation Increased Over Time in iPrEX OLE**
Hong-Ha M. Truong (University of California, San Francisco, United States)
- P03.31 Acceptability and Uptake of Oral Pre-exposure Prophylaxis Amongst MSM in the TRANSFORM Study, Johannesburg**
Siyanda Tenza (Wits Reproductive Health and HIV Institute, South Africa)
- P03.33 How Well Does the Bandason HIV Risk Screening Tool Perform in the Nigerian Setting? Findings From a Large-scale Field Implementation**
Kunle Kakanfo (Family Health International (FHI 360, Nigeria), Nigeria)

Download Program (PDF)

- P03.35 Participant Adherence Events: Uptake, Outcomes and Modification in a South African HIV Prevention Trial**
Thando Gwetu (MatCH Research Unit, South Africa)
- P03.37 Integrating Clinical Trial Participants From a Discontinued Research Center in South Africa: Start-up Activities**
Thando Gwetu (MatCH Research Unit, South Africa)
- P03.39 Challenges Faced by Pregnant and Postnatal Adolescents in Uganda Affecting Uptake of HIV/STI Prevention Services: Observations From the HI-4-TU Study**
Miscah Babirye Otim (MUJHU Research Collaboration / MUJHU Care Ltd, Uganda)
- P03.41 Interactions Between Young Female Sex Workers and Paying and Nonpaying Sexual Partners in Western Kenya: Implications for HIV Prevention Interventions**
Kawango Agot (Impact Research & Development Organization, Kenya)
- P03.43 “Stigma Is Killing so Many People”: Barriers to HIV Testing Among HIV-negative Adolescent Girls and Young Women Around Lake Victoria in Western Kenya**
Joanne E. Mantell (ICAP at Columbia University, United States)
- P03.45 Factors Associated With Interest in Using PrEP Among Men Who Have Sex With Men (MSM) Respondents to the Community-based Survey Flash! PrEP in Europe**
Daniela Rojas Castro (Coalition PLUS, Community-based Research Laboratory, France)
- P03.47 Using Photovoice to Understand the Experience and Realities of Female Sex Workers in the Context of HIV Self-testing in Blantyre, Malawi**
Wezzie Lora (Malawi Liverpool Wellcome Trust-Clinical Research Program, Malawi)
- P03.49 The Ice Has Been Broken: PrEP Readiness Among Men Who Have Sex With Men (MSM) in Ukraine**
Iana Sazonova (ICF “Alliance for Public Health”, Ukraine)
- P03.51 “You Get HIV Because There is No Hope:” Qualitative Assessment of Transgender Women’s HIV Vulnerabilities in Three South African Cities**
Allanise Cloete (Human Sciences Research Council, South Africa)
- P03.53 Acceptability and Feasibility of CHARISMA: Results of a Pilot Study Addressing Relationship Dynamics, Intimate Partner Violence and Microbicide Use**
Elizabeth Montgomery (RTI International, United States)
- P03.55 HIV Testing Patterns, Acceptability and Barriers to Use of Oral Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex With Men (MSM) in Nairobi, Kenya**
Rodah Wanjiru (Partners for Health and Development, Kenya)
- P03.57 Impact of Childhood Sexual Abuse Among Sub-Saharan African Men who Have Sex with Men and Transgender Women in HPTN 075**
Yamikani Mbilizi (College of Medicine Johns Hopkins Research Project, Malawi)
- P03.59LB The Positive and Negative Impact of PrEP Use on the Sexual Well-being of Men Who Have Sex With Men (MSM) - Qualitative Results**
Hanne Zimmermann (Public Health Service of Amsterdam, Netherlands)
- P03.63LB Preventing Intimate Partner Violence Among Women in Mwanza, Tanzania: Findings from the MAISHA Trial and Implications for HIV Prevention**
Shelley Lees (LSHTM, United Kingdom)

Download Program (PDF)

- P03.65LB CashPlus: Adolescent Health, Livelihood and Well-being Intervention as Part of Tanzania's Productive Social Safety Network**
Lusajo Kajula (UNICEF Office of Research-Innocenti, Tanzania, United Republic of)

Poster
17:30 - 19:30

Poster Hall

P06 Community Engagement in Prevention Research

- P06.01 Attitudes of Church Leaders on HIV Prevention in Mizoram, Northeast India - a Limited-resource Setting**
Lalchhanhima Ralte (Grace Home, Synod Hospital Durtlang, India)
- P06.03 Adjusted Criteria for POC HIV-RNA Testing Improved Detection of Acute HIV Infections**
Michael Meulbroek (BCN Checkpoint, Spain)
- P06.05 High Study Retention and on Time Visit Attendance in a Simulated HIV Vaccine Efficacy Trial in High-risk Single Zambian Women**
Amanda Tichacek (Emory University, United States)
- P06.07 Benefits of Prescreening Workshops on Participants' Understanding of CHOICE, ADHERENCE and OPEN REPORTING in MTN-025 Study: Kampala Site Experience**
Doreen Kemigisha (MU-JHU Research Collaboration/MU-JHU Care Ltd, Uganda)
- P06.09 Need for a Multi-purpose Dapivirine Vaginal Ring to Address Sexual and Reproductive Health Challenges: Lessons Learnt from South Western Uganda**
Sylvia Kusemererwa (MRC/UVRI Uganda Research Unit on AIDS, Uganda)
- P06.11 Stakeholder Engagement During a Vaccine Demonstration Project in Nigeria: Lessons on Implementation of the Good Participatory Practice Guidelines**
Morenike Ukpog-Folayan (Obafemi Awolowo University, Nigeria)
- P06.13 Motivators for Participation in an Open Label Extension Microbicide Trial in South Western Uganda**
Sylvia Kusemererwa (MRC/UVRI Uganda Research Unit on AIDS, Uganda)
- P06.15 Voice and Visibility: What Communities Wish Researchers Knew!**
Tian Johnson (Vaccine Advocacy Resource Group, South Africa)
- P06.17 Effective Interventions at Community Level Positively Impact Study Retention and Product Adherence**
Petina Musara (UZCHS-CTRC, Zimbabwe)
- P06.19 Impact of Good Participatory Practices in Engaging Mobile Fishing Communities in Vaccine Trials in Entebbe, Uganda**
Gertrude Nanyonjo (UVRI-IAVI HIV Vaccine Program, Uganda)
- P06.21 Community Engagement in HIV Biomedical Prevention Research: Use of Mobile Technologies and the Asset Based Community Development Approach**
Ethel Makila (IAVI-Nairobi, Kenya)
- P06.23 Meaningful Engagement of Religious Leaders in Promoting Uptake of HIV Prevention, Counselling, Testing and Treatment Services in Kenya**
Dismas Oketch (Kenya Medical Research Institute, Kenya)

Download Program (PDF)

- P06.25 Examining the Relationship Between Multiple Sexual Partners and Adherence to the Dapivirine Vaginal Ring in a Trial in South Western Uganda**
Sylvia Kusemererwa (MRC/UVRI Uganda Research Unit on AIDS, Uganda)
- P06.27 Community-led Structural Intervention to Address Multidimensional Vulnerabilities Among Female Sex Workers in India**
Bidhubhusan Mahapatra (Population Council, India)
- P06.29LB Good Participatory Practice (GPP) Online Training Course: Evaluations and Progress Over Four Years**
Anne Schley (AVAC: Global Advocacy for HIV Prevention, United States)

Poster
17:30 - 19:30

Poster Hall

P07 Contraception, Pregnancy and HIV Prevention

- P07.01 Cost-effectiveness of Integrated HIV Prevention and Family Planning Services for Zambian Couples**
Alexandra Hoagland (Zambia Emory HIV Research Project (ZEHRP), Zambia)
- P07.03 The Effect of Depot Medroxyprogesterone Acetate on Stress Hormone Level: Impact on the Mucosal Immune Response**
Julie Lajoie (University of Manitoba, Canada)
- P07.05 HIV-1 Infection Is Modulated by Relative Levels and Cross-talk Between the Progesterone Receptor and the Glucocorticoid Receptor**
Kim Enfield (University of Cape Town, South Africa)
- P07.07 Differential Biocharacter and Effects on HIV-1 Infection of Synthetic Progestins via the Glucocorticoid Receptor Ex Vivo**
Maleshigo Komane (University of Cape Town, South Africa)
- P07.09 Contraception Use and Pregnancy Incidence in Young African Women Using PrEP**
Murugi Micheni (Kenya Medical Research Institute, Kenya)
- P07.11 Uptake and Use of Reliable Contraceptives and Correlates of Use in Women Participating in HIV Efficacy Preparatory Trials in Key Populations in Uganda**
Andrew Abaasa (MRC/UVRI, Uganda Research Unit on AIDS, Uganda)
- P07.13 Pregnancy Incidence and Outcomes Among Women Using Dapivirine Vaginal Ring for HIV Prevention in a Phase III Clinical Trial in South Western Uganda**
Sylvia Kusemererwa (MRC/UVRI Uganda Research Unit on AIDS, Uganda)
- P07.15 Voluntary Medical Male Circumcision Uptake Among M-F+ HIV Serodiscordant Couples**
Hanzunga Halumamba (Zambia Emory HIV Research Project, Zambia)
- P07.17 TDF/FTC Electrospun Nanofibers for Topical Prevention of HIV Transmission**
Sarah Bogas (Centro de Física das Universidades do Minho e Porto (CF-UM-UP), Departamento de Física, Universidade do Minho, Portugal)
- P07.19 Maternal and Infant Outcomes of the World Health Organization Option B+ Strategy Implementation in the Eastern Cape, South Africa**
Oladele Vincent Adeniyi (Walter Sisulu University, South Africa)

Download Program (PDF)

- P07.21 Acceptance of HIV Self-tests for Male Partners Among Pregnant and Postpartum Women in Maternal Child Health (MCH) Clinics in Kenya**
Jillian Pintye (University of Washington, United States)

Poster
17:30 - 19:30

Poster Hall

P15 Innate Immunity

- P15.01 Immunosuppressive Factors Within Seminal Plasma Muzzle Anti-HIV-1 Immune Responses of Granulocytes and Monocytes**
Kevin John Selva (Peter Doherty Institute for Infection and Immunity, Australia)
- P15.03 FREM1 Modulates Pro-inflammatory Responses During Vaginal HIV/SIV Infection via Association With TLR4**
Robert Were Omange (University of Manitoba, Canada)

Poster
17:30 - 19:30

Poster Hall

P09 Delivery Technologies: Novel Approaches, Formulation and Multi-purpose

- P09.01 Exploring the Use of Nano-particulate Zera®-induced HIV-1 Env "Protein Bodies" as Vaccines**
Phindile Ximba (Division of Medical Virology, Department of Pathology, University of Cape Town, South Africa)
- P09.03 Lipid-based Nanocarriers for Antiretroviral Drug Delivery: an HIV Topical Prevention Strategy**
Maria Faria (Centro de Física das Universidades do Minho e Porto (CF-UM-UP), Departamento de Física, Universidade do Minho, Portugal)
- P09.05 Impact of Intermittent Use on In Vitro Release and Residual Content of 25 mg Dapivirine Rings**
Clare F. McCoy (Queen's University Belfast, United Kingdom)
- P09.07 Impact of Particle Size and Release Testing Media on Release of Dapivirine From a Silicone Elastomer Vaginal Ring**
Diarmaid Murphy (School of Pharmacy, Queen's University Belfast, United Kingdom)
- P09.09 Embracing Medidata Rave in the 21st Century: Tips for Successful Implementation**
Justine Nakyeeyune (Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Uganda)
- P09.11 Vectorization of Vaccinal mRNA Encoding HIV Antigen Using Biodegradable Poly (Lactic Acid) Nanoparticles Targeting Dendritic Cells**
Anne-Line Coolen (LBTI, UMR 5305, CNRS/UCBL, France)
- P09.13 Formulation Development of a Commingled Dapivirine-DS003 Intravaginal Ring for the Concurrent Delivery of Two Microbicides**
Wendy Blanda (International Partnership for Microbicides, United States)

Download Program (PDF)

- P09.15 Compatibility Screening for Excipients for Delivery of Dapivirine and DS003 Concurrently From an Intravaginal Ring**
Wendy Blanda (International Partnership for Microbicides, United States)
- P09.17 The Potential of Saquinavir-loaded Nanoparticles for Rectal Microbicide Development**
Avelino Ferreira (i3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal, Portugal)
- P09.19 Density Mediated Drug Release From Dapivirine Vaginal Rings Produced by Additive Manufacturing**
Nicole Welsh (Queen's University Belfast, United Kingdom)
- P09.23 End-user Opinions About the Future of HIV Prevention: Results From a Global Internet Survey About Multipurpose Prevention Technologies (MPTs)**
Marlena Plagianos (Population Council, United States)

Poster
17:30 - 19:30

Poster Hall

P10 Discovery and Evaluation of Biomedical Agents

- P10.01 Synthesis of a FITC Conjugated Anti-gp120 Aptamer That Can Be Used as a Reagent for the Detection of HIV-1 by Flow Cytometry**
Kanyane Bridgett Malatji (University of the Witwatersrand, Faculty of Health Sciences, South Africa)

Poster
17:30 - 19:30

Poster Hall

P11 Epidemiology of HIV

- P11.01 Risk Factors for HIV-1 Acquisition Among 18-21 Year Old South African Women Participating in an HIV Prevention Trial**
Jennifer Balkus (University of Washington, United States)
- P11.03 What Proportion of Female Sex Workers Practice Anal Intercourse and How Frequently? A Systematic Review and Meta-analysis**
Branwen Nia Owen (Imperial College London, United Kingdom)
- P11.05 HIV-1 Recombinant Viruses From West Africa Display Higher Replication Capacity Compared to Recombinants From East Africa**
Omotayo Farinre (HIV Pathogenesis Programme, Nelson Mandela School of Medicine, University of KwaZulu-Natal, South Africa)
- P11.07 Significant Reduction in HIV Prevalence Among Men Who Have Sex With Men. Possible Effect of Antiretroviral Treatment?**
Lucia Guzman (Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, UBA-CONICET, Argentina)
- P11.09 Factors Associated With Being a First-time HIV Tester Among Clients of Voluntary Counselling and Testing Centers in Kilifi County, Kenya, 2006-2017**
Peter Mugo (Kemri-Wellcome Trust Research Programme, Kenya)
- P11.11 HIV Sero-positivity and Associated Risky Sexual Behaviour Among Male Regular Partners of Female Sex Workers in a Peri-urban Clinic in Kampala, Uganda**
Gertrude Namale (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)

Download Program (PDF)

- P11.13 Hepatitis B and C Prevalence Among Female Sex Workers in Kigali, Rwanda.**
Julien Nyombayire Mutagisha (Projet San Francisco, Rwanda Zambia HIV Research Group, Emory University, Rwanda)
- P11.15 Role of Food Security and Disability on HIV Risk Among Caregivers of Orphaned and Vulnerable Children in Tanzania**
Amon Exavery (Pact/Tanzania, Tanzania, United Republic of)
- P11.17 High Chlamydia and Gonorrhea Prevalences and Low Performance of Syndromic Management Among Brazilian Transwomen**
Carolina Caracas (Federal University of the State of Rio de Janeiro, Brazil)
- P11.19 APOBEC3G/3H Polymorphism Does Not Influence Progression to AIDS in a Mexican Population**
Francisco Lopez Marquez (University Autonomous of Coahuila, Mexico)
- P11.21 Prevention and Treatment: Key Groups and Key Areas in EECA Region**
Tetiana Saliuk (Alliance for Public Health, Ukraine)
- P11.23 Knowledge and Use of HIV Prevention Strategies for Transwomen (TW) in São Paulo, Brazil**
Aline Borges Moreira da Rocha (Santa Casa de São Paulo Medical School, Brazil)

Poster
17:30 - 19:30

Poster Hall

P12 Ethics in HIV Prevention Research

- P12.01 Vaccine Education Session for an Upcoming HIV Vaccine Trial: An Ethical Addition to the Informed Consent Process**
Ana-Maria Visoiu (Zambia Emory HIV Research Project, Rwanda Zambia HIV Research Group, Emory University, Zambia)
- P12.03 Engaging Minors in Nationwide At-home HIV Prevention Research in the U.S.: The UNITE Cohort Study Challenges and Implications for Future Directions**
H. Jonathon Rendina (Hunter College of the City University of New York, United States)

Poster
17:30 - 19:30

Poster Hall

P13 Immunogenetics (Host Immunity and Restriction Factors)

- P13.03 The Generation and Validation of Autologous CD8 and CD4 T Cell Lines for Use as Assay Controls in HIV Viral Inhibition Assays**
Natalia Fernandez (Imperial College London, United Kingdom)
- P13.05 CCR5 Expression-related Gene Variants and Natural HIV-1 Control in Black South Africans**
Gemma Whitney Koor (University of the Witwatersrand, Faculty of Health Sciences, South Africa)
- P13.07 KIR3DL1-/Bw4 CD8 T Cells and NK Cell Activation Control HIV-1 Infection**
Bin Su (Beijing You'an Hospital, Capital Medical University, China)
- P13.09 SERINC Expression Varies Significantly Within CD4 T Cells and Monocytes Among Healthy Adults**
Syna K Gift (U.S. Military HIV Research Program, United States)

Download Program (PDF)

P13.11LB Subtype Differences in Nef-mediated SERINC3/5 Antagonism Across Viral Subtypes Modulates HIV-1 Infectivity

Steven W. Jin (Simon Fraser University, Canada)

Poster
17:30 - 19:30

Poster Hall

P16 Mathematical Modeling: Impact and Effectiveness

P16.01 Understanding HIV Transmission Dynamics and the Impact of Past HIV Interventions Among MSM in Baltimore: A Modelling Study for HPTN 078

Romain Silhol (Imperial College London, United Kingdom)

P16.03 Modeling the Impact of Biomedical Interventions to Break the Cycle of HIV Transmission

Katharine Kripke (Avenir Health, Project SOAR, United States)

P16.05 Modulating Effects of Revaccination Rates and Immune Refractoriness on the Projected Impact of Future HIV Vaccination in South Africa

Simon de Montigny (University of Montreal, Canada)

P16.07 Deducing Mucosal Pharmacokinetics and Pharmacodynamics for Anti-HIV Molecules From Measurements in Blood

Sachin Govil (Duke University, United States)

P16.09 Evaluating the Potential Impact and Cost-effectiveness of Dapivirine Ring Pre-exposure Prophylaxis for HIV Prevention

Katharine Kripke (Avenir Health, Project SOAR, United States)

P16.11 Pooling Strategies as a Cost-effective Solution to Acute HIV-1 Infection Detection in High Risk, Seronegative Individuals in Lusaka and Ndola, Zambia

Etienne Karita (Project San Francisco, Rwanda)

P16.13 Modeling Probability of Infection and Its Alteration by Microbicides by Integrating HIV Transport and Infection Dynamics With Drug Transport & Action

Daniel Adrianzen (Duke University, United States)

P16.15 Measles, Mumps and Rubella Vaccination to Reduce the Risk of Measles During HIV Vaccine Trials

Susan Allen (Rwanda Zambia HIV Research Group-Emory University, United States)

Poster
17:30 - 19:30

Poster Hall

P17 Microbiome & STI: Impact on Prevention

P17.01 High Level of Macrolide Resistance of Mycoplasma Genitalium Found Among MSM at High Risk for HIV in a Belgian PrEP Demonstration Project

Irith De Baetselier (Institute of Tropical Medicine, Belgium)

P17.03 Lymphogranuloma Venereum Among MSM Using PrEP in Belgium. Time to Test!

Irith De Baetselier (Institute of Tropical Medicine, Belgium)

Download Program (PDF)

- P17.05 Preparation of Chlamydia Trachomatis Antigens to Evaluate Inflammatory Responses and Correlates of Protection That May Influence HIV Risk in Women**
Rubina Bunjun (University of Cape Town, South Africa)
- P17.07 Development of an In Vivo Model to Study the Impact of the Microbiota on Sexually Transmitted Infection Control and Immune Responses**
Cindy Adapen (CEA-Université Paris Sud-Inserm U1184, Immunology of viral infections and autoimmune diseases/IDMIT Department/DRF/IBFJ, France)
- P17.09 Persistent Increase in the Incidence of STIs and Hepatitis C in MSM in Madrid**
Oskar Ayerdi (Centro Sanitario Sandoval, IdISSC, Spain)
- P17.11 Pathogen Inhibitory Properties of Vaginal Lactobacillus Isolates From South African Women at High Risk of HIV Infection**
Andrea Gillian Abrahams (Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town, South Africa)
- P17.13 Alterations in Key Vaginal Bacteria Among Women Initiating DMPA**
Bridget M. Whitney (University of Washington, United States)
- P17.15 Hepatitis C Seroconversions in a Sexually Transmitted Infections Clinic in Madrid**
Oskar Ayerdi (Centro Sanitario Sandoval, IdISSC, Spain)
- P17.17 An Algorithm to Reduce Cost of Chlamydia, Gonorrhea and Trichomoniasis Diagnosis in Lusaka and Ndola, Zambia: Pooled Testing Using GeneXpert**
Constance Himukumbwa (Zambia Emory HIV Research Project, Zambia)
- P17.19 BV-associated Bacteria Cause Molecular and Physiological Dysfunction of the Vaginal Epithelium**
Alicia Berard (University of Manitoba, Canada)

Poster
17:30 - 19:30

Poster Hall

P18 Mucosal Immunology

- P18.01 Pre-exposure Prophylaxis Differentially Alters Circulating and Mucosal Immune Cell Activation in HSV-2 Seropositive Women**
Jennifer Lund (Fred Hutchinson Cancer Research Center, United States)
- P18.03 The Rectal Mucosal Transcriptome of Transgender Women on Cross-sex Hormone Therapy Is Distinct From Cisgender Men**
Colleen Kelley (Emory University School of Medicine, United States)
- P18.05 HIV-1 Specific Mucosal IgA Antibodies Detected in Highly Exposed but Persistently IgG Seronegative (HEPS) Individuals From Southern India**
Kailapuri.G. Murugavel (YRG Centre for AIDS Research and Education, India)
- P18.07 Identification of HIV-1 Clade C Transmitted Founder Viruses that Replicate Efficiently in Human Rectal and Vaginal Tissue Explant Cultures**
Robert Langat (IAVI Human Immunology, Imperial College London, United Kingdom)
- P18.09 C. trachomatis Infection Results in Elevated HIV Target Cell Densities and Differential Chemokine Expression Between the Inner and Outer Foreskin**
Kyle L. O'Hagan (University of Cape Town, South Africa)

Download Program (PDF)

- P18.11 Vaccination with ALVAC-HIV/AIDS VAX (R) B/E of Non-human Primates (NHPs) Elicits Distinct Mucosal and Systemic Responses**
Carolina Herrera (Imperial College London, United Kingdom)
- P18.13 A Regional Mucosal Immunology Approach to Measuring HIV Susceptibility at Barrier Tissue Sites**
Alison Swaims-Kohlmeier (CDC, United States)
- P18.15 MAdCAM Signals Through Integrin- α ₄ β ₇ Inducing Cellular Activation and HIV Replication**
Livia Ramos Goes (National Institutes of Health, National Institute of Allergy and Infectious Diseases, United States)
- P18.17 Collection of Secreted IgG in Rectal Secretions Using OriCol Devices**
Julie Czartoski (Fred Hutchinson Cancer Research Center, United States)
- P18.19 The Effect of DMPA Use on the Human Cervical Epithelium - Mechanisms Revealed by Image Analysis**
Gabriella Edfeldt (Karolinska Institute, Sweden)
- P18.21LB Association of Persistent HPV Infection With Immune Activation in the Anorectal Mucosa**
Yoojin Choi (University of Toronto, Canada)

Poster
17:30 - 19:30

Poster Hall

P19 Novel Vaccine and Prevention Approaches

- P19.01 Immune Responses Induced by Live-attenuated Zoster Vaccine in Healthy Kenyan Women: Setting the Stage for a Potential VZV-based HIV Vaccine**
Kelly MacDonald (University of Manitoba, Canada)
- P19.03 Efficient Induction of T-cell Responses Against Conserved HIV-1 Regions by Mosaic Vaccines Delivered as Self-amplifying mRNA**
Nathifa Moyo (University of Oxford, United Kingdom)
- P19.05 Construction and Characterization of Recombinant MTBVAC.HIV, a New Live Attenuated Vaccine Against HIV and Tuberculosis**
Narcís Saubi (Hospital Clinic de Barcelona-IDIBAPS, Spain)
- P19.07 Use of Encapsulated TLR7 Ligand for Increasing Germinal Centers and Enhancing HIV Humoral Responses**
Capucine Phelip (Institut de Biologie et Chimie des Protéines, LBTI, UMR 5305 CNRS/Université de Lyon, France)
- P19.09 Broadly Neutralizing Nanobodies From Env-immunized Dromedaries for Prophylactic Lactobacillus-based Approaches Against HIV-1**
Sarah Kalusche (Georg-Speyer-Haus, Germany)
- P19.11 Schistosoma mansoni Eggs in the Absence of Live Worms Suppresses Induction of HIV-1 Env-specific Antibody Responses**
Godfrey Dzhivhuho (University of Cape Town, South Africa)

Download Program (PDF)

- P19.13 DNA and MVA Vaccines Expressing HIV-1 Virus-like Particles Presenting Modified HIV-1 Env Generate Tier 2 Autologous Neutralising Antibodies**
Michiel T. van Diepen (University of Cape Town, Institute of Infectious Disease and Molecular Medicine, South Africa)
- P19.15 Cervicovaginal Inflammatory Cytokine and Chemokine Responses to Two Different SIV Vaccines in Mauritian Cynomolgus Macaques**
Nikki P. L. Toledo (University of Manitoba, Canada)
- P19.17 Novel Trimeric HIV-1 Clade C Envelope Vaccine Candidates Exhibit Increased Stability and Optimal Antigenic Properties In Vitro and In Vivo**
Alexandra Hauser (University of Regensburg, Institute of Medical Microbiology and Hygiene, Germany)
- P19.19 A Novel Immunogen Selectively Eliciting CD8+ T Cells but Not CD4+ T Cells Targeting Viral Antigens**
Tetsuro Matano (National Institute of Infectious Diseases, Japan)
- P19.21 A Clade C Env Obtained From an Elite Neutralizer Induced Potent Autologous Neutralizing Antibodies Similar to that Elicited in Natural Infection**
Rajesh Kumar (Translational Health Science and Technology Institute, India)
- P19.23 In Vitro Evaluation of Self-amplifying Alphavirus Replicons Delivered as DNA or RNA Expressing HIVgp140 as Potential RNA Based Vaccine Candidates**
Manel Enric Bargallo Mares (AIDS Research Unit, IDIBAPS, Spain)
- P19.25 HIV Neutralizing Antibodies Induced by Native-like Envelope Trimers Incorporated Into a Rhabdoviral Vector Vaccine**
Janine Kimpel (Medical University of Innsbruck, Austria)
- P19.27 Mumps and PIV5 Pseudotyped Virus-like Particles for HIV-1 Env Trimer Display**
Yoann Aldon (Imperial College London, United Kingdom)
- P19.29 Novel gp41 W614A-3S Peptide-conjugated Adjuvanted Vaccine Promote T Follicular Helper Cells for Broadly Neutralizing Antibodies Against HIV-1**
Behazine Combadière (CIMI-Paris, France)
- P19.31 Cross-reactivity Between HIV-1 bNAbs and Parasite Glycans**
Isabella Huettnner (King's College London, United Kingdom)
- P19.33 Immunogenicity of HIV-1 gp120 DNA Prime and Env gp145 Protein Boost Vaccine Regimen in Combination With Novel Adjuvants**
Poonam Pegu (U.S. Military HIV Research Program, Henry M. Jackson Foundation for the Advancement of Military Medicine, United States)
- P19.35 A New Envelope Based Antigen Forming Soluble Hexamers Triggers Potent Humoral Responses Against HIV-1**
Suresh Chithathur Raman (Centro Nacional de Biotecnología, Spain)
- P19.37 An Escape Mutation in the V2 Region of the HIV Envelope Protein of a T/F Virus Guides Vaccine Design to Elicit Broadly Reactive V2-directed Antibodies**
Swati Jain (The Catholic University of America, United States)
- P19.39 Sequential Immunization Strategies to Elicit HIV-1 bNAbs in Animal Models With a Polyclonal B Cell Repertoire**
Amelia Escolano (The Rockefeller University, United States)

Download Program (PDF)

- P19.41 Structural Basis for Neutralization of Diverse HIV-1 Strains by Antibodies Elicited From Fusion Peptide Immunizations in Rhesus Macaques**
Yiran Wang (National Institute of Allergy and Infectious Diseases, United States)
- P19.43LB Development and Pre-clinical Immunogenicity of a Formulated saRNA Replicon Vaccine Expressing Designed Native-like ConSOSL.UFO HIV Env Glycoproteins**
Paul F McKay (Imperial College London, United Kingdom)
- P19.45LB Comparison of Monoclonal Antibodies Induced by BG505 SOSIP Trimer Immunization and BG505 SHIV Infection in Non-human Primates**
Jelle van Schooten (Amsterdam University Medical Center, University of Amsterdam, Netherlands)
- P19.47LB Structure and Immunogenicity of a Stabilized HIV-1 Envelope Trimer Based on a Group M Consensus Sequence**
Kwinten Sliepen (Amsterdam UMC, Netherlands)
- P19.49LB Development of a Point of Care Urine Tenofovir Test - A PrEP and ART Adherence Tool**
Giffin Daughtridge (Perelman School of Medicine, United States)
- P19.51LB Sequential Immunization With Different Repaired and Stabilized HIV-1 Envelope Trimers Induces Broad Tier2 Neutralization in Rabbits**
Johannes Langedijk (Janssen Vaccines & Prevention, Netherlands)

Poster
17:30 - 19:30

Poster Hall

P20 Passive Immunization

- P20.01 An Additional Late Boost of AIDSVAX B/E in RV144 Participants Induced Plasma HIV Env-specific IgG4 and IgG1 With Enhanced Durability**
Siriwat Akapirat (Armed Forces Research Institute of Medical Sciences, Thailand)
- P20.03 Limited Impact of Fc-dependent Functions on the Efficacy of the Anti-HIV-1 Broadly Neutralizing Antibody PGT121 in Macaques**
Stephen Kent (University of Melbourne, Australia)
- P20.05LB Rectal Biopsies From Men and Women Infused Intravenously With VRC01 mAb Show Partial Protection That Wanes Over Time in Ex Vivo HIV-1 Challenges**
Maria P. Lemos (Fred Hutchinson Cancer Research Center, United States)

Poster
17:30 - 19:30

Poster Hall

P21 Pharmacology/PK and PD Studies

- P21.01 Tenofovir-diphosphate as a Marker of PrEP Use Among East African Men and Women**
Maria Pyra (University of Washington, United States)
- P21.03 Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir: Increased Tenofovir Diphosphate in Depot Medroxyprogesterone Acetate Users**
Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)
- P21.05 Pharmacokinetics of Dapivirine Vaginal Ring During Ring Removals and Re-insertions**
Neliette Van Niekerk (International Partnership for Microbicides, South Africa)

Download Program (PDF)

Poster
17:30 - 19:30

Poster Hall

P22 Phylogenetics and Viral Diversity

- P22.01 Prediction of VRC01 Neutralization Sensitivity by HIV-1 gp160 Sequence Features**
Craig A. Magaret (Fred Hutchinson Cancer Research Center, United States)
- P22.03 Characterization of HIV-1 Envelope Genes in a Long-term Nonprogressor With Broadly Neutralizing Activity**
Kunxue Hong (National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, China)
- P22.05LB Recent HIV Infection Is a Major Driver of Incident Cluster Growth**
Susan Little (University of California, San Diego, United States)

Poster
17:30 - 19:30

Poster Hall

P23 Policy and Advocacy

- P23.01 Policy Recommendation for First-line DTG-based ART in PrEP Seroconverters**
Lisa Levy (FHI 360, United States)
- P23.03 Engaging Youth to Achieve the 90-90-90 Goal in Uganda Through Community Outreach Programs: A Young Generation Alive (YGA) Innovation**
Stella Nanyonga (Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Uganda)
- P23.05 Reservations About and Opportunities for PrEP Introduction: Perspectives of Policymakers in Tanzania**
Nanlesta Pilgrim (Population Council, United States)
- P23.07LB Tracking the Impact of the Expanded Mexico City Policy on PEPFAR Implementing Partners**
Jennifer Sherwood (amfAR, The Foundation for AIDS Research, United States)

Poster
17:30 - 19:30

Poster Hall

P24 Pre-clinical Studies for HIV Prevention

- P24.01 Comparison of Dissolution Testing Methods for the 25 mg Dapivirine Vaginal Ring**
Karl Malcolm (Queen's University Belfast, United Kingdom)
- P24.03 The CAVD DataSpace Data Sharing and Discovery Tool Facilitates HIV Immunological Data Exploration From Pre-clinical and Clinical HIV Vaccine Studies**
Bryan Mayer (Fred Hutchinson Cancer Research Center, United States)
- P24.05 HIV Env Antibody Can Provide Sterilizing Immunity in the Strictest Sense**
Klaus Überla (Universitätsklinikum Erlangen, Germany)
- P24.07 Efficacy of a Trimeric Envelope Protein Vaccine From an Indian Clade C HIV-1 Isolate Against Heterologous Clade C SHIV Isolate Challenges in Macaques**
Ranajit Pal (Advanced BioScience Laboratories, Inc., United States)

Download Program (PDF)

- P24.09 Vaccine that Targets In Vivo HIV-1 Env to Human CD40-expressing Antigen-presenting Cells Elicits Env-specific IgG+ B Cells and Memory Tfh Cells**
Veronique Godot (Université Paris-Est-Créteil, France)
- P24.11 Reversible Modulation of the Endocannabinoid System as an Anti-HIV-1 Prevention Strategy**
Carolina Herrera (Imperial College London, United Kingdom)
- P24.13 Sheep Genital Outcomes After Use of Chemical Irritants: Positive Control for Toxicity Studies**
Kathleen Vincent (University of Texas Medical Branch, United States)
- P24.15 Heterologous Combination of VSV and NYVAC Vectors Expressing Trimeric HIV Env Elicits Higher T and B Cell Responses Compared With Homologous Regimen**
Beatriz Perdiguerro (Centro Nacional de Biotecnología (CNB-CSIC), Spain)
- P24.17 In Vitro-In Vivo and In Vivo-In Vivo Correlations of TAF Release From a Novel Subdermal Implant**
John Moss (Oak Crest Institute of Science, United States)
- P24.19 Development of an Extended Release MK-2048 Vaginal Film**
Lisa Rohan (University of Pittsburgh, United States)
- P24.21 Post-exposure Prophylaxis with Single Doses of Combination EVG/COBI/FTC/TAF Protect Macaques Against Rectal SHIV Infection**
Ivana Massud (Centers for Disease Control and Prevention, United States)
- P24.25LB G2-S16 Dendrimer as a New Innovative a Promising Drug Close to a Clinical Trial**
M^a Ángeles Muñoz-Fernández (Hospital General Universitario Gregorio Marañón, Sección Immunología, Laboratorio InmunoBiología Molecular, IISGM, CIBER-BBN and Spanish HIV-HGM BioBank, Spain)
- P24.27LB Novel Protocol to Compare PrEP Drugs, Dosing and Schedule Using Ex Vivo Challenge on Resected Foreskin Tissue: Protocol for the CHAPS RCT**
Carolina Herrera (Imperial College London, United Kingdom)

Poster
17:30 - 19:30

Poster Hall

P25 Product Acceptability and Adherence

- P25.01 PrEP “Can Make You Have Peace”: Perspectives on PrEP Among Young Female Sex Workers and Their Male Clients in Kisumu, Kenya**
Joanne E. Mantell (ICAP at Columbia University, United States)
- P25.03 From Theory to Practice: Implementation of Client Centered Adherence Counselling at the Kampala Site for the HOPE Study**
Aisha Zalwango Sesaaazi (MUJHU Care Ltd / MUJHU Research Collaboration, Uganda)
- P25.05 Interviewer Adjustment of Smart Pillbox Monitoring Did Not Improve Accuracy in Measuring Oral PrEP Adherence in HPTN 067**
Bonnie J. Dye (FHI 360, United States)
- P25.07 Interest in Long-acting Injectable PrEP by One’s History of Oral PrEP Use Among Men Who Have Sex with Men in Washington, DC**
Matthew Levy (George Washington University Milken Institute School of Public Health, United States)

Download Program (PDF)

- P25.09 PrEP Access and Adherence: Identifying Barriers and Assessing the Utility of Tenofovir Urine Testing**
Travis Hunt (Thomas Jefferson University, United States)
- P25.11 Anonymous Internet-aided Urine-based HIV Testing Service for the Patients in Sexually Transmitted Diseases Clinics and Their Sexual Partners**
Xianlong Ren (Beijing Center for Diseases Prevention and Control, China)
- P25.13 Acceptance and Adherence to a Vaccination Schedule in a SiVET Among Adults in Fishing Communities of Lake Victoria, Uganda**
Ali Ssetaala (UVRI-IAVI HIV Vaccine Program, Uganda)
- P25.15 Adherence and Acceptability of Rectal Microbicides: A Synthesis Review**
Omar Bruce (University of Pennsylvania, United States)
- P25.17 Challenges With Oral Pre-exposure Prophylaxis (PrEP) Disclosure Among Adolescent Girls and Young Women (AGYW) in Kenya and South Africa**
Sarah T. Roberts (RTI International, United States)
- P25.19 Factors Associated With PrEP Discontinuation Among Men Who Have Sex With Men in Washington, DC**
Anya Agopian (George Washington University Milken Institute of Public Health, United States)
- P25.21LB One Year Retention in PrEP Care Outcomes in a Three-site Implementation Science Program in the United States**
Amy Nunn (Brown University School of Public Health, United States)
- P25.23LB Quo Vadis HIV Prevention? Marketing Research on the Acceptance of Long-acting PrEP Among Men Having Sex With Men and Medical Practitioners in the U.S.**
Ewa Bryndza Tfailey (Northwestern University Feinberg School of Medicine, United States)

Poster
17:30 - 19:30

Poster Hall

P26 Systems Immunobiology Approaches & Sequencing Technologies

- P26.01 Classification of HIV Controllers in an Acute Infection Cohort to Enable Systems Investigation of Signatures Associated With Control of Infection**
Julia Makinde (Imperial College London, United Kingdom)
- P26.03 Systems Analysis of the Innate and Adaptive Immune Responses to the RV144 ALVAC HIV Vaccine in a South African HIV Uninfected Cohort**
Lamar Fleming (Fred Hutchinson Cancer Research Center, United States)

Poster
17:30 - 19:30

Poster Hall

P27 Therapeutic Vaccine, Viral Latency and Cure

- P27.01 Combinations of Maraviroc With Other Latency Reversing Drugs to Reactivate Latent HIV-1**
María Rosa López Huertas (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, Spain)

Download Program (PDF)

- P27.03 Selective miRNAs Inhibition Fails to Activate HIV-1 Replication in In Vitro Latency Models**
María Rosa López Huertas (Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Hospital Universitario Ramón y Cajal, Spain)
- P27.05 Tandem Bispecific Neutralizing Antibodies Inhibit HIV-1 Infection in Humanized Mice**
Mengyue Niu (AIDS Institute and Department of Microbiology, State Key Laboratory of Emerging Infectious Diseases, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong)
- P27.07 Impact of HCV Coinfection in the Splicing of HIV Proviral DNA**
Paula Martínez-Román (Institute of Health Carlos III, National Center of Microbiology, Spain)
- P27.09 Vedolizumab-mediated Integrin $\alpha 4\beta 7$ Blockade Enhances HIV-1 SF162 Rebound Following cART Interruption in Humanized Mice**
Lijun Ling (The University of Hong Kong, Hong Kong)
- P27.11 HIV-1 Reservoirs Form in Urethral Tissue Macrophages of Patients Under Antiretroviral Therapy**
Morgane Bomsel (Institut Cochin CNRS UMR8104, France)
- P27.13 Unique and Expanded Breadth Estimate of CD8 T-cell Responses to Cohort-specific HIV-1 GAG Protein Peptides**
Clive Michelo (Zambia Emory HIV Research Project, Zambia)
- P27.15LB Mapping Acute Viral Dynamics and Rebound Post ART Interruption in SIV Infected Macaques Using Total Body ImmunoPET/CT**
Mariluz Arainga (University of Louisiana at Lafayette, United States)

Poster
17:30 - 19:30

Poster Hall

P28 Transmission of HIV

- P28.01 Past or Active Schistosome Infection Is Associated With Incident HIV Transmission and Disease Progression Risk in Men and Women, Zambia**
Susan Allen (Rwanda Zambia HIV Research Group-Emory University, United States)
- P28.03 Biological Properties of Envelope Glycoproteins for Early and Late HIV-1 Variants Issued From a Same Transmission Cluster**
Maxime Beretta (INSERM U1259, France)
- P28.05 Near Full-length Genome Characterization of HIV-1 Subtypes Among Drug Users in Kenya**
Thando Zulu (University of KwaZulu-Natal, South Africa)
- P28.07 Characterizing Env-specific Monoclonal Antibodies Isolated From U.S. and Malawian HIV-infected Non-transmitting and Transmitting Women**
David R. Martinez (Duke Human Vaccine Institute, United States)
- P28.09 Per Act HIV Transmission Risk Through Anal Intercourse: An Updated Systematic Review and Meta-analysis**
Marie-Claude Boily (Imperial College, United Kingdom)
- P28.11 Transmission of Unique Intersubtype HIV-1 Recombinants Predominate in Both Single and Multiple Variant Infections in Uganda**
Sheila Nina Balinda (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)

Download Program (PDF)

- P28.13 Comparison of Genetic Sequences From Donor and Recipient Viruses From Linked Subtype A Transmission Pairs**
Samantha McNally (Emory University, United States)
- P28.15 Receptive Anal Intercourse as a Risk Factor of HIV Infection in Women: A Systematic Review and Meta-analysis**
James Stannah (Imperial College London, United Kingdom)
- P28.17 Seminal Plasma Enhances SIV Replication in Macaque Colorectal Tissue Explants and Induces Intraepithelial Recruitment of Antigen Presenting Cells**
Mariangela Cavarelli (CEA, France)
- P28.19 Pretreatment With an Anti-MAdCAM mAb Increases the Susceptibility of Macaques to Mucosal Challenge by SIV**
Claudia Cicala (National Institute of Allergy and Infectious Diseases, NIH, United States)
- P28.21LB Back to the Future: Even in the ART Era, Men Co-infected With HIV and Urethritis Pose a Potential Transmission Threat**
Jane S. Chen (University of North Carolina at Chapel Hill, United States)
- P28.23LB Test and Treat in Malawi: HIV Seminal Viral Load Response to ART Initiation Among Men Co-infected With Urethritis**
Mitch Matoga (University of North Carolina Project Lilongwe, Malawi)
- P28.25LB Circumcision Increases the Barrier Function of the Glans Epithelium**
Gianguido C. Cianci (Feinberg School of Medicine, Northwestern University, United States)
- P28.27LB Enhanced Selection for HIV-1 Transmitted/Founder Viruses in BLT Humanized Mice Following Intravaginal Exposure**
Daniel Claiborne (Ragon Institute of MGH, MIT and Harvard, United States)

Poster
17:30 - 19:30

Poster Hall

P29 Treatment as Prevention

- P29.01 Protection Efficacy of the Virucidal Small Peptide C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice**
Philippe Gallay (The Scripps Research Institute, United States)
- P29.03 Evaluating Psycho-social Support in Improving Adherence Among HIV-positive Adolescents Aged 10-19 Years at Gertrude's Children's Hospital, Nairobi**
Kevin Munene Njue (Gertrude's Children's Hospital, Kenya)
- P29.05 Treatment as Prevention and Viral Response in a Cohort of Female Sex Workers in Cotonou, Benin**
Mamadou Diallo (Université Laval, Canada)
- P29.07 Real-time Antiretroviral Adherence Monitoring Intervention in Young African American Men Who Have Sex With Men: Acceptability and Monitoring Results**
Mark Dworkin (University of Illinois at Chicago, United States)
- P29.09 Test and Treat Care Cascade in General and Key Populations in Coastal Kenya**
Elizabeth Wahome (KEMRI-Wellcome Trust Research Programme Centre for Geographic Medicine Research, Kenya)

Download Program (PDF)

P29.11 Late Entry Into HIV Care Is a Threat to Treatment-as-prevention in Ho Chi Minh City, Vietnam

Thuy Dao (Hanoi Medical University, Viet Nam)

P29.13LB Hypo-osmolar Rectal Douche Delivers Tenofovir to the Rectal Mucosa and Effectively Protects Macaques Against Repeated SHIV Challenges

Francois Villinger (University of Louisiana at Lafayette, United States)

Poster
17:30 - 19:30

Poster Hall

P05 Clinical Trial Results

P05.01 Finding MSM who may be Potential Amplified HIV Transmitters: Results from HPTN 078

Theresa Gamble (FHI 360, United States)

P05.03 Characteristics of Women Who Enrolled Into an Open Label Extension Trial of the Dapivirine Intravaginal Ring for HIV-1 Prevention

Nyaradzo Mgodi (University of Zimbabwe Collaborative Research Program, Zimbabwe)

P05.05 Final Report of ANRS COV1-COHVAC Cohort of Healthy Volunteers From Preventive HIV-1 Vaccine Trials

Christine Durier (INSERM US19, France)

P05.07 HIV Vaccine Trials in Uganda: Barriers and Facilitators

Violet Mirembe (UVR-I-IAVI HIV Vaccine Program, Uganda)

P05.09 Potential Causes for Decreased Enrollment of Acutely Infected Participants in the ASPIRE Trial Compared to VOICE

Edward Livant (Magee-Womens Research Institute, United States)

P05.11 A Phase 1 Trial of AAV1 Vected Immunoprophylaxis for HIV

Huub C Gelderblom (International AIDS Vaccine Initiative, United States)

P05.13LB HIV, ART, Vedolizumab and Analytical Treatment Interruption (ATI): Rebound Viremia Kinetics in the Dose-ranging HAVARTI Trial

Michaeline McGuinty (University of Ottawa at The Ottawa Hospital Research Institute, Canada)

P05.15LB Vaccine-induced Seropositivity in Participants of the APPROACH Study (HIV-V-A004)

L. Lavreys (Janssen Pharmaceutica NV, Belgium)

P05.17LB Retention in the Ongoing AMP Trials of VRC01, a Broadly Neutralizing Antibody (bnAb) to Prevent HIV in Women, MSM & Transgender (TG) People

Philip Andrew (FHI 360, HIV Prevention Trials Network, United States)

P05.19LB Griffithsin Administered Vaginally for 14 Days Is Well-tolerated, With Anti-HIV Activity Up to 8 Hours Post Dose in the First-in-human Trial

Barbara Friedland (Population Council, United States)

Poster
17:30 - 19:30

Poster Hall

P08 Correlates of Protection and Exposure

Download Program (PDF)

- P08.01 Older Age at Infection and Nulliparity Are Associated with Long-term Non-progression in Female Sex Workers Infected with Non-Subtype B HIV-1**
Vernon Mochache (National AIDS Control Council, Kenya)
- P08.03 Prevalence and Predictors of Violence Against Female Sex Workers in Rwanda**
Kalonde Malama (Aix-Marseille University, France)
- P08.05 Female Sex Workers in Kigali, Rwanda: A Key Population at Risk of HIV, Sexually Transmitted Infections and Unplanned Pregnancy**
Rosine Ingabire (Project San Francisco, Rwanda)
- P08.07 Estrogen, Progesterone and Sex-hormone Binding Globulin in Association With Innate Immunity Correlates of HIV Risk and Protection**
Raina Fichorova (Brigham and Women's Hospital, Harvard Medical School, United States)

Poster
17:30 - 19:30

Poster Hall

P14 Implementation Science, Including Structural Interventions, PrEP & VMMC

- P14.01 Online Survey about Reasons for Stopping PrEP is an Opportunity to Re-engage Inactive PrEP Clients**
Chelsea Shover (University of California, Los Angeles, United States)
- P14.03 Acceptability of Infant Circumcision Among Traditionally Circumcising Communities in Kenya: Views of Traditional Circumcisers and Councils of Elders**
Kawango Agot (Impact Research & Development Organization, Kenya)
- P14.05 Adherence to Daily Antiretroviral Pre-exposure Prophylaxis Among Heterosexual Serodiscordant Partners in the Nigeria PrEP Demonstration Project**
Nancin Dadem (Jos University Teaching Hospital, Nigeria)
- P14.07 Ensuring Potential Volunteers Are the "Right Fit" for Study Participation: Insights From the CAPRISA eThekweni Clinical Research Site**
Kalendri Naidoo (CAPRISA, South Africa)
- P14.09 Correlates of Retention in Care Among HIV Infected Adolescents and Young Adults Enrolled in an HIV Program in Kenya**
Lawrence Mwhaki (Christian Health Association of Kenya (CHAK), Kenya)
- P14.11 Correlates of Attrition Among MSM Followed in a HIV-1 Vaccine Feasibility Cohort Study in Kenya**
Elizabeth Wahome (KEMRI-Wellcome Trust Research Programme Centre for Geographic Medicine Research, Kenya)
- P14.13 Fidelity Monitoring to Ensure Accurate Implementation of an Evidence-based Adherence Counseling Intervention in MTN-025 (the HOPE Study)**
Iván Balán (New York State Psychiatric Institute and Columbia University, United States)
- P14.15 Frontline PrEP Champions Accelerating Effective Integration of PrEP Delivery for HIV Serodiscordant Couples in Public Health Facilities in Kenya**
Kenneth Mugwanya (University of Washington, United States)
- P14.17 Enhanced Adherence Counseling 1, 2, 3: Our Success Story in Achieving Viral Suppression in HIV Positive Key Population Clients**
Maureen Akolo (Kenya AIDS Control Program, Kenya)

Download Program (PDF)

- P14.19 PrEP Implementation: Retention Challenges Among Female Sex Workers in Nairobi, Kenya**
Maureen Akolo (Kenya AIDS Control Program, Kenya)
- P14.21 Experiences from PrEP Rollout Among HIV-1 Serodiscordant Couples in Western Kenya**
Josephine Odooyo (Kenya Medical Research Institute, Kenya)
- P14.23 Association Between Intimate Partner Violence and Uptake of HIV Pre-exposure Prophylaxis (PrEP) Among Adolescent Girls and Young Women (AGYW) in Kenya**
Lina Digolo (LVCT Health, Kenya)
- P14.25 Understanding Service Providers' Knowledge of Oral PrEP and Attitudes Toward Provision to Populations at Substantial HIV Risk in South Africa**
Mercy Murire (Wits Reproductive Health & HIV Institute, South Africa)
- P14.27 Health Care Providers' Knowledge, Attitudes and Practices Towards Provision of PrEP to Adolescent Girls and Young Women in Kenya: A Descriptive Study**
Maryline Mireku (LVCT Health, Kenya)
- P14.29 Perspectives of Young Men Who Have Sex With Men on Peer Navigation to Improve Adherence to PrEP**
Kenneth H. Mayer (Fenway Health, United States)
- P14.31 PrEP Delivery Platforms: Are Family Planning Clinics an Option?**
Victor Omollo (Kenya Medical Research Institute, Kenya)
- P14.33 Measuring HEART: Validity of a HEAlthy Relationships Assessment Tool to Guide Tailored Counseling in the CHARISMA Pilot Study**
Elizabeth (Betsy) Tolley (FHI 360, United States)
- P14.35 Low Costs and Opportunities for Efficiency in the First Year of Programmatic PrEP Delivery in Kenya's Public Sector**
Kathryn Peebles (University of Washington, United States)
- P14.37 Increasing Uptake of Pre-exposure Prophylaxis (PrEP) in Cleveland, Ohio, Through Community- and Provider-focused Interventions**
Rustin Zomorodi (Case Western Reserve University, United States)
- P14.39 Platforms, Processes and Perceptions of PrEP Delivery Through DREAMS in a Rural Setting in KwaZulu-Natal, South Africa**
Natsayi Chimbindi (Africa Health Research Institute (AHRI), South Africa)
- P14.41 How Do We Roll Out PrEP for Adolescent Girls and Young Women (AGYW)? Hearing From AGYW, Male Partners, Parents, Healthcare Providers and Policymakers**
Nanlesta Pilgrim (Population Council, United States)
- P14.43 Differences by Wave of Respondent-driven Sampling Recruitment Among Gay Men and Other Men Who Have Sex With Men in 4 U.S. Cities: Results From HPTN 078**
Stefan Baral (Johns Hopkins, United States)
- P14.45 How Can Men's Perceptions of PrEP and ART in Lesotho Help Inform Strategies for Promoting Adherence?**
Mathabang Mokoena (JHPIEGO, Lesotho)
- P14.47 Attitudes and Knowledge About HIV PrEP Among Infectious Diseases Physicians in Brazil**
Natalia Cerqueira (University of Sao Paulo, Brazil)

Download Program (PDF)

- P14.49** **Willingness to Pay and Actual Costs for HIV Pre-exposure Prophylaxis Users in the United States Private Health System**
Rupa Patel (Washington University in St. Louis, United States)
- P14.51LB** **A Descriptive Analysis of Calls and Text Messaging Communication Between Participants and Health Care Providers**
Harriet Fridah Adhiambo (Kenya Medical Research Institute, Kenya)
- P14.53LB** **Attitudes in Assessing Patients for Pre-exposure Prophylaxis Among Pediatric and Internal Medicine Residents Training in New York City**
Jeremy A.W. Gold (Columbia University Irving Medical Center, United States)
- P14.55LB** **Benefits of Girl-only Club Participation on HIV Risk Reduction: Experiences of Very Young Out of School Adolescent Girls Aged 10-14 in Rural Malawi**
Wanangwa Chimwaza (University of Malawi, Malawi)
- P14.57LB** **Pre-exposure Prophylaxis (PrEP) Uptake Among Predominantly Black and Latina Women at Risk for HIV Acquisition in New York**
Deborah A. Theodore (Columbia University Medical Center, United States)

Poster
17:30 - 19:30

Poster Hall

Poster Session 01

Odd-numbered abstracts will be presented in Poster Session 01 on Tuesday, 23 October. Even-numbered abstracts will be presented in Poster Session 02 on Wednesday, 24 October.

Download Program (PDF)

Wednesday, 24 October 2018

Plenary
08:30 - 10:00

Auditorium

PL03 The Future is Now: Next Steps in Developing New Prevention Options

Plenary 3 answers the question, "What's new in prevention?" with a look at systemic and topical agents in development, new approaches to vaccines and new methods of delivery that could transform the future of HIV prevention.

Chairs:

Julia del Amo (Instituto de Salud Carlos III, Spain)
Ian McGowan (Orion Biotechnology, Spain)

PL03.01	Beyond TDF/FTC: The Future of Systemic Pre-exposure Prophylaxis Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)	08:30 - 09:00
PL03.02	On-demand Topical Agents for HIV Pre-exposure Prophylaxis Craig Hendrix (Johns Hopkins University, United States)	09:00 - 09:30
PL03.03	Vaccine Design 2.0: The Pipeline Novel HIV-1 Envelope Proteins to Induce Neutralizing Antibodies Rogier Sanders (Amsterdam University Medical Centers (Amsterdam UMC), University of Amsterdam, Netherlands)	09:30 - 10:00

Oral
10:30 - 12:00

Londres

OA09 Translating Immunity From Pre-clinical Animal Models to Humans

Chairs:

Mariangela Cavarelli (CEA, France)
David R. Martinez (Duke Human Vaccine Institute, United States)

OA09.01	Co-crystal Structure of SIVmac239 gp120 with rhCD4 and Neutralizing Antibody ITS90.03 Reveals Similar Sites of Vulnerability Between HIV-1 and SIV Env Jason Gorman (NIH/NIAID/VRC, United States)	10:30 - 10:45
OA09.02	Native HIV-1 Env Circulating During the Development of Breadth in Human Subjects Elicits Tier 2 Heterologous Neutralizing Monoclonal Antibodies in NHP Ann Hessel (Oregon Health and Science University, United States)	10:45 - 11:00
OA09.03	Macaque SHIV Induction of 2G12-like Broadly Neutralizing Antibodies Wilton Bryan Williams (Duke University, United States)	11:00 - 11:15
OA09.04	Tight Control of SHIV BaL.P4 Challenge in Rhesus Macaques Co-immunized With DNA and Protein HIV Vaccine Regimen Miroslaw K. Gorny (New York University School of Medicine, Department of Pathology, United States)	11:15 - 11:30

Download Program (PDF)

- | | | |
|------------------|--|----------------------|
| OA09.05 | Tracking Cy5-conjugated VRC01 Following IV Injection in the Rhesus Macaque Reveals That Tissue Distribution Can Take 1 Week to Achieve Steady State
Jeffrey Schneider (Northwestern University, United States) | 11:30 - 11:45 |
| OA09.06LB | A Meta-analysis to Evaluate the Relationship Between Serum Antibody Neutralizing Titer and Protection Against SHIV Challenge in Nonhuman Primates
Ying Huang (Fred Hutchinson Cancer Research Center, United States) | 11:45 - 12:00 |

Oral
10:30 - 12:00

Bristol

OA10 Key to the Response: Populations, Partners and Prevention

Chairs:

Kenneth H. Mayer (Fenway Health, United States)
Valdilea Veloso (Fundação Oswaldo Cruz, Brazil)

- | | | |
|------------------|---|----------------------|
| OA10.01 | Male Partners of Adolescent Girls and Young Women (AGYW) in Durban, South Africa: How High Is Their HIV Risk and What Groups Are Most at Risk?
Julie Pulerwitz (Population Council, United States) | 10:30 - 10:45 |
| OA10.02 | Help-seeking Behavior of Women Reporting Intimate Partner Violence in Mwanza, Tanzania, and Its Implications for HIV: Findings From the MAISHA Study
Sheila Harvey (London School of Hygiene & Tropical Medicine, United Kingdom) | 10:45 - 11:00 |
| OA10.03 | Undercurrents of Sex Work: Characteristics and Experiences of Female Sex Workers in Kisumu, Kenya
Kawango Agot (Impact Research & Development Organization, Kenya) | 11:00 - 11:15 |
| OA10.04LB | HIV Incidence Among Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa: Findings From the Multi-country HPTN 075 Cohort Study
Theo G.M. Sandfort (New York State Psychiatric Institute, United States) | 11:15 - 11:30 |
| OA10.05 | Young Transwomen in Brazil Have High HIV Risk and Low Prevention Use
Erin C Wilson (San Francisco Department of Public Health, United States) | 11:30 - 11:45 |
| OA10.06 | An Integrated Intervention to Increase ART and MAT Reduces Mortality Among PWID: Results From the HPTN 074 Randomized Trial
Kostyantyn Dumchev (Ukrainian Institute on Public Health Policy, Ukraine) | 11:45 - 12:00 |

Oral
10:30 - 12:00

Oxford

OA11 Novel Vaccine Strategies

Chairs:

Yoann Aldon (Imperial College London, United Kingdom)
Susan Barnett (Bill and Melinda Gates Foundation, United States)

Download Program (PDF)

OA11.01	Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to an HIV-1 Clade C Envelope Vaccine Robin Shattock (Imperial College, United Kingdom)	10:30 - 10:45
OA11.02	Fusion Peptide-directed Antibodies Elicited in Immunized Rhesus Macaques Neutralized 59% of 208 Wildtype HIV-1 Strains Rui Kong (Vaccine Research Center, NIAID, NIH, United States)	10:45 - 11:00
OA11.03	Vaccination of Rabbits and Macaques With V1V2-scaffold Immunogens Induces V1V2-specific Antibody Responses With Antiviral Functions Svenja Weiss (Icahn School of Medicine at Mount Sinai, United States)	11:00 - 11:15
OA11.04	Immune Control of SHIV Infection in Rhesus Macaques by PD-1-based Vaccine Yik Chun Wong (AIDS Institute, The University of Hong Kong, Hong Kong)	11:15 - 11:30
OA11.05	Vaccine-elicited Cross-neutralizing HIV Antibodies (bNAbs) to Two Env Sites of Vulnerability Following Heterologous NFL Trimer Liposome Prime: Boosting Richard Wyatt (IAVI Neutralizing Antibody Center at Scripps, United States)	11:30 - 11:45
OA11.06LB	Immune Responses to PENNVAX-GP (R) HIV DNA Vaccine Plus IL-12 Are Equivalent or Superior When Delivered by Intradermal vs. Intramuscular Electroporation Srilatha Edupuganti (Emory University, United States)	11:45 - 12:00

Symposium
10:30 - 12:00

Marsella, Burdeos & Estrasburgo

SY11 ARVs for Prevention in Women of Childbearing Age

Chairs:

Susan Buchbinder (San Francisco Department of Public Health, United States)
Gita Ramjee (South African Medical Research Council, South Africa)

SY11.01	No Woman Left Behind: An Ethical Framework for Prevention Studies in Reproductive Age Women Annie Lyster (University of North Carolina, United States)	10:30 - 10:52
SY11.02	Efavirenz and Dolutegravir: A Tale of Two ARVs Elaine Abrams (Columbia University, United States)	10:52 - 11:14
SY11.03	Studying Periconception Outcomes in Women on ARVs in Brazil Adele Benzaken (Ministry of Health, Brazil, Brazil)	11:14 - 11:36
SY11.04	Striking a Balance Sharon Hillier (University of Pittsburgh, United States)	11:36 - 11:58

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Meet the Experts Lunch
12:00 - 13:00

Toulouse & Lyon

ME02 Meet the Experts Lunch

Daily meet the experts lunches provide early-career investigators and community advocates with valuable opportunities for informal, in-depth exchange with experts representing a cross-section of research issues, implementation challenges, and HIV-affected communities.

Chairs:

Elaine Abrams (Columbia University, United States)
Rama Amara (Emory University, United States)
Adele Benzaken (Ministry of Health, Brazil, Brazil)
Martha Brady (PATH, United States)
Wendy Burgers (Institute of Infectious Disease and Molecular Medicine, UCT, South Africa)
Mary Carrington (Frederick National Laboratory for Cancer Research, United States)
Alex Coutinho (Partners in Health, Rwanda)
Anthony Cunningham (The Westmead Institute, The University of Sydney, Australia)
Maria del Rosario Leon (Impacta Salud y Educacion, Peru)
Sarit Golub (Hunter College, United States)
Renee Heffron (University of Washington, United States)
Craig Hendrix (Johns Hopkins University, United States)
Sharon Hillier (University of Pittsburgh, United States)
Tony Kelleher (Kirby Institute, UNSW Sydney, Australia)
Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)
Maximilian Muenchhoff (Pettenkofer-Institute, Germany)
Zaza Ndhlovu (University of KwaZulu Natal, South Africa)
Nneka Nwokolo (Chelsea & Westminster Hospital, United Kingdom)
R. Keith Reeves (Beth Israel Harvard, United States)
Rogier Sanders (Amsterdam University Medical Centers (Amsterdam UMC), University of Amsterdam, Netherlands)
Hasina Subedar (Department of Health, South Africa)

Meet the Experts Lunch

12:00 - 13:00

Oral
13:00 - 14:30

Londres

OA12 Contraception and HIV Risk: Still Between a Rock and a Hard Place

Chairs:

Maureen Goodenow (Office of AIDS Research, National Institutes of Health, United States)
Charles Morrison (FHI 360, United States)

- | | | |
|------------------|--|----------------------|
| OA12.01 | MPA, Used in Injectable Contraception, Increases HIV-1 Replication ex vivo by a Different Mechanism Compared to Luteal Phase Progesterone Levels | 13:00 - 13:15 |
| | Chanel Avenant (University of Cape Town, South Africa) | |
| OA12.02LB | Safety and Pharmacokinetics of Dapivirine and Levonorgestrel Vaginal Rings for Multipurpose Prevention of HIV and Pregnancy | 13:15 - 13:30 |
| | Sharon Achilles (University of Pittsburgh, United States) | |
| OA12.03 | Increased CCR5 Levels Result in Increased R5-HIV Replication by Medroxyprogesterone Acetate, Unlike Norethisterone, via the Glucocorticoid Receptor | 13:30 - 13:45 |
| | Janet Hapgood (University of Cape Town, South Africa) | |

Download Program (PDF)

OA12.04	Effect of Depot-medroxyprogesterone Acetate on T Cell Expression of Immunosuppressive Markers, PD-1 and CTLA-4 in HIV-negative Women Taguma. A Matubu (University of Zimbabwe College of Health Sciences Clinical Trials Research Centre, Zimbabwe)	13:45 - 14:00
OA12.05	Successful Use of Safer Conception Strategies Resulting in High Pregnancy Rates and no HIV Transmissions Among Kenyan HIV-discordant Couples Renee Heffron (University of Washington, United States)	14:00 - 14:15
OA12.06	Risk of HIV-1 Acquisition Among South African Women Using a Variety of Contraceptive Methods in a Prospective Study Thesla Palanee-Phillips (Wits Reproductive Health and HIV Institute, South Africa)	14:15 - 14:30

Oral
13:00 - 14:30

Bristol

OA13 Virus Control: Therapeutic Interventions

Chairs:

Mariano Esteban (Centro Nacional De Biotecnología, Spain)
Moses Nsubuga (Stigmaless Uganda, Uganda)

OA13.01	Setting the Stage for Meaningful Community Engagement and Participation in HIV Cure-related Research: Lessons Learned From the HIV Prevention Field Melissa Hermerding (Forum for Collaborative Research, University of California, Berkeley, School of Public Health, United States)	13:00 - 13:15
OA13.02	A Novel Approach to Inhibit CD4 Exhaustion: Results of a Placebo-controlled Phase II Study of a gp41 Peptide Vaccine in HIV-1 Patients Under ART Behazine Combabièrre (CIMI-Paris, France)	13:15 - 13:30
OA13.03	DNA-GTU/LIPO-5 Vaccine Followed by Supervised Treatment Interruption (STI) in a Therapeutic HIV Phase II Randomized Trial: VRI02 ANRS 149 LIGHT Christine Lacabartz (Vaccine Research Institute/VRI, France)	13:30 - 13:45
OA13.04	Therapeutic Vaccination With a Combination of IDLV-SIV-Gag and IDLV-PGT121 Results in Prolonged Virus Control in Chronically SHIV-infected Macaques Maria Blasi (Duke University Medical Center, United States)	13:45 - 14:00
OA13.05	Long-term Delivery of Anti-HIV Monoclonal Antibodies Jose M. Martinez-Navio (University of Miami - Miller School of Medicine, United States)	14:00 - 14:15
OA13.06LB	Tissue Viral Seeding Drives SHIV Pathogenesis in Infant Macaques and Is Reduced by Early bNAb Therapy Ann Hessel (Oregon Health and Science University, United States)	14:15 - 14:30

Download Program (PDF)

Oral
13:00 - 14:30

Oxford

OA14 Antibody Functions Beyond Neutralization

Chairs:

Cynthia Derdeyn (Emory University, United States)
Christiane Moog (INSERM U1109, FMTS, Université de Strasbourg, France)

- | | | |
|------------------|--|----------------------|
| OA14.01 | HIV gp120 V2 Mimics IgSF Domain 1 of MAdCAM, the Natural Ligand of Integrin $\alpha_4\beta_7$
James Arthos (NIAID, NIH, United States) | 13:00 - 13:15 |
| OA14.02 | IgG3 Hinge Length Enhances Neutralization Potency and Fc Effector Function of an HIV V2-specific Broadly Neutralizing Antibody
Simone Irene Richardson (Centre for HIV & STIs, National Institute for Communicable Diseases, South Africa) | 13:15 - 13:30 |
| OA14.03 | Neutralizing and ADCC Activity of Anti-HIV-1 Antibodies Against Acute Subtype C Envs: Implications for Prevention and Treatment of HIV-1 Infection
Dieter Mielke (Duke University, United States) | 13:30 - 13:45 |
| OA14.04 | Structural Characterization of Rhesus Macaque Fc Domains of IgG1-4 and the FcγRIIIa1-IgG1Fc Complex
William Tolbert (Institute of Human Virology, University of Maryland, School of Medicine, United States) | 13:45 - 14:00 |
| OA14.05 | IgA Inhibits HIV-specific Antibody-dependent Neutrophil Phagocytosis
Matthew Worley (The Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Australia) | 14:00 - 14:15 |
| OA14.06LB | Tight Control of SHIV_{BaL} in Rhesus Macaques Immunized With gp160 DNA + gp120 Proteins (Clades E and B) Correlates With V2p Antibodies
Svenja Weiss (Icahn School of Medicine at Mount Sinai, United States) | 14:15 - 14:30 |

Oral
13:00 - 14:30

Marsella, Burdeos & Estrasburgo

OA15 New ARVs for Prevention

Chairs:

Juan Berenguer (Infectious Diseases at Hospital General Gregorio Marañón, Spain)
Anton Pozniak (Chelsea and Westminster Hospital, United Kingdom)

- | | | |
|----------------|---|----------------------|
| OA15.01 | Pharmacokinetic and Pharmacodynamic Evaluation of the Antiretroviral Compound MK-2048 Released From an Intravaginal Ring in Rhesus Macaques
James Cummins (Division of AIDS, NIAID, NIH, United States) | 13:00 - 13:15 |
| OA15.02 | Efficacy of UAMC01398 Gel Formulation in NHP Model of HIV Vaginal Transmission
Delphine Desjardin (CEA Université Paris Sud, Inserm u1184, IDMIT Department, France) | 13:15 - 13:30 |

Download Program (PDF)

OA15.03	Dose-ranging Pharmacokinetic Assessment of Vaginally Administered EVG/TAF Inserts in Macaques for PrEP Charles Dobard (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, Laboratory Branch, United States)	13:30 - 13:45
OA15.04	HIV Prevention in Healthy Women: Safety and Pharmacokinetics of a Potential New Tenofovir Alafenamide Fumarate (TAF)-based Oral PrEP Regimen Jill Schwartz (CONRAD Eastern Virginia Medical School, United States)	13:45 - 14:00
OA15.05	Cabotegravir (CAB) Long-acting (LA) Phase 3 (Ph3) PrEP Dose Selection Based on Population Pharmacokinetics (PPK) in Healthy and HIV-infected Adults Susan Ford (PAREXEL International, United States)	14:00 - 14:15
OA15.06LB	Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final Results Raphael Landovitz (UCLA Center for Clinical AIDS Research & Education, United States)	14:15 - 14:30

Symposium
15:00 - 16:30

Londres

SY05 Close Encounters of the Third Kind: Innate and Adaptive Immune Responses in HIV Dissemination

This session will review host responses to HIV/SIV infection within mucosal and lymphoid tissues in humans and nonhuman primates. Topics will include the role of molecular pathways implicated in natural immune control, early host response, novel mucosal innate lymphocyte subsets, and relevant findings from acute HIV infection studies.

Chairs:

Guido Ferrari (Duke University Medical Center, United States)
Hendrik Streeck (Institute for HIV Research, Germany)

SY05.01	Interfering with Interferons: How HIV Subverts the Interferon System to Facilitate Sexual HIV Transmission Anthony Cunningham (The Westmead Institute, The University of Sydney, Australia)	15:00 - 15:22
SY05.02	Fixed Characteristics of HLA Class I Alleles That Impact HIV Disease Mary Carrington (Frederick National Laboratory for Cancer Research, United States)	15:22 - 15:44
SY05.03	HIV Persistence and the Immune Microenvironment in Lymph Nodes Following Initiation of cART During Hyperacute HIV-1 Infection Zaza Ndhlovu (University of KwaZulu Natal, South Africa)	15:44 - 16:06
SY05.04	The First Line Against HIV/SIV: Innate Immune Effectors at the Virus-Mucosae Interface R. Keith Reeves (Beth Israel Harvard, United States)	16:06 - 16:28

Download Program (PDF)

Roundtable
15:00 - 16:30

Bristol

RT01 Accelerating Product Introduction for Impact

Millions of new HIV infections occur yearly despite availability of novel and effective HIV prevention products. This session will explore best practices for introduction of prevention products, and discuss successes and challenges using lessons learnt from completed demonstration projects. Best practices from sexual and reproductive health technologies and experiences from non-HIV vaccines will be used as examples of implementation planning for product introduction.

Chairs:

Nyaradzo Mgodi (University of Zimbabwe Collaborative Research Program, Zimbabwe)
Mitchell Warren (AVAC, United States)

RT01.01	Preparing for Successful Implementation of Prevention Strategies Hasina Subedar (Department of Health, South Africa)	15:00 - 15:10
RT01.02	Learning From the Past: Planning for Future Success in Implementing Biomedical HIV Prevention Products Alex Coutinho (Partners in Health, Rwanda)	15:10 - 15:20
RT01.03	Successes and Shortcomings in Introducing Sexual and Reproductive Health Technologies: Insights From End-users, Providers and Policy Makers Martha Brady (PATH, United States)	15:20 - 15:30
RT01.04	Learning from History: Roll-out of Non-HIV Vaccines Swati Gupta (International Aids Vaccine Initiative, United States)	15:30 - 15:40
RT01.05	Introduction of New Health Technologies in HIV Prevention and Treatment Trials: Best Practices of Community Engagements and Communication in Peru Maria del Rosario Leon (Impacta Salud y Educacion, Peru)	15:40 - 15:50
	Panel Discussion	15:50 - 16:30

Symposium
15:00 - 16:30

Oxford

SY06 Let's Talk T Cells!

There is an urgent need to revisit approaches to elicit cell-mediated immunity for both vaccine prevention and cure strategies. The session will cover the latest and greatest candidates in pre-clinical and clinical development, as well as address the need to strike the right balance of T cell immunity.

Chairs:

Paul Goepfert (University of Alabama at Birmingham, United States)
Julia G. Prado (AIDS Research Institute Irsicaixa, Spain)

SY06.01	T Cell Responses in HIV-infected Children: Potential for Prevention or Cure? Maximilian Muenchhoff (Pettenkofer-Institute, Germany)	15:00 - 15:18
SY06.02	T Cells in Vaccine Trials Wendy Burgers (Institute of Infectious Disease and Molecular Medicine, UCT, South Africa)	15:18 - 15:36

Download Program (PDF)

SY06.03	What Defines an Effective T-cell Response to HIV? Christian Brander (IrsiCaixa, Spain)	15:36 - 15:54
SY06.04	Role of Tfh in Protective Immunity Tony Kelleher (Kirby Institute, UNSW Sydney, Australia)	15:54 - 16:12
SY06.05	Vaccine-induced Th1-biased CD4 T Cell Responses: Too Much can be Bad Rama Amara (Emory University, United States)	16:12 - 16:30

Symposium
15:00 - 16:30

Marsella, Burdeos & Estrasburgo

SY07 Optimizing PrEP Delivery for PrEP Users

This session will discuss the next phase of PrEP implementation – removing barriers to uptake and persistence of PrEP. The talks will focus on integrating PrEP with family planning. They will include: discussion of MPTs; discussion of new PrEP delivery strategies, such as pharmacy- or telemedicine-based delivery; exploration of “positive frame” methods of describing PrEP to help individuals determine whether they might benefit from PrEP; and discussion of new technologies for increasing uptake and persistence of PrEP.

Chairs:

Will Nutland (PrEPster, United Kingdom)
Omar Sued (Fundacion Huesped, Argentina)

SY07.01	Integrating PrEP and Reproductive Health Services and Preparing for MPT Delivery Renee Heffron (University of Washington, United States)	15:00 - 15:22
SY07.02	New Delivery Approaches: Improving PrEP Uptake and Persistence Nneka Nwokolo (Chelsea & Westminster Hospital, United Kingdom)	15:22 - 15:44
SY07.03	PrEP Messaging: Taking “Risk” Out of the Pitch Sarit Golub (Hunter College, United States)	15:44 - 16:06
SY07.04	Mobilizing Communities Through Innovations to Improve PrEP Uptake Nittaya Phanuphak (Thai Red Cross AIDS Research Centre, Thailand)	16:06 - 16:28

Poster Discussion
16:45 - 17:30

Londres

PD06 Mechanisms of Natural Control

Chairs:

Yves Levy (INSERM, France)
Marianne Mureithi (University of Nairobi, Kenya)

PD06.01	Distinct Antibody Profile Associated With HIV Controllers J�romine Klingler (UMR S_1109, France)	16:45 - 16:54
PD06.02	Broadly Neutralizing Sera From Long-term Non-progressors Predominantly Target Envelope Epitopes Within the V3 Glycan-dependent Region Nuria Gonzalez (Instituto de Salud Carlos III, Spain)	16:54 - 17:03

Download Program (PDF)

PD06.03LB	Single-cell Cloning of HIV-specific Natural Killer Cells in Humans Olivier Lucar (Harvard Medical School/Beth Israel Deaconess Medical Center, United States)	17:03 - 17:12
PD06.04	Heightened Inflammatory Response to Acute HIV-1 Infection in Zambian Women Compared to Men Elina El-Badry (Emory University, United States)	17:12 - 17:21
PD06.05	Synergistic Interactions Between Microbial RNA and DNA Sensing Pathways Lead to Improved HIV-1 Immune Recognition by cDCs in Elite Controllers Enrique Martin-Gayo (Ragon Institute of MGH, MIT and Harvard, United States)	17:21 - 17:30

Poster Discussion
16:45 - 17:30

Bristol

PD07 Beyond Acronyms: Understanding Young Women's Dreams, Realities and Perceptions

Chairs:

Margaret McCluskey (USAID/GH/OHA/RES, United States)
Definate Nhamo (Pangaea Zimbabwe AIDS Trust (PZAT), Zimbabwe)

PD07.01	Quantitative Study for HIV Prevention Reveals a Typology Consisting of Six Distinct Types Among South African Adolescent Girls and Young Women Kenyon Crowley (University of Maryland, United States)	16:45 - 16:54
PD07.02	HIV Risk and Perception Among Adolescent Girls and Young Women (AGYW) Accessing Oral Pre-exposure Prophylaxis (PrEP) in Kenya Daniel Were (Jhpiego, Kenya)	16:54 - 17:03
PD07.03	"DREAMS Means Future and Hope." Perceptions of Young Women Selling Sex of How the DREAMS Package Is Affecting Their HIV Risk in Zimbabwe Phillis Mushati (Centre for Sexual Health HIV and AIDS Research (CeSHHAR), Zimbabwe)	17:03 - 17:12
PD07.04	Population Characteristics and Implications for Prevention Interventions for Young Female Sex Workers in Kisumu, Kenya Julie Franks (ICAP at Columbia University, United States)	17:12 - 17:21
PD07.05	How Does Relationship Power Influence HIV Risk Among Adolescent Girls and Young Women in Kenya? Ann Gottert (Population Council, United States)	17:21 - 17:30

Poster Discussion
16:45 - 17:30

Oxford

PD08 Trials and Tribulations in Roll Out

Chairs:

Stacey Hannah (AVAC, United States)

Download Program (PDF)

PD08.01	Adaptive Non-inferiority Margins in HIV Prevention Trials Brett Hanscom (Fred Hutch Cancer Research Center, United States)	16:45 - 16:54
PD08.02	What Do Women Prefer in a Vaginal HIV Prevention Product? Findings From a Discrete Choice Experiment in Southern Africa Erica Browne (RTI International, United States)	16:54 - 17:03
PD08.03	No Discontinuations of TDF-based PrEP Use Due to Changes in Renal Function in a Longitudinal Clinical Cohort Rupa Patel (Washington University in St. Louis, United States)	17:03 - 17:12
PD08.04	PrEP Side-effects and Discontinuation in Pregnant and Non-Pregnant Women Jillian Pintye (University of Washington, United States)	17:12 - 17:21
PD08.05	Project Moxie: A Pilot-study of Video Counseling and Home-based HIV Testing for Transgender Youth Rob Stephenson (University of Michigan Center for Sexuality and Health Disparities, United States)	17:21 - 17:30

Poster Discussion
16:45 - 17:30

Marsella, Burdeos & Estrasburgo

PD09 Long-acting Prevention Agents in Experimental Models

Chairs:

Stephanie Barrett (Merck & Co., Inc., United States)

PD09.01	Ultra-long-acting Tunable, Biodegradable and Removable Injectable Formulation: Sustained Delivery of Dolutegravir in BLT Mice and Macaques S. Rahima Benhabour (University of North Carolina, Chapel Hill, United States)	16:45 - 16:54
PD09.02	Novel Parenteral Platforms for Tunable Long-acting Administration of Hydrophobic HIV Compound Nima Akhavein (GSK, United States)	16:54 - 17:03
PD09.03	Multispecies, In Vivo Evaluation of Subdermal Implants Delivering Tenofovir Alafenamide: Of Mice, Dogs and Sheep Marc M Baum (Oak Crest Institute of Science, United States)	17:03 - 17:12
PD09.04	A Subcutaneous Biodegradable Implant for Sustained Delivery of Tenofovir Alafenamide (TAF) for HIV Pre-exposure Prophylaxis (PrEP) Leah Johnson (RTI International, United States)	17:12 - 17:21
PD09.05	Novel Vaginal Ring Design for the Controlled Release of the Macromolecule Microbicide 5P12-RANTES John McBride (Queen's University Belfast, United Kingdom)	17:21 - 17:30

Download Program (PDF)

Poster Discussion
16:45 - 17:30

Dresden & Stuttgart

PD10 Roadmaps for bNAb Elicitation

Chairs:

Amelia Escolano (The Rockefeller University, United States)
Ralf Wagner (University Of Regensburg, Germany)

PD10.01	Expansion of VH1-2*02 Env-specific B Cells in a Non-neutralizing HIV-1 Env Vaccine Regimen Lamar Ballweber Fleming (Fred Hutchinson Cancer Research Center, United States)	16:45 - 16:54
PD10.02	Assessment of the Frequency of VRC01 Class Naïve B Cells in Different Populations That Can Potentially Engage an HIV CD4 Binding Site Immunogen David Leggat (NIH, VRC, United States)	16:54 - 17:03
PD10.03	Mechanistic Insights Into Vaccine Induction of V2 Apex-directed, Heterologous Tier 2 Neutralizing Responses in CH103 UCA Knock-in Mice Laurent Verkoczy (San Diego Biomedical Research Institute, United States)	17:03 - 17:12
PD10.04	Epitope Focusing by Priming and Sequential Boosting With Glycan-altered Immunogens Induces Immune Responses That Neutralize Heterologous Viruses Tongqing Zhou (VRC, United States)	17:12 - 17:21
PD10.05LB	Dual Maturation Pathways from the Unmutated Common Ancestor of HIV-1 Envelope Broadly Neutralizing Antibodies Overcome Glycan Barriers Mattia Bonsignori (Duke Human Vaccine Institute, Duke University Medical Center, United States)	17:21 - 17:30

Poster
17:30 - 19:30

Poster Hall

P01 Antibody Functions (Neutralizing and Non-neutralizing)

P01.02	Glycoengineering HIV-1 Env Creates "Supercharged" and "Hybrid" Glycans to Increase Neutralizing Antibody Potency, Breadth and Saturation James Binley (San Diego Biomedical Research Institute, United States)
P01.06	Molecular and Structural Characterization of a Highly Neutralization Resistant Tier 3 HIV-1 Strain Thandeka Moyo (International Centre for Genetic Engineering and Biotechnology, South Africa)
P01.08	HIV Neutralising Monoclonal Antibodies With Optimised Antibody Effector Functions Damian Purcell (Doherty Institute, University of Melbourne, Australia)
P01.10	iMab-CAP256, a Novel, Highly Potent Bi-specific Antibody That Targets HIV-1 Tumelo Moshoele (University of the Witwatersrand, Faculty of Health Sciences, South Africa)
P01.12	Impact of Env Conformation and CD4 Downregulation on ADCC Responses Andres Finzi (CRCHUM / Université de Montréal, Canada)

Download Program (PDF)

- P01.14 Plasma Antibodies with Broadly Cross-neutralizing Activity Show an Enhanced Ability to Block HIV-1 Binding to the DC-SIGN Receptor**
Kabamba Bankoledi Alexandre (Council for science and industrial research, South Africa)
- P01.16 Vaccine Induction of V2 Apex-directed, Cross-reactive Neutralizing Antibodies in CH01 UCA “HC Only” Knock-in Mice**
Raiees Andrabi (The Scripps Research Institute, United States)
- P01.18 Immortalization of Murine B Cells After HIV-1 Fusion Peptide Immunization Induces In Vitro Expansion and Maturation of Antibody Secreting B Cells**
Yongping Yang (NIH, United States)
- P01.20 Role of Conventional Antibodies in Control of HIV-1 CRF01_AE Viruses**
Takeo Kuwata (Kumamoto University, Japan)
- P01.22 Pro-inflammatory Cytokine Profiles and HIV-specific Antibody Responses in the Male Genital Tract**
Thevani Pillay (CAPRISA, University of KwaZulu-Natal Nelson Mandela Medical School, South Africa)
- P01.24 Higher HIV Neutralization Breadth in Young Children Than in Chronically Infected Adults**
Genevieve Fouda (Duke University Medical Center, United States)
- P01.26 Structural Comparison of Human Anti-HIV-1 gp120 V3 MAbs of the Same Gene Usage Induced by Vaccination and Chronic Infection**
Xiangpeng Kong (NYU School of Medicine, United States)
- P01.28 Initiation and Early Development of Three MPER-directed Neutralizing Antibody Lineages From a Single HIV-1 Infected Individual**
Nicole A. Doria-Rose (National Institutes of Health, United States)
- P01.30 Immortalization of HIV-1-specific B Cells for Long-term Culture Facilitates Neutralizing Antibody Discovery and Characterization**
Evan Cale (Vaccine Research Center, NIAID, NIH, United States)
- P01.32 Cross-clade ADCC Activities in Human Volunteer Sera Elicited by a Polyvalent DNA Prime-protein Boost HIV Vaccine DP6-001**
Shan Lu (University of Massachusetts Medical School, United States)
- P01.34LB Delineating HIV-1 Evolutionary Pathways Associated With Development of a Broadly Neutralizing Antibody Response**
Vinita Joshi (Ragon Institute of MGH, MIT and Harvard, United States)
- P01.36LB A Co-receptor-mimicking Antibody Stabilizes the Displaced V1V2 Loops in a Partially Open sCD4-bound HIV-1 Envelope Complex**
Christopher Barnes (California Institute of Technology, United States)

Poster
17:30 - 19:30

Poster Hall

P02 Antiretroviral Resistance and Impact on Prevention

- P02.02 Circulating HIV-1 Drug Resistance Mutations in Dar Es Salaam, Tanzania: Implication for Pre-exposure Prophylaxis**
Godfrey Barabona (Centre for AIDS Research, Kumamoto University, Japan)

Download Program (PDF)

- P02.04 Emergence of Novel HIV Polymerase Mutations in Non-B Clades Associated with Treatment Intensification in Cameroon**
Ralf Duerr (New York University - School of Medicine, United States)
- P02.06LB Fully-phased SMRT HIV-pol Sequencing Unravels the Complexity of Viral Quasispecies During Treatment Failure**
Dario Dileina (Emory University Rwanda Zambia HIV Research Group, United States)

Poster
17:30 - 19:30

Poster Hall

P05 Clinical Trial Results

- P05.02 Safety and Acceptability of the PrePex™ Device in Contraindicated Adolescent Boys Age 10-12 Years in Kisumu, Kenya**
Risper Bosire (Impact Research and Development Organization, Kenya)
- P05.04 Post-Exposure Prophylaxis for HIV infection in Sexual Assault Victims.**
Alexy Inciarte (Hospital Clinic/IDIBAPS/University of Barcelona, Spain)
- P05.06 Sexual Risk and Study Drug Detection in MSM Participants in a Phase II Study of Maraviroc (MVC) +/- Tenofovir DF (TDF) or FTC versus TDF/FTC for PrEP**
Kenneth H. Mayer (Fenway Health, United States)
- P05.08 Safety and Pharmacokinetics of DS003 When Administered to Women as a Vaginal Tablet**
Chantél Friend (International Partnership for Microbicides, South Africa)
- P05.10 Vaginal Film Administration and Placement Study in Women (FLAG Trial)**
Sravan Kumar Patel (University of Pittsburgh, United States)
- P05.12 High-risk Single Women as HIV Vaccine Trial Participants: A Suitable Population With High HIV Incidence and Good Retention**
Amanda Tichacek (Emory University, United States)
- P05.14LB HVTN114: A Phase 1 Trial to Evaluate Late Boosts With AIDSVAX B/E of Participants Previously Vaccinated With MVA/HIV62B in DNA/MVA or MVA Regimens**
Paul Goepfert (University of Alabama at Birmingham, United States)
- P05.16LB DNAVAC: Clinical Optimization of DNA Vaccination for Experimental Medicine Trials of gp140 Immunogens**
Hannah M. Cheeseman (Imperial College London, United Kingdom)
- P05.18LB Antibody Mediated Prevention: Proof-of-concept, Randomized, Blinded, Placebo-controlled Trials to Assess Safety and Efficacy of VRC01 to Prevent HIV-1**
Srilatha Edupuganti (Emory University, United States)
- P05.20LB Tetravalent Janssen Mosaic Ad26/Protein HIV Vaccine Shows Increased Clade C Env-specific CD4+ T-cell and Antibody Responses Versus Trivalent Vaccine**
Nicole Frahm (Fred Hutchinson Cancer Research Center, United States)

Poster
17:30 - 19:30

Poster Hall

P28 Transmission of HIV

Download Program (PDF)

- P28.02 Heterosexual Anal Intercourse Practices and Associated HIV Risk in Two Recent Cohort Studies in Eastern and Southern Africa**
Romain Silhol (Imperial College London, United Kingdom)
- P28.04 Targeting Viral Infection Frequency but Not Burst Size Is Effective at Extinguishing Initial Infection in a Model of Suboptimal PrEP**
Ana Moyano de las Muelas (Africa Health Research Institute, South Africa)
- P28.06 Pol-driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection**
Doty Ojwach (HIV Pathogenesis Programme, South Africa)
- P28.08 Providing PrEP Navigation to High-risk Populations With Multiple Health Disparities in Los Angeles, CA, USA: A Comparison of MSM and Trans Women**
Cathy Reback (Friends Research Institute, United States)
- P28.10 Association of Herpes Simplex Virus Type 2 (HSV-2) and HIV Infection Amongst Men Who Have Sex With Men (MSM) in the TRANSFORM Study, Johannesburg**
Cecilia Mokoena (Wits Reproductive Health and HIV Institute (WRHI), South Africa)
- P28.12 Development of a Predictive Algorithm for Transmitted/Founder Phenotype Through In Silico Identification of HIV-1 Envelope Signatures**
Francisco Díez-Fuertes (Instituto de Salud Carlos III, Spain)
- P28.14 Induction of Neutralizing Antibodies Against Autologous Viruses in HIV-1 Infected Pregnant Women Immunized With a gp120/160 Vaccine**
Eliza D. Hompe (Duke University School of Medicine, United States)
- P28.16 Deciphering HIV-1 Infection Into Mucosal Tissues**
Mariangela Cavarelli (CEA, France)
- P28.18 Exploring the Transmission Dynamic of HIV-1 Epidemic Spread in Serbia Using Birth-death Skyline Plot**
Valentina Cirkovic (Institute of Microbiology and Immunology, University of Belgrade Faculty of Medicine, Serbia)
- P28.20 Quantitative Examination of the Capture of HIV-1 Primary Viruses by Human PBMCs in the Presence of Broadly Neutralizing Antibodies**
Jiae Kim (The Henry M. Jackson Foundation for the Advancement of Military Medicine, United States)
- P28.22LB Differential Infection of Cultured Peripheral and CNS Cells by Distinct Transmitted/Founder HIV-1 Infectious Molecular Clones (IMC)**
David Chang (U.S. Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, United States)
- P28.24LB In Vivo Analysis of Penile HIV-1 Acquisition**
Martina Kovarova (University of North Carolina at Chapel Hill, United States)

Poster
17:30 - 19:30

Poster Hall

P14 Implementation Science, Including Structural Interventions, PrEP & VMMC

- P14.02 Testing the Testers: Are Young Men Who Have Sex with Men Receiving Adequate HIV Testing Services?**
Jose Bauermeister (University of Pennsylvania, United States)

Download Program (PDF)

- P14.06 Associations Between Perceived Risk of HIV and PrEP Eligibility, Willingness to Use PrEP, and Actual PrEP Use Among Young MSM in Washington, DC**
Hannah Yellin (George Washington University Milken Institute School of Public Health, United States)
- P14.08 Missed Opportunities: Barriers to PrEP Use Among Patients With Recently Acquired HIV Infection in Northern California**
Jonathan Volk (Kaiser Permanente San Francisco Medical Center, United States)
- P14.10 Awareness and Uptake of DREAMS Interventions and Packages Among Young Women in Kenya and South Africa: Analysis of Population-based Surveys**
Jane Osindo (Africa Population and Health Research Center, Kenya)
- P14.12 Implementing a Patient-centered Peer Counselling Intervention for HIV Treatment in Kenya**
Sarah Iguna (Kenya Medical Research Institute, Kenya)
- P14.14 Outcomes for PrEP Users in the Southern U.S.: Persistence and STIs**
Meredith Clement (Duke University Medical Center, United States)
- P14.16 High Incidence of STIs Among MSM in PrEP Without a Significant Increase**
Oskar Ayerdi (Centro Sanitario Sandoval, IdISSC, Spain)
- P14.18 Using Differentiated HIV Testing Service (HTS) Approaches to Scale up Pediatric HIV Diagnosis on the Roadmap Towards the 90-90-90 Targets in Uganda**
Kiiza Cornelius (AIDS Healthcare Foundation (AHF)-Uganda Cares, Uganda)
- P14.20 Training Health Care Providers to Scale Up PrEP for HIV Serodiscordant Couples Attending Public Health Facilities in Western and Central Kenya**
Josephine Odoyo (Kenya Medical Research Institute, Kenya)
- P14.22 Providing PrEP for People Who Inject Drugs: Are Syringe Services Programs the Way to Go?**
Mehri McKellar (Duke University, United States)
- P14.24 Developing an Effective HIV PrEP Program at STD Clinic**
Jodie L Suh (Ridgewood High School, United States)
- P14.26 Creatively Empowered: The Role of a Creative Concept and IEC Materials in Influencing Decision-making to Use Oral PrEP**
Elmari Briedenhann (Wits Reproductive Health & HIV Institute, South Africa)
- P14.28 Health Care Workers' Knowledge, Attitudes, and Practices About Oral PrEP Provision to Adolescent Girls and Young Women in Zimbabwe**
Definate Nhamo (Pangaea Zimbabwe AIDS Trust (PZAT), Zimbabwe)
- P14.30 Successful Recruitment Strategies Used in Pre-exposure Prophylaxis (PrEP) Study at Kisumu Site, Kenya**
Eric Ochieng Sedah (Kenya Medical Research Institute, Kenya)
- P14.32 Health Care Provider Experiences Delivering PrEP to HIV Serodiscordant Couples in Public HIV Clinics in Kenya**
Kenneth Ngure (School of Public Health, Jomo Kenyatta University of Agriculture and Technology, Kenya)
- P14.34 Baseline and Early Changes in HIV Risk Behavior Among Key Populations Initiating Pre-exposure Prophylaxis (PrEP) in Kenya: Lessons From a PrEP Program**
Griffins Manguro (International Center for Reproductive Health Kenya, Kenya)
- P14.36 Limited Awareness of PrEP Among People Who Inject Drugs in Athens, Greece**
Georgios Nikolopoulos (Medical School, University of Cyprus, Cyprus)

Download Program (PDF)

- P14.38 \$1 a Day PrEP: Sustainable Delivery of Pre-exposure Prophylaxis by the PrEP-30 Program in Bangkok, Thailand**
Nittaya Phanuphak (Thai Red Cross AIDS Research Centre, Thailand)
- P14.40 Characteristics of Oral Pre-exposure Prophylaxis (PrEP) Users From the General Population as Part of Kenya's National PrEP Rollout**
Abednego Musau (Jilinde Project, Jhpiego, Kenya)
- P14.42 A Mixed Methods Study Assessing Readiness for Oral PrEP in a Rural Area of KwaZulu-Natal, South Africa**
Sarah Nakasone (The University of Chicago, United States)
- P14.44 A Model for Mentoring Skills Training in Scientific Writing for HIV Researchers From Low- and Middle-income Countries**
Matthew Price (University of California San Francisco, United States)
- P14.46 Risk Assessment Tools and the Identification of Individuals at High-risk of HIV Infection in the Delivery of Oral PrEP**
Megan S. Dunbar (AVAC, United States)
- P14.48 Factors Associated With Pre-exposure Prophylaxis Adherence in Black Men Who Have Sex With Men and Transgender Women in a Community Setting**
Julie Franks (ICAP at Columbia University, United States)
- P14.50 Using Transportability to Understand Differences in PrEP Effectiveness between Men who Have Sex with Men and Transgender Women in iPrEx**
Megha L. Mehrotra (University of California San Francisco, United States)
- P14.52LB Do VMMC Strategies Increase HIV Testing and Proportion Positive Among Young Men Compared to Non-VMMC Strategies in Kisumu County?**
Harriet Fridah Adhiambo (Kenya Medical Research Institute, Kenya)
- P14.56LB Does Community Distribution of HIV Self-test Kits Increase Uptake of HIV Testing at Population Level? Results of a Cluster-randomised Trial in Zambia**
Melissa Neuman (London School of Hygiene & Tropical Medicine, United Kingdom)
- P14.58LB Results From PEPFAR's DREAMS Partnership: Implications for Prevention Programming for Adolescent Girls and Young Women**
Shannon Allen (USAID, United States)

Poster
17:30 - 19:30

Poster Hall

P03 Behavioral and Social Science Research

- P03.02 Alcohol and Stimulant Use, STIs and Condomless Sex Among HIV-positive Persons With and Without Partners on Pre-exposure Prophylaxis**
J. Carlo Hojilla (University of California, San Francisco, United States)
- P03.04 Acceptability of iCON, an Online Life Skills WebApp for Young Men Who Have Sex With Men and Transgender Women in Metro Detroit**
Jose Bauermeister (University of Pennsylvania, United States)
- P03.06 Functional Knowledge of PrEP and PrEP Use and Willingness Among Male Couples in South Africa and Namibia**
Rob Stephenson (University of Michigan Center for Sexuality and Health Disparities, United States)

Download Program (PDF)

- P03.08 HIV Self-test Distribution by Young Women: An Innovative Way to Reach Men in Rural South Africa**
Linda Kimaru (University of North Carolina, Chapel Hill, United States)
- P03.10 Social Impact of Participating in a Simulated Vaccine Efficacy Trial on Lake Victoria, Uganda**
Emily Keneema (UVRI-IAVI HIV Vaccine Program, Uganda)
- P03.12 Perspectives of South African Health Providers on the Design of an HIV Prevention Implant: Learning From Challenges With Contraceptive Implant Rollout**
Emily A. Krogstad (University of Washington, United States)
- P03.14 Use of Recreational Drugs for Sex in Recent HIV Seroconverters**
Oskar Ayerdi (Centro Sanitario Sandoval, IdISSC, Spain)
- P03.16 SMARTtest: User-designed Smartphone App to Facilitate HIV Self and Partner Testing, Interpretation of Results, and Linkage-to-Care**
Iván Balán (New York State Psychiatric Institute and Columbia University, United States)
- P03.18 Invisible Even Among the Unseen: A Methodological Review of Inclusion of Transgender Persons as Participants in HIV Prevention Research**
Ana María del Río-González (George Washington University, United States)
- P03.20 Perceived Acceptability of Intravenous Infusion of Broadly Neutralizing Antibodies Among Individuals Residing in NYC High HIV Prevalence Areas**
Joanne E. Mantell (ICAP at Columbia University, United States)
- P03.22 What We Talk about When We Talk about Risk: Perceived Sources of HIV Risk Among Young Female Sex Workers and Their Male Clients in Kisumu, Kenya**
Julie Franks (ICAP at Columbia University, United States)
- P03.24 Understanding Chinese Gay Men's Sexual Health Needs to Prepare for Implementation of PrEP in China**
Kathrine Meyers (Aaron Diamond AIDS Research Center, United States)
- P03.26 Characterization of Behavioral and Clinical Risk Factors for HIV Risk Among Transgender Women**
Tanyaporn Wansom (Armed Forces Research Institute of Medical Sciences, Thailand)
- P03.28 Post-exposure Prophylaxis: An Underutilized Biomedical HIV Prevention Method Among MSM in China**
Yumeng Wu (The Rockefeller University, United States)
- P03.30 Dose-response Association Between Cocaine Use and Adherence to HIV Pre-exposure Prophylaxis (PrEP)**
J. Carlo Hojilla (University of California, San Francisco, United States)
- P03.32 "It Takes Two to Tango": Negotiating Condom Use Among Female Sex Workers and Their Male Clients in Kisumu, Kenya**
Kawango Agot (Impact Research & Development Organization, Kenya)
- P03.34 "There Is Nothing to Hide": Disclosure of PrEP Use by Young Women in South Africa and Tanzania - Findings From a Demonstration Project**
Sinead Delany-Moretlwe (University of the Witwatersrand, South Africa)
- P03.36 Intimate Partner Violence and Women Testing for HIV: Findings From the MAISHA Study in North-Western Tanzania**
Sheila Harvey (London School of Hygiene & Tropical Medicine, United Kingdom)

Download Program (PDF)

- P03.38 Characteristics of Male Sexual Partners and Knowledge of Partner's HIV Status Among Women Who Sell Sex Enrolled in an Evaluation of DREAMS, Zimbabwe**
Phillis Mushati (Centre for Sexual Health HIV and AIDS Research (CeSHHAR), Zimbabwe)
- P03.40 High Interest in PrEP and Economic Interventions for HIV Prevention Among Male Sex Workers in Mexico**
Alberto Edeza (Brown University School of Public Health, United States)
- P03.42 Empowerment Among Adolescent Girls and Young Women in Korogocho and Viwandani Slums in Nairobi: Perceptions and Implications for the "E" in DREAMS**
Jane Osindo (Africa Population and Health Research Center, Kenya)
- P03.44 Exploring Perceptions and Experiences of Adolescent Girls and Young Women Participating in DREAMS in Rural Northern KwaZulu-Natal, South Africa**
Thembelihle Zuma (Africa Health Research Institute (AHRI), Nelson Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa)
- P03.46 Stigma, Self-esteem and Depressive Symptoms in HIV-infected Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa (HPTN 075)**
Erica Hamilton (FHI 360, United States)
- P03.50 Testing the Role of Collectivization on Safe Sex Behavior With Occasional Clients Among Female Sex Workers Using Structural Equation Modelling**
Monika Walia (Population Council, India)
- P03.52 Intersectionality of HIV Risk Groups: Substance Using Men Who Have Sex With Men in Lower Socioeconomic Positions**
Tomás Delgado Jr. (University of Miami, United States)
- P03.54 Never Have I Ever: Factors Associated With Never Testing for HIV and With Testing Positive for HIV at First HIV Test in Peruvian MSM and TW**
Steven Shoptaw (UCLA Medical Center, Santa Monica, United States)
- P03.56 Stigma and Mobile App Use Among Young Black Men who Have Sex with Men**
Anna L. Rosengren-Hovee (University of North Carolina Chapel Hill, United States)
- P03.58 Acceptability and Determinants of Uptake of Oral Pre-exposure Prophylaxis (PrEP) among Fishing Communities in Uganda: A Discrete Choice Experiment**
Monica.O. Kuteesa (Medical Research Council/Uganda Virus Research Institute and LSHTM, Uganda research unit, Uganda)
- P03.60LB Which Out-of-school Adolescent Girls and Young Women (AGYW) Should Be Reached With HIV Programming?**
Nanlesta Pilgrim (Population Council, United States)
- P03.64LB Use of Primary Care Providers to Promote Access to HIV Pre-exposure Prophylaxis (PrEP) Among Female Patients in Oakland, California, United States**
Kimberly Koester (University of California, San Francisco, United States)
- P03.66LB Understanding HIV Prevention From the Perspective of Adolescent Girls & Young Women by Applying Behavioral Economics & Human Centered Design**
Anabel Gomez (AVAC, United States)

Download Program (PDF)

Poster
17:30 - 19:30

Poster Hall

P04 Cellular Immunity

- P04.02 Antibody-mediated Phagocytosis of HIV Targets by Leukocytes Isolated From Human Breast Milk**
Rebecca Powell (Icahn School of Medicine at Mount Sinai, United States)
- P04.04 Regulation of CD8+ T Cell Cytotoxic Activity by TGF β in the Human Female Reproductive Tract**
Charles Wira (Geisel School of Medicine at Dartmouth, United States)
- P04.06 ALVAC-HIV/AIDS VAX (R) B/E Late Boost Strategies (RV306) Increase the Proliferative Capacity of CD4+ Effector Memory T Cells**
Alexandra Schuetz (MHRP Thailand, Thailand)
- P04.08 Immunization of BLT Humanized Mice Redirects T Cell Responses to Gag and Enhances Immune Control of HIV-1**
Christian Boutwell (Ragon Institute of MGH, MIT and Harvard, United States)
- P04.10 Induction and Relationship of HIV Envelope-specific B Cells in the Peripheral Blood and Bone Marrow Following Vaccination in Humans**
James Kobie (University of Rochester, United States)
- P04.12 High GILZ Levels in Dendritic Cells From HIV-1+ cART Patients Decrease Their Ability to Induce Effector T Cells and Prevent Effective Vaccination**
Lola Vigouroux (Université Paris-Est-Créteil, France)
- P04.14 Betamethasone Reduces HIV Infection Through Modulation of Cytokine Expression**
Ross Cromarty (Centre for the AIDS Programme of Research in South Africa, South Africa)
- P04.16 Low CCR5 Expression Protects Specific CD4+ T Cells of HIV Controllers From Viral Entry**
Lisa A. Chakrabarti (Pasteur Institute, France)
- P04.18 The Induction of Follicular-like CD8 T-cells by TGF-beta and IL-23 Is Hampered by PD-1 in HIV-infected Patients**
Maria T. Rugeles (Universidad de Antioquia, Colombia)

Poster
17:30 - 19:30

Poster Hall

P06 Community Engagement in Prevention Research

- P06.02 An Electronic Clinic Flow Chart to Optimize Retention at a Community-based HIV Prevention Clinical Trial Centre in South Africa**
Ayman Osman (Setshaba Research Centre, South Africa)
- P06.04 Client-initiated Voluntary Counseling and Testing at an HIV Vaccine Preparedness Rural Research Clinic in South Western Uganda**
Freddie Mukasa Kibengo (MRC/UVRI and LSHTM, Uganda Research Unit, Uganda)
- P06.06 Innovative Approaches for Effective Recruitment of Former Trial Participants Into MTN 025/HOPE Open Label Trial; How Kampala Team Did It!"**
Sophie Clare Nanziri (Makerere University-Johns Hopkins University (MU-JHU) Research Collaboration, Uganda)

Download Program (PDF)

- P06.08 Comparing and Contrasting Evaluation Findings From PrEP and TasP Implementation Projects in a Community Setting From 2015 to 2017**
Gregory Phillips (Northwestern University, United States)
- P06.10 Effective Community Engagement in HIV Prevention Trials: Experience from a Microbicide Trial in South-Western Uganda**
Sylvia Masawi (MRC/UVRI Uganda Research Unit on AIDS, Uganda)
- P06.12 Catalyzing India-Africa Regional Collaboration on Engaging Key Populations in HIV Biomedical Research**
Nikhil Singla (International AIDS Vaccine Initiative (IAVI), India)
- P06.14 Recruitment and Retention of a Highly Mobile Cohort of Fisherfolks At-risk of HIV Acquisition: Experience From a Rural Research Center in SW Uganda**
Freddie Mukasa Kibengo (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)
- P06.16 Transformative Partnerships: Perspectives on Implementing Research Best Practice With Key Populations in Kenya**
George Victor Owino (International AIDS Vaccine Initiative (IAVI), Kenya)
- P06.18 Preparing Ugandan Fishing Communities for HIV Prevention Efficacy Trials: A Cross-sectional Survey of Healthcare Use and Barriers to Access**
Ali Ssetaala (UVRI-IAVI HIV Vaccine Program, Uganda)
- P06.20 Should Good Participatory Practice (GPP) Become a Trial Standard? A Report From the First Global GPP Think Tank**
Stacey Hannah (AVAC, United States)
- P06.22 HIV/STI Prevalence and Contraceptive, Reproductive and Sexual Health of High Risk Women Receiving Services at Two Zambian Research Centers**
Constance Himukumbwa (Zambia Emory HIV Research Project, Zambia)
- P06.24 Capacity Building of Community Advocates Critical for Achieving UNAIDS 90-90-90 Target**
Oluwatosin Alaka (New HIV Vaccine and Microbicide Advocacy Society (NHVMAS), Nigeria)
- P06.26 Assessing Strategies and Capacity for Gender Integration in HIV Biomedical Research**
Ethel Makila (IAVI-Nairobi, Kenya)
- P06.28LB High PrEP Awareness Among Kenyan Young People in High HIV Burden Counties**
Jillian Pintye (University of Washington, United States)

Poster
17:30 - 19:30

Poster Hall

P07 Contraception, Pregnancy and HIV Prevention

- P07.02 An SMS and Clinic-based Tablet Application to Support Safer Conception Among HIV Serodiscordant Couples in Kenya: Feasibility and Acceptability Study**
Jennifer Velloza (University of Washington, United States)
- P07.04 Condom Use Among Young Women Who Sell Sex Enrolled in an Impact Evaluation of DREAMS in Zimbabwe**
Phillis Mushati (Centre for Sexual Health HIV and AIDS Research (CeSHHAR), Zimbabwe)

Download Program (PDF)

- P07.06 Low Levels of Serum Medroxyprogesterone Acetate (MPA) Are Associated With Increased HIV Risk**
Renee Heffron (University of Washington, United States)
- P07.08 One-month PrEP Continuation Among Adolescent Girls and Young Women in Routine Maternal Child Health and Family Planning Clinics**
Kenneth Mugwanya (University of Washington, United States)
- P07.10 Dapivirine Vaginal Ring Use and Cervical Cytology Abnormalities: Data From the Placebo-controlled MTN-020/ASPIRE Trial**
Krishnaveni Reddy (Wits Reproductive Health and HIV Institute, South Africa)
- P07.12 Progestin and ARV Interactions in Cells and Tissues of the Female Reproductive Tract: Implications for Choice of Combination Therapy**
Salndave Bongani Skosana (University of Cape Town, South Africa)
- P07.14 Acceptability of Genital Mucosal Sampling Nested Within a Randomized Contraceptive Trial Among Women in Africa**
Caitlin Scoville (University of Washington, United States)
- P07.18 “Had I Known Before” - Using Peer Led Interventions to Change HIV/STI Risk Behavior Among Adolescents: Health Improvement-4-teen Ugandans Study**
Juliane Etima (MU-JHU Research Collaboration, Uganda)
- P07.20 Implementation of a Safer Conception Program for HIV-affected Men and Women in Uganda**
Lynn T. Matthews (Massachusetts General Hospital, United States)
- P07.22LB No Association Found Between Prenatal PrEP Use and Adverse Infant Outcomes: Results From a Large PrEP Implementation Program in Kenya**
Julia C. Dettinger (University of Washington, United States)

Poster
17:30 - 19:30

Poster Hall

P08 Correlates of Protection and Exposure

- P08.02 Health Workers Perceived Barriers and Attitudes Towards Identifying and Responding to Gender-based Violence in Afghanistan**
Basant Motawi (University of Maryland, United States)
- P08.04 The Interleukin 21 (IL 21)/ microRNA-29 (miR-29) Axis Is Correlated With Natural Resistance to HIV-1 Infection**
Irma Saulle (Università degli studi di Milano, Italy)
- P08.06 Comparison of Baseline Characteristics of Female Sex Workers and Single Mothers in Zambia**
William Kilembe (Zambia Emory HIV Research Project, Zambia)
- P08.08 Ontogeny of T Regulatory and Th17 Cells in HIV-exposed Uninfected Infants From Birth to 36 Weeks**
Sonwabale Dzanibe (University of Cape Town, South Africa)

Download Program (PDF)

Poster
17:30 - 19:30

Poster Hall

P09 Delivery Technologies: Novel Approaches, Formulation and Multi-purpose

- P09.02 DAPTA-modified Nanoparticles as Potential Microbicide Drug Carriers for Targeting CCR5+ Cells**
Catarina Coutinho (i3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal, Portugal)
- P09.04 Solid State ¹³C-NMR Spectroscopy Provides Direct Evidence for Reaction Between Ethinyl Estradiol and a Silicone Elastomer Vaginal Ring**
Clare F. McCoy (Queen's University Belfast, United Kingdom)
- P09.06 Mechanical Testing Protocols for Vaginal Ring Formulations**
Clare F. McCoy (Queen's University Belfast, United Kingdom)
- P09.08 Effect of Exposure of the 25 mg Dapivirine Vaginal Ring to Cleaning Solutions and Personal Lubricants**
Diarmaid Murphy (School of Pharmacy, Queen's University Belfast, United Kingdom)
- P09.10 Microarray Patches (MAPs) for Delivery of Long-acting HIV PrEP and Contraception**
Annie Rein-Weston (PATH, United States)
- P09.12 Systematic Review of the Performance and Clinical Utility of Point-of-care HIV-1 RNA Tests for Diagnosis and Care**
Clara A Agutu (KEMRI-Wellcome Trust Research Programme, Kenya)
- P09.14 Formulation Development of a Segmented Intravaginal Ring for the Concurrent Delivery of Dapivirine and DS003**
Wendy Blanda (International Partnership for Microbicides, United States)
- P09.16 Compatibility Screening for Excipients for Delivery of Dapivirine and Darunavir Concurrently From an Intravaginal Ring**
Wendy Blanda (International Partnership for Microbicides, United States)
- P09.18 Targeted Adolescent HIV Testing in Two South African Health Sub-districts**
Sinead Delany-Moretlwe (University of the Witwatersrand, South Africa)
- P09.20 Vaginal Ring for Sustained Release of DL-lactide as a Lactic Acid Pro-drug**
Vicky-Leigh Young (Queen's University Belfast, United Kingdom)
- P09.22 Monoclonal Antibodies Against CD52g, a GPI-anchored Glycoprotein in Semen, Co-agglutinate Sperm and Capture Semen-exposed HIV**
Gabriela Baldeon Vaca (Boston University School of Medicine, United States)
- P09.24 Mucus-diffusive Nanoparticles Provide Enhanced Local Pharmacokinetics of Efavirenz Following Rectal Administration**
Rute Nunes (i3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal, Portugal)

Poster
17:30 - 19:30

Poster Hall

P10 Discovery and Evaluation of Biomedical Agents

Download Program (PDF)

- P10.02 A New Humic Substance (HS)-based Potential Microbicide Strongly Active Against HIV**
Andrei Siniavin (Gamaleya Center for Epidemiology and Microbiology, Russian Federation)

Poster
17:30 - 19:30

Poster Hall

P11 Epidemiology of HIV

- P11.02 Baseline Socio-demographic Characteristics Associated With HIV Prevalence Rates Among MSM in the TRANSFORM Study, Johannesburg, South Africa**
Thesla Palanee-Phillips (Wits Reproductive Health and HIV Institute, South Africa)
- P11.04 Prevalence and Determinants of Anal Intercourse Among Female Sex Workers in Swaziland**
Branwen Nia Owen (Imperial College London, United Kingdom)
- P11.06 Experience of Violence Is Associated With HIV Prevention Uptake and HIV Infection Among Young Women Who Self-identify as Sex Workers in Mombasa, Kenya**
Michael Pickles (Imperial College London, United Kingdom)
- P11.08 Epidemiological Trade-offs: How Much Yield Is Sacrificed When Reaching Men and Implementing Workplace Services?**
Dorian Smith (CareWorks, South Africa)
- P11.10 Prevalence and Factors Associated With Recreational Drug Use Among Volunteers in a High-risk Fisher Folk Community in South Western Uganda**
Freddie Mukasa Kibengo (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)
- P11.12 A Meta-analysis of Metabolic Syndrome Prevalence in HIV Infected and Uninfected Populations in Sub-Saharan Africa**
Olamide Todowede (University of KwaZulu-Natal, South Africa)
- P11.14 High Incidence Rate of HIV Infection Among a MSM Cohort in Tokyo**
Daisuke Mizushima (National Center for Global Health and Medicine, Japan)
- P11.16 Pooling Strategy to Detect Acute HIV-1 Infection (AHI) Among At-risk Women**
William Kilembe (Zambia Emory HIV Research Project, Zambia)
- P11.18 Common Signs and Symptoms of Sexually Transmitted Infections Among Most at Risk Populations in the Early Capture Cohort Study in Kampala, Uganda**
Douglas Makumbi (Makerere University Walter Reed Project, Uganda)
- P11.20 Evidence of Growing HIV Epidemic Among Men Who Have Sex With Men in Ukraine**
Tetiana Saliuk (Alliance for Public Health, Ukraine)
- P11.22 Sexual Behavior and HIV Incidence Among High Risk Women Cohorts in Two Urban Cities in Zambia**
Ana-Maria Visoiu (Zambia Emory HIV Research Project, Rwanda Zambia HIV Research Group, Emory University, Zambia)
- P11.24 Number of Sexual Partners Does Not Predict HIV Status in a Brazilian STI Clinic**
Ricardo Vasconcelos (Medicine School of University of São Paulo, Brazil)

Download Program (PDF)

Poster
17:30 - 19:30

Poster Hall

P12 Ethics in HIV Prevention Research

- P12.02 Roll-over: Experience of Switching Participants to Active Treatment Arm During a Phase III Placebo-controlled Trial**
Annalene Nel (International Partnership for Microbicides, South Africa)
- P12.04LB Is Parental Consent Needed to Access PrEP? Parents, Adolescents and Providers Weigh In**
Nanlesta Pilgrim (Population Council, United States)

Poster
17:30 - 19:30

Poster Hall

P13 Immunogenetics (Host Immunity and Restriction Factors)

- P13.02 A Rapid Protocol for Enriching Peptide-specific CD8 T Cell Lines to Determine Their Contribution to Viral Inhibition**
Julia Makinde (Imperial College London, United Kingdom)
- P13.04 Polymorphisms in Host Factors Fc-gamma Receptors IIa and IIIa Demonstrate Insignificant Impact on Heterosexual HIV Acquisition and Disease Progression**
Sarah Connolly (Emory Vaccine Center and Yerkes National Primate Research Center, United States)
- P13.06 Evaluation of Protective Genetic Variants in HIV-1-infected cART Treated Patients**
Elisa Maria Lori (Università degli Studi di Milano, Italy)
- P13.08 Possible Effect of Hyperthermia on Accessibility of Cellular and Viral miRNAs to mRNAs Involved in HIV Replication**
Lucia Guzman (Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, UBA-CONICET, Argentina)
- P13.10 Development of Neutralizing Antibody Responses in SHIV CH505-infected Adult and Infant Rhesus Macaques**
Ashley N. Nelson (Duke University School of Medicine, United States)

Poster
17:30 - 19:30

Poster Hall

P15 Innate Immunity

- P15.02 Association of Vaginal Microbiota With Mucins in the Cervicovaginal Fluid**
Bernard J Moncla (University of Pittsburgh School of Medicine, United States)

Poster
17:30 - 19:30

Poster Hall

P16 Mathematical Modeling: Impact and Effectiveness

- P16.02 Shortened Time to ART Initiation in MSM Reduces Risk of HIV-1 Sexual Transmission**
Juan Berenguer (Infectious Diseases at Hospital General Gregorio Marañón, Spain)

Download Program (PDF)

- P16.04 Oral Pre-exposure Prophylaxis for HIV Prevention in Lesotho: Modeling the Potential Cost-effectiveness and Impact**
Robert Manda (U.S. Agency for International Development, Lesotho)
- P16.06 Potential Competition Between PrEP and HIV Vaccines in Seattle, WA**
Blythe Adamson (University of Washington, United States)
- P16.08 A Compositional Transform Reveals HIV Exposure Induced Shifts in the Fecal Microbiota of Nigerian Infants**
Bryan Brown (Seattle Children's Research Institute, United States)
- P16.10 Modelling the Impact of Prevention and Treatment Interventions on HIV and Hepatitis C Virus Transmission Among PWID in Nairobi**
Jack Stone (University of Bristol, United Kingdom)
- P16.12 Impact of Scaling Up Pre-exposure Prophylaxis Among Female Sex Workers in South Africa: A Modelling Analysis**
Jack Stone (University of Bristol, United Kingdom)
- P16.14 The Potential Impact of Risk Compensation in Response to an HIV Vaccine: Accelerated Rates of Viral Adaptation and Reduced Cost-effectiveness**
Kathryn Peebles (University of Washington, United States)
- P16.16LB Modeling Pharmacokinetics and Pharmacodynamics of Luminally Acting Microbicides Delivered by Vaginal Inserts: Application to Griffithsin**
Alan Sze (Duke University, United States)

Poster
17:30 - 19:30

Poster Hall

P17 Microbiome & STI: Impact on Prevention

- P17.02 Impact of the 25 mg Dapivirine and Placebo Vaginal Rings on the Vaginal Microbiota of Adolescents, Lactating and Post-menopausal Women**
Sharon Hillier (University of Pittsburgh, United States)
- P17.04 Immune Modulatory Effects of Vaginal Microbiota Organic Acid Metabolites on Ectocervical Epithelial Cells**
David Delgado Diaz (Burnet Institute, Australia)
- P17.06 Repopulating the Cervicovaginal Microbiome With Beneficial Lactobacillus sp. to Prevent HIV Acquisition**
Laurel Lagenaur (Osel Inc., United States)
- P17.08 Metabolomics as a Novel Safety Measure in the Vaginal Delivery of Antiretroviral Drugs**
Marc M Baum (Oak Crest Institute of Science, United States)
- P17.10 Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using Placebo, Tenofovir and Tenofovir/Levonorgestrel Vaginal Rings**
Andrea Ries Thurman (CONRAD Eastern Virginia Medical School, United States)
- P17.12 Reducing Genital Inflammation and HIV Risk: Assessing the Role of Point-of-care STI/BV Testing With Expedited Partner Therapy**
Nigel Garrett (CAPRISA, University of KwaZulu-Natal, South Africa)

Download Program (PDF)

- P17.14** **Cost Effective Approach for Detection of HIV1, HIV2, HCV & HBV in Blood Plasma Using Multiplex PCR & Validating Result by Liquid Hybridization Assay**
Priyanka Sharma (Seth Research Foundation, India)
- P17.16** **Cohort-level Analysis of the Functional Variation of the Vaginal Microbiome**
Sarah Mutch (University of Manitoba, Canada)
- P17.18** **Longitudinal Comparison of Diagnosis of Bacterial Vaginosis Using Nugent Criteria Compared to cpn60 Microbial Profiling Among African Women**
Elinor Shvartsman (University of Manitoba, Canada)
- P17.20LB** **Altered Composition and Elevated Diversity in the Enteric Virome of HIV Exposed Uninfected South African Infants**
Bryan Brown (Seattle Children's Research Institute, United States)

Poster
17:30 - 19:30

Poster Hall

P18 Mucosal Immunology

- P18.02** **Clearance of Sexually Transmitted Infections and the Impact of Genital Inflammation in HIV-infected Women**
Andile Mtshali (Centre for the AIDS Programme of Research in South Africa, South Africa)
- P18.04** **Neutralization Potency Can Account for the Majority of Antibody-mediated Protection Observed in ex vivo Vaginal Explant Models of Early HIV Infection**
Rena D. Astronomo (Fred Hutchinson Cancer Research Center, United States)
- P18.06** **Abundant Highly Activated Th17 Cells in the Lower Reproductive Tract of Adolescent Girls at Risk for HIV Infection**
Iyaloo Konstantinus (University of Cape Town, South Africa)
- P18.08** **Altered CD4+ CCR5+ Expression and Cellular Activation in Mucosal and Lymphoid Tissues of Transgender Women**
Sandhya Vasan (Military HIV Research Program, Henry M. Jackson Foundation, Thailand)
- P18.10** **Relationship Between Vitamin D Deficiency and Genital Mucosal Immunity in Young South African Women Related to Risk for HIV and HPV Infections**
Ramla F Tanko (University of Cape Town, Institute of Infectious Disease and Molecular Medicine (IDM), South Africa)
- P18.12** **Fibroblasts Protect Against HIV Infection of the Human Female Reproductive Tract**
Mickey Patel (Geisel School of Medicine at Dartmouth, United States)
- P18.14** **Women Recently Exposed to Sexual Violence Have Increased Levels of Plasma C-reactive Protein, an Inflammatory Marker Associated With HIV Infection**
Mimi Ghosh (George Washington University, United States)
- P18.16** **Liver Bacterial Dysbiosis Persists During Antiretroviral Therapy of SIV+ Macaques**
Bridget Fisher (Center for Infectious Disease Research, United States)
- P18.18** **Metaproteomics Based Methodologies for Large-scale Analysis of Host and Microbial Function in a Human Cohort**
Michelle Perner (University of Manitoba, Canada)

Download Program (PDF)

- P18.20 Anti-HIV miRNAs Protect CD4+ T Cells from the Human Female Reproductive Tract from HIV Infection**
Mickey Patel (Geisel School of Medicine at Dartmouth, United States)
- P18.22LB Exploring the Impact of HIV-1 Infection on Overall and HIV-specific Gut Mucosal B Cells and Antibody Excretion in a Kenyan Cohort**
Xinyan Wang (Department of Immunology, University of Toronto, Canada)

Poster
17:30 - 19:30

Poster Hall

P19 Novel Vaccine and Prevention Approaches

- P19.02 Vector-mediated Delivery of Broadly Neutralizing Antibodies (bNAbs) Targeting the V2 Apex**
Nigel Aminake Makoah (National Institute for Communicable Diseases, South Africa)
- P19.04 Development of a Scalable Plant-based Expression System for the Production of Soluble HIV-1 Envelope Protein Trimers**
Emmanuel Margolin (Institute of Infectious Diseases and Molecular Medicine, University of Cape Town, South Africa)
- P19.06 Differential Induction of Antibody Responses to V1V2 and V3 of HIV Envelope gp120 by Immune Complex Vaccines**
Catarina Hioe (Icahn School of Medicine at Mount Sinai, United States)
- P19.08 Designing an Indian Clade C 4-2.J41 Based Soluble Trimeric Env With Targeted Glycan Holes to Improve Immune-focusing**
Shubbir Ahmed (Translational Health Science and Technology Institute, India)
- P19.10 Gene Editing to Solve the Proteolysis Problem in the Production of Env Vaccines Expressed in CHO Cells**
Sophia Li (University of California, Santa Cruz, United States)
- P19.12 Scaffold-based Epitope Designing: Reorienting Focus Towards HIV Env Surface**
Tripti Shrivastava (Translational Health Science and Technology Institute, India)
- P19.14 Differential Regulation of HIV-1 Envelope Protein Intracellular Trafficking by Cytoplasmic Tail**
Sweety Samal (Translational Health Science and Technology Institute, India)
- P19.16 Army Liposome Formulations, ALFA and ALFQ, Are Potent Adjuvants**
Zoltan Beck (Henry M. Jackson Foundation for the Advancement of Military Medicine, United States)
- P19.18 Variants of HIV Envelope Glycoprotein With Enhanced Affinity for Precursors to Broadly Neutralizing Antibodies Identified Using Yeast Surface Display**
Mark Dumont (University of Rochester, United States)
- P19.20 Sendai Virus Particles Carrying an HIV Env-Sendai Virus F Chimeric Protein for Induction of Anti-HIV Antibodies**
Hiroshi Ishii (National Institute of Infectious Diseases, Japan)
- P19.22 Virus-like Particle (VLP) and Stabilized Trimer (SOSIP) Immunogens Based on HIV-1 Envelopes From Patients With Early Broadly Neutralizing Responses**
Carolina Beltrán Pavez (Institute of Health Carlos III, Spain)

Download Program (PDF)

- P19.24 Anti-PD-1 Antibody Combined With IL15/IL15R α Improves In Vitro Polyfunctional HIV-1 Specific T-cell Responses to Dendritic Cell-therapeutic Vaccination**
Audrey Hubert (Inserm, U955, Equipe 16, France)
- P19.26 A New Generation of C-terminally Stabilized Env BG505 SOSIP Trimers: Structural and Immunogenic Characterization**
Guidenn Sulbarán (Univ. Grenoble Alpes, CEA, CNRS, IBS, France)
- P19.28 Potent HIV-1-specific CD8 T Cell Responses Induced in Mice After Immunization With a Heterologous DNA-TMEP Prime/ MVA-B Vaccine Boost Regimen**
Carmen Elena Gómez (Centro Nacional de Biotecnología (CNB-CSIC), Spain)
- P19.30 Recombinant BCG:tHIVconsvX Prime-ChAdOx:tHIVconsvX Boost Regimen Was Safe, Stable and Elicited Specific HIV-1 T-cell Immune Responses in BALB/C Mice**
Athina Kilpeläinen (Hospital Clínic/IDIBAPS-HIVACAT, Spain)
- P19.32 A Heterologous HIV-1/SIV gp140 Prime-boost Regimen Induces Broad HIV-1 Antibody-dependent Cellular Cytotoxicity Responses**
Jeanette Linnea Tingstedt (Statens Serum Institut, Denmark)
- P19.34 MVA Vaccine Candidates Expressing Trimeric HIV-1 Clade C Envelopes as Immunogens Against HIV**
Juan García-Arriaza (Centro Nacional de Biotecnología (CNB-CSIC), Spain)
- P19.36 gp41 Residues Modulate CD4-induced Conformational Changes in the Env and Evolution of a Relaxed Conformation of gp120**
Carol Weiss (FDA, United States)
- P19.38 Optimizing Murine Vaccination Regimens to Elicit HIV-1 Neutralizing Responses Targeting Diverse Fusion Peptide Sequences**
Hui Geng (Vaccine Research Center, NIAID, NIH, United States)
- P19.40 Potent Expression of HIV-1 Broadly Neutralizing Antibodies Using DNA Encoded Monoclonal Antibody Technology**
Megan Wise (Inovio Pharmaceuticals, United States)
- P19.42 Integrase-defective Strains of HIV Are Transcriptionally Active and Immunogenic in BLT Humanized Mice**
Daniel Claiborne (Ragon Institute of MGH, MIT and Harvard, United States)
- P19.44LB IV-1 Lineage Envelope Proteins Based on Viral Sequences From Elite Neutralizers**
Anna Schorcht (AMC Amsterdam, Netherlands)
- P19.46LB Development of HIV-1 gp120 Core-based Immunogens for Priming CD4 Binding Site bNAbs**
Quentin Sattentau (Sir William Dunn School of Pathology, United Kingdom)
- P19.48LB HIV-1 Incidence, Adherence to Ring Use and Safety in an Open-label Trial of Dapivirine Vaginal Ring - DREAM**
Annalene Nel (International Partnership for Microbicides, South Africa)
- P19.50LB Co-administration of 3 Doses of DNA/Protein Improves Antibody Responses to a Prime-boost Approach, but Needle-free Injection of DNA Shows No Benefit**
Mina Hosseinipour (University of North Carolina at Chapel Hill, Malawi)

Download Program (PDF)

Poster
17:30 - 19:30

Poster Hall

P20 Passive Immunization

- P20.02 Pushing the Envelope With Rationally Designed Multi-NAbs**
James Steinhardt (Institute for Bioscience and Biotechnology Research, United States)
- P20.04 Determinants of Transplacental Transfer of Protective Maternal IgG in HIV-infected Women**
David R. Martinez (Duke Human Vaccine Institute, United States)
- P20.06LB Engineering Enhanced HIV Broadly Neutralizing Antibodies (ebnAbs) With Improved Potency**

Poster
17:30 - 19:30

Poster Hall

P21 Pharmacology/PK and PD Studies

- P21.02 Pharmacodynamic Activity of DS003, a Novel gp120 Blocker, When Administered to Women as a Vaginal Tablet**
Jeremy Nuttall (International Partnership for Microbicides, United States)
- P21.04 Pharmacokinetics (PK) of Dapivirine Vaginal Ring (25 mg) Co-administered With Clotrimazole**
Neliette Van Niekerk (International Partnership for Microbicides, South Africa)
- P21.06 Anti-HIV Activity and Drug Concentrations in Tenofovir-based Products: Intravaginal Ring Versus Oral Tablet**
Jill Schwartz (CONRAD Eastern Virginia Medical School, United States)

Poster
17:30 - 19:30

Poster Hall

P22 Phylogenetics and Viral Diversity

- P22.02 Analysis of Vpu-mediated CD4 and Tetherin Downregulation Across Major HIV-1 Group M Subtypes**
Gisele Umviligihozo (Simon Fraser University, Canada)
- P22.04 Characterization of HIV-1 Transmission Clusters Actively Expanding in Spain**
Elena Delgado (Instituto de Salud Carlos III, Spain)
- P22.06LB Tracing HIV-1 Evolution in a Dually Infected Subject Developing a Broadly Neutralizing Antibody Response**
Ruchi M. Newman (Ragon Institute of MGH, MIT and Harvard, United States)

Poster
17:30 - 19:30

Poster Hall

P23 Policy and Advocacy

Download Program (PDF)

- P23.02 Evolution in the Adoption of National Policies on PMTCT in Relation to WHO Guidelines: A Policy Review From South Africa, Tanzania and Malawi 2013-2017**
Mosa Moshabela (Africa Health Research Institute, South Africa)
- P23.04 Planning for Dapivirine Ring Introduction: Summarizing Lessons Learned from Like-product Experiences**
Elizabeth Gardiner (AVAC, United States)
- P23.06 Civil Society Role in HIV Vaccine Research: A Report From the Vaccine Advocacy Resource Group (VARG)**
Stacey Hannah (AVAC, United States)
- P23.08LB HIV Prevention Research & Development Funding Trends 2016-2017: Investing to End the Epidemic as a Public Health Threat**
Fatima Riaz (AVAC, United States)

Poster
17:30 - 19:30

Poster Hall

P24 Pre-clinical Studies for HIV Prevention

- P24.02 Combination of Griffithsin and Broadly Neutralizing Antibodies Results in Antiviral Synergy Against HIV-1**
José A. Fernández Romero (Borough of Manhattan Community College, United States)
- P24.04 Exploring the Causes of Attrition in HIV Vaccine Clinical Trials Among Men Who Have Sex With Men (MSM)**
Hellen Babu (Partners for Health and Development in Africa, Kenya)
- P24.06 Pharmacokinetic Comparison of DS003, a Novel gp120 Blocker, Delivered by Vaginal Tablet or Vaginal Ring in Pigtailed Macaques**
Jeremy Nuttall (International Partnership for Microbicides, United States)
- P24.08 Investigation of the South African Medicinal Plant Lobostemon Trigonus as a Potential HIV-1 Microbicide**
Phindiwe Felicia Chawuke (Council for Scientific and Industrial Research, South Africa)
- P24.10 Env-2dCD4S60C Complexes Elicit Potent, Broadly Neutralizing Antibodies Against Clinically Relevant Viruses in Chinese Origin Rhesus Macaques**
Roberto Carlos Rebelo Pereira (University of the Witwatersrand, Faculty of Health Sciences, South Africa)
- P24.12 Comparison of p24 and Spliced RNA to Quantify Viral Growth and Drug Response in Cervicovaginal Explants**
Lindsey Brewers (University of Minnesota, United States)
- P24.14 Analysis of the Genital Tract Metaproteome in South African Women: From Bacterial Vaginosis Biomarkers to HIV Prevention**
Arghavan Alisoltani (University of Cape Town, South Africa)
- P24.16 Ovine Vaginal Microbiome and Cytokine Profiles as Safety Markers for Vaginal Drug Delivery Studies**
Richard Pyles (University of Texas Medical Branch, United States)

Download Program (PDF)

- P24.18 Comparison of Droplet Digital PCR Techniques to Characterize HIV-1 Replication in Explant Models**
Rhonda M. Brand (University of Pittsburgh School of Medicine, United States)
- P24.20 Preclinical Progressive Selection of a Tenofovir Prodrug Enema for HIV Pre-exposure Prophylaxis**
Thuy Hoang (Johns Hopkins School of Medicine, United States)
- P24.22 Mucosal Elicitation of Anti-V2, a4b7-site-targeted Antibodies**
Timothy Cardozo (New York University School of Medicine, United States)
- P24.26LB Assessing Immunogenicity of Novel Envelope Components for Ad26/gp140 Protein-based Vaccines in Rhesus Monkeys**
Frank Wegmann (Crucell Holland B.V., a Janssen pharmaceutical company of Johnson & Johnson, Netherlands)

Poster
17:30 - 19:30

Poster Hall

P25 Product Acceptability and Adherence

- P25.02 Assessing the Uptake and Acceptability of PrEP Among Sex Workers One Year After Scale-up in Nairobi, Kenya**
Hellen Babu (Partners for Health and Development in Africa, Kenya)
- P25.04 Understanding the Acceptability of Removable Implanted Medication Delivery Devices (RIMDDs) as a Possible New HIV Prevention Method**
Christine Tagliaferri Rael (Columbia University, United States)
- P25.06 Empowering Trial Participants to Use the Dapivirine Vaginal Ring: Experience from an Open Label Extension Trial in South Western Uganda**
Irene Nassuuna (MRC/UVRI & LSHTM Uganda Research Unit, Uganda)
- P25.08 Sharing Residual Drug Levels With Trial Participants: Experience From an Open Label Extension Microbicide Trial in South Western Uganda**
Anita Kabarambi (MRC/UVRI and LSHTM, Uganda Research Unit, Uganda)
- P25.10 Challenges to Collecting PrEP Adherence Data in the New York City (NYC) Site of the HPTN 067 Study**
Sharon Mannheimer (Columbia University/Mailman School of Public Health/ICAP, United States)
- P25.12 Feasibility and Effect of Integrated Next Step Counseling on Subjects' Adherence to HIV Pre-exposure Prophylaxis in the Senegal Demonstration Project**
Eric Tousset (Aardex Group, Belgium)
- P25.14 Comparison of Accuracy of MEMs, Missed Dosages and Pill Count Against Tenofovir Blood Level Tests, for PrEP Adherence Among Key Population in Kenya**
Christian Ochieng (LVCT Health, Kenya)
- P25.16 Post-use Ring Weight, Residual Drug Content and Drug Depletion Zone Thickness as Objective Measures of Vaginal Ring Adherence**
Diarmaid Murphy (School of Pharmacy, Queen's University Belfast, United Kingdom)
- P25.18 Retention and Persistence on PrEP for MSM and TGW: 96-week Results of the PrEP Brazil Demonstration Study**
Valdilea Veloso (Fundação Oswaldo Cruz, Brazil)

Download Program (PDF)

P25.20LB There Is No Difference in Usability and Performance of Oral and Blood Based HIV Self Screening Tests in South Africa

Mohammed Majam (University of the Witwatersrand, South Africa)

P25.22LB Delivering PrEP: Lessons From Early Demonstration Projects

Elizabeth Gardiner (AVAC, United States)

Poster
17:30 - 19:30

Poster Hall

P26 Systems Immunobiology Approaches & Sequencing Technologies

P26.02 miRNAs Profile of PBMCs Show Higher Disruption of TGF-beta Signaling Pathway in HIV/HCV Patients

Óscar Brochado-Kith (Institute of Health Carlos III, National Center of Microbiology, Spain)

Poster
17:30 - 19:30

Poster Hall

P27 Therapeutic Vaccine, Viral Latency and Cure

P27.02 Development of Human Follicular Dendritic Cells and B Cell Follicles Supports Enhanced HIV Replication in BLT Humanized Mice

Todd Allen (Ragon Institute of MGH, MIT and Harvard, United States)

P27.04 CD4-mimetic Compounds Sensitize Simian-human Immunodeficiency Viruses Infected Cells to ADCC

Andres Finzi (CRCHUM / Université de Montréal, Canada)

P27.06 Fully MHC-matched Allogeneic Hematopoietic Stem Cell Transplantation in cART-suppressed Macaques Indicates GVHD as a Reservoir Clearance Mechanism

Helen L Wu (Oregon Health and Science University, United States)

P27.08 Nef HLA-I Downregulation Function in Early HIV Infection Correlates With Latent Reservoir Size on cART

Fredrick Omondi (Simon Fraser University, Canada)

P27.10 In-situ Detection of HIV Latency via Super-resolution Imaging

Rhonda M. Brand (University of Pittsburgh School of Medicine, United States)

P27.12 Autologous HIV-1 Isolation Under GMP Conditions by Co-culturing Macrophages Derived From Monocytes and CD8- T Cells

Sonsoles Sánchez-Palomino (IDIBAPS, Spain)

P27.16LB HIV Cure Means "I Wake Up in the Morning and My Shadow Is Not There:" Cure Research Findings Every HIV Prevention Researcher Should Know

George Greene (Northwestern University, United States)

Download Program (PDF)

Poster
17:30 - 19:30

Poster Hall

P29 Treatment as Prevention

- P29.02 HIV-specific Antibody Mediated Targeting of ENV+ Tissues by Exosomes**
Xue Zou (Nanjing University, China)
- P29.04 From “Treatment as Prevention” to Undetectable=Untransmittable: Advancing the Research and Policy Agenda to Ensure Relevance for All Women**
Judith Auerbach (University of California, San Francisco, United States)
- P29.06 Increases Over Time in HIV Testing Among MSM in Africa: A Systematic Review and Meta-analysis**
Kate M. Mitchell (Imperial College London, United Kingdom)
- P29.08 Sub-optimal Engagement of African MSM in the HIV Treatment Cascade: A Systematic Review and Meta-analysis**
James Stannah (Imperial College London, United Kingdom)
- P29.10 The Mechanism of Action of the Potential HIV-1 Microbicide Hydroxytyrosol Involves Viral Integration and Transcription**
Luis Miguel Bedoya (Universidad Complutense de Madrid, Spain)
- P29.12 Improving ART Programs for Prevention Impact in Ukraine**
Kostyantyn Dumchev (Ukrainian Institute on Public Health Policy, Ukraine)

Poster
17:30 - 19:30

Poster Hall

Poster Session 02

Odd-numbered abstracts will be presented in Poster Session 01 on Tuesday, 23 October. Even-numbered abstracts will be presented in Poster Session 02 on Wednesday, 24 October.

Download Program (PDF)

Thursday, 25 October 2018

Oral
08:30 - 10:00

Londres

OA16 Tickling the Germline

Chairs:

Marit van Gils (Amsterdam AMC, University of Amsterdam, Netherlands)
Ian Wilson (The Scripps Research Institute, United States)

OA16.01	Targeted Selection of an Improbable HIV-1 Antibody Mutation Critical for Broadly Neutralizing Reactivity With a Designed Immunogen Kevin Wiehe (Duke University, United States)	08:30 - 08:48
OA16.02	Carbohydrate Mimicry for Eliciting Oligomannose-targeting Neutralizing Antibodies to HIV-1 Ralph Pantophlet (Simon Fraser University, Canada)	08:48 - 09:06
OA16.03	Vaccine Induction of VRC01-class Neutralizing Antibodies in a Knock-in Mouse Model Xuejun Chen (Vaccine Research Center/NIAID/NIH, United States)	09:06 - 09:24
OA16.05	Phenotypic Deficits in the HIV-1 Envelope Are Associated With the Maturation of a V2-directed Broadly Neutralizing Antibody Lineage Lucia Reh (University of Zurich, Switzerland)	09:24 - 09:42
OA16.06	Chimpanzee SIV Envelope-derived Trimer Guides an Immunofocused HIV Cross-neutralizing Ab Response in V2-apex bnAb UCA Expressing Knock-in Mice Raiees Andrabi (The Scripps Research Institute, United States)	09:42 - 10:00

Oral
08:30 - 10:00

Bristol

OA17 Factors Influencing Viral Transmission and Spread

Chairs:

Jason Brenchley (Niaid, United States)
Nabila Seddiki (Inserm U955, Team 16, France)

OA17.01	HLA Pre-adaptation in Gag Influences Viral Evolution in the New Host Daniela Monaco (Emory University, United States)	08:30 - 08:45
OA17.02LB	Treatment of Schistosoma mansoni Infection in Ugandan Women Reduces HIV Entry Into Cervical CD4 T Cells and Induces Type I Interferon Pathways Rupert Kaul (University of Toronto, Canada)	08:45 - 09:00
OA17.03	The Eclipse Phase Lasted a Week in HIV-1-infected Adults in East Africa and Thailand Morgane Rolland (MHRP HJF, United States)	09:00 - 09:15

Download Program (PDF)

OA17.04	Infection With Multiple Transmitted/Founder (TF) HIV-1 Viruses Impacts Peak VL and HIV-1 Pathogenesis Gladys Macharia (IAVI Human immunology Lab, Imperial College London, United Kingdom)	09:15 - 09:30
OA17.05	Localization of Infection in Neonatal Rhesus Macaques After Oral Viral Challenge Roslyn A. Taylor (Northwestern University, United States)	09:30 - 09:45
OA17.06	Gp41 Ectodomain-specific IgG is Associated with Increased Vertical HIV-1 Transmission Nicole Naiman (Fred Hutchinson Cancer Research Center, United States)	09:45 - 10:00

Oral
08:30 - 10:00

Oxford

OA18 Opinion 360: Meaningful Engagement From Research to Roll Out

Chairs:

Manju Chatani-Gada (AVAC, United States)
Kundai Chinyenze (International AIDS Vaccine Initiative, Kenya)

OA18.01	Beneficial Impacts Related to Participating in an International HIV Prevention Trial Involving People Who Inject Drugs Jeremy Sugarman (John Hopkins, United States)	08:30 - 08:45
OA18.02	Standardized Metrics Can Reveal Region-specific Opportunities in Community Engagement to Aid Recruitment in HIV Prevention Trials Gail Broder (Fred Hutchinson Cancer Research Center, United States)	08:45 - 09:00
OA18.03	Ethical Considerations for Involving Adolescents Aged 16-17 in HIV Prevention Clinical Trials: Community Perspectives from Uganda Rita Nakalega (Makerere University - Johns Hopkins University (MU-JHU) Research Collaboration, Uganda)	09:00 - 09:15
OA18.04	The Luxuriant Future of Microbicides: Planning for Success Marc-André LeBlanc (HIV Prevention Advocate, Canada)	09:15 - 09:30
OA18.05	Planning for PrEP: Facilitating Collaborative Cross-country Learning Neeraja Bhavaraju (FSG, United States)	09:30 - 09:45
OA18.06	Princess PrEP Program: A Successful Key Population-led PrEP Model in Thailand Forming Through Meaningful Participation of Key Populations Nittaya Phanuphak (Thai Red Cross AIDS Research Centre, Thailand)	09:45 - 10:00

Oral
08:30 - 10:00

Marsella, Burdeos & Estrasburgo

OA19 Stay With Me: Retention on PrEP

Chairs:

Alex Carballo-Diéguez (Columbia University, HIV Center for Clinical and Behavioral Studies at New York State Psychiatric Institute and Columbia University, United States)
Ferran Pujol Roca (Projecte dels NOMS-Hispanosida, Spain)

Download Program (PDF)

OA19.01	PrEP Uptake and Retention Among Men and Women Receiving PrEP Integrated in Public Health HIV Care Clinic Settings Kenneth Mugwanya (University of Washington, United States)	08:30 - 08:45
OA19.02	Examining PrEP Interruptions in a Safety-net Primary Care Network: Missed Opportunities to Re-engage PrEP Users Accessing non-PrEP Services Matthew Spinelli (University of California, San Francisco, United States)	08:45 - 09:00
OA19.03	Early Persistence of HIV Pre-exposure Prophylaxis (PrEP) in African Adolescent Girls and Young Women (AGYW) from Kenya and South Africa Elzette Rousseau-Jemwa (Desmond Tutu HIV Foundation, South Africa)	09:00 - 09:15
OA19.04	Intimate Partner Violence and Early PrEP Adherence Among Adolescent Girls and Young Women in Cape Town, South Africa: A Longitudinal Analysis Sarah T. Roberts (RTI International, United States)	09:15 - 09:30
OA19.05	Early Antiretroviral Therapy and Daily Pre-exposure Prophylaxis for HIV Prevention Among Female Sex Workers in Cotonou, Benin: A Demonstration Study Michel Alary (CHU de Québec, Canada)	09:30 - 09:45
OA19.06	Trends in Engagement in the HIV Prevention and the Care Cascade among Young Women who Sell Sex in Zimbabwe Sue Napierala (RTI International, United States)	09:45 - 10:00

Oral
10:30 - 12:00

Londres

OA20 Into the Future With Delivery Technologies

Chairs:

Charles Lacey (University of York, United Kingdom)
Zeda Rosenberg (IPM, United States)

OA20.01	Nanoparticles-in-thermosensitive Enemas as Potential Vehicles for Microbicide Development Mélanie Melo (i3S - Instituto de Investigação e Inovação em Saúde & INEB - Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal, Portugal)	10:30 - 10:45
OA20.02LB	Development of an End-user Informed Tenofovir Alafenamide (TAF) Implant for Long-acting (LA)-HIV Pre-exposure Prophylaxis (PrEP) Ariane van der Straten (RTI International, United States)	10:45 - 11:00
OA20.03	Tenofovir Douche for PrEP: On-demand, Behaviorally-congruent Douche Rapidly Achieves Colon Tissue Concentration Targets (DREAM 01 Study) Ethel Weld (Johns Hopkins University, United States)	11:00 - 11:15
OA20.04	Self-administered Griffithsin and Carrageenan Containing Microbicide Fast-dissolving Insert as Pre-exposure Prophylaxis Against HIV and HPV Infections Thomas Zydney (Population Council, United States)	11:15 - 11:30

Download Program (PDF)

OA20.05	Innovative 3D Printed Intravaginal Rings: Reengineering Multipurpose Intravaginal Rings for Prevention of HIV and Unintended Pregnancy S. Rahima Benhabbour (University of North Carolina, Chapel Hill, United States)	11:30 - 11:45
OA20.06	The Dapivirine and Levonorgestrel MPT Ring: Understanding the Levonorgestrel Binding Reaction with Silicone Elastomer Karl Malcolm (Queen's University Belfast, United Kingdom)	11:45 - 12:00

Oral
10:30 - 12:00

Bristol

OA21 Linking Arms in Defense: Innate, Cellular and Humoral

Chairs:

Francesca Chiodi (Karolinska Institutet, Sweden)
Montserrat Plana (Institut d'Investigacions Biomèdiques August Pi i Sunyer, Spain)

OA21.01	Vaccine-induced Activation of Inflammasome in Classical Monocytes and Th2 Cell Responses Correlates With Decreased Risk of SIV_{mac251} Acquisition Monica Vaccari (NCI, NIH, United States)	10:30 - 10:45
OA21.02	Soluble Immune Activation Biomarkers Predict Accelerated Viral Rebound During Treatment Interruption in Fiebig I-treated Individuals Bonnie M. Slike (US Military HIV Research Program/WRAIR, United States)	10:45 - 11:00
OA21.03	Recombinant MVA Prime Elicits Neutralizing Antibody Responses by Inducing Antigen-specific B Cells in the Germinal Center Sampa Santra (Beth Israel Deaconess Medical Center, Harvard Medical School, United States)	11:00 - 11:15
OA21.04	Targeting HIV gp140 Env to Human Langerhans Cells Drives Tfh Differentiation and Antibody Responses Jérôme Kervevan (Inserm U955 - Institut Mondor de Recherche Biomédicale, UPEC, France)	11:15 - 11:30
OA21.05	Broadly Neutralizing Antibodies in Children Correlate With Increased HIV-specific T-follicular Helper and Regulatory Cells Within Germinal Centers Julia Roeder (Ludwig-Maximilians-University, Germany)	11:30 - 11:45
OA21.06LB	The Impact of Vaccination on SIV Evolution Following Break-through Infection Kathryn Foulds (VRC/NIAID/NIH, United States)	11:45 - 12:00

Oral
10:30 - 12:00

Oxford

OA22 Antibody Virus Tango

Chairs:

Katie Doores (King's College London, United Kingdom)
Feng Gao (Duke University, United States)

Download Program (PDF)

OA22.01	Targeted Viral Selection Is Associated With the Development of HIV Broadly Neutralizing Antibodies Batsirai Mabvakure (Center for HIV and STIs, National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa)	10:30 - 10:45
OA22.02	Next-generation Sequencing Delineates the Developmental Pathway of Fusion Peptide-directed Broadly Neutralizing Antibody N123-VRC34.01 Chen-Hsiang Shen (Vaccine Research Center, NIAID, NIH, United States)	10:45 - 11:00
OA22.03	Early Antibodies Against the Transmitted/Founder HIV-1 Envelope gp120 Are Dominated by the Immunoglobulin Heavy Chain Germline VH1-69 S. Abigail Smith (Emory University, United States)	11:00 - 11:15
OA22.04	“Designer” SHIVs Elicit V2 bNAbs in Rhesus Macaques Ryan S. Roark (University of Pennsylvania, United States)	11:15 - 11:30
OA22.05	eCD4-Ig Is More Difficult to Escape Than Broadly Neutralizing Antibodies Christoph H. Fellingner (The Scripps Research Institute, United States)	11:30 - 11:45
OA22.06	Defining and Characterizing the ‘Escapability’ of Potent Broadly Neutralizing Antibodies Against HIV in Humanized Mice Cailin Deal (The Ragon Institute of MGH, MIT and Harvard, United States)	11:45 - 12:00

Oral
10:30 - 12:00

Marsella, Burdeos & Estrasburgo

OA23 Great Expectations: The Impact of PrEP

Chairs:

Ume Abbas (Baylor College of Medicine, United States)
Hong-Ha M. Truong (University of California, San Francisco, United States)

OA23.01	HIV Incidence in Persons Using Truvada (FTC/TDF) for HIV Pre-exposure Prophylaxis (PrEP): Worldwide Experience From 46 Studies Jared Baeten (University of Washington, United States)	10:30 - 10:45
OA23.02	Sensitive Next-generation Sequencing of HIV-1 From Seroconverters in the MTN-020/ASPIRE Dapivirine Vaginal Ring Study Urvi Parikh (University of Pittsburgh, United States)	10:45 - 11:00
OA23.03	Transgender Women on Estrogen Have Significantly Lower Tenofovir/Emtricitabine Concentrations During Directly Observed Dosing When Compared to Cis Men Craig Hendrix (Johns Hopkins University, United States)	11:00 - 11:15
OA23.04LB	Decreased HIV Incidence Among PrEP Users Compared to Non-users in a Boston Community Health Center, 2012-2017 Kenneth H. Mayer (Fenway Health, United States)	11:15 - 11:30
OA23.05	Mathematical Modeling to Evaluate the Impact and Cost-effectiveness of Oral Pre-exposure Prophylaxis for HIV Prevention in Uganda Katharine Kripke (Avenir Health, Project SOAR, United States)	11:30 - 11:45
OA23.06	Potential Impact of Increased ART and PrEP Coverage on the HIV Epidemic Among MSM in Atlanta: Mathematical Modelling for HPTN 078 Kate M. Mitchell (Imperial College London, United Kingdom)	11:45 - 12:00

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

Meet the Experts Lunch
12:00 - 13:00

Toulouse & Lyon

ME03 Meet the Experts Lunch

Chairs:

John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)
Connie Celum (University of Washington, United States)
Guido Ferrari (Duke University Medical Center, United States)
Genoveffa Franchini (National Cancer Institute, United States)
Michael Gale (University of Washington, United States)
Jessica Haberer (Massachusetts General Hospital/Harvard Medical School, United States)
Diane Havlir (University of California at San Francisco, United States)
Heather Jaspan (University of Cape Town/ Seattle Children's Research Institute, South Africa)
Sudhir Kasturi (Emory University, United States)
Colleen Kelley (Emory University School of Medicine, United States)
Maureen Luba (Centre for the Development of People (CEDEP), Malawi)
John Mascola (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, United States)
Michael Meulbroek (BCN Checkpoint, Spain)
Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)
Wanjiru Mukoma (LVCT Health, Kenya)
Ram Prasad (Final Mile, United States)
Robert H. Remien (NY State Psychiatric Institute and Columbia University, United States)
Bruce Richman (U=U, United States)
Lena Serghides (University Health Network and University of Toronto, Canada)
Monica Vaccari (NCI, NIH, United States)
Ariane van der Straten (RTI International, United States)
Cara Wilson (University of Colorado, United States)

Meet the Experts Lunch

12:00 - 13:00

Symposium
13:00 - 14:30

Londres

SY08 Translating Vaccine Concepts to the Clinic: What We Need to Know

Based on current vaccine concepts, we will do a deep dive into immune mechanisms of protection. Using appropriate animal models, we will evaluate the crosstalk between adaptive and innate immunity, and signatures of protection. Finally, we will examine the role of susceptibility and how to modulate responses.

Chairs:

Nathalie Dereuddre-Bosquet (CEA, France)
Sandhya Vasan (Military HIV Research Program, Henry M. Jackson Foundation, Thailand)

SY08.03	Antibody Interference and Durable Monocyte Innate Memory Decrease SIVmac251 Acquisition Risk Following Immunization with the DNA/ALVAC/gp120 Regimen	13:00 - 13:18
	Genoveffa Franchini (National Cancer Institute, United States)	
SY08.02	Influence of Vaccine Composition on Envelope Recognition by HIV-1 Vaccine-induced Antibody-dependent Cellular-mediated Cytotoxic Responses	13:18 - 13:36
	Guido Ferrari (Duke University Medical Center, United States)	
SY08.01	Insights Into NK Cell Suppressor Activity in Secondary Lymphoid Organs Revealed by Animal Models	13:36 - 13:54
	Michaela Muller-Trutwin (Institut Pasteur, France)	

HIVR4P 2018,
HIV Research for Prevention 2018,
Madrid, Spain,
21 - 25 October 2018

Download Program (PDF)

SY08.04	Protective Gene Expression Signature of the RhCMV/SIV Vaccine: Lessons for Human Studies	13:54 - 14:12
	Michael Gale (University of Washington, United States)	
SY08.05	Modulating Durability of HIV-1 Env Specific Humoral Immunity With 3M-052, a TLR7/8 Targeted Adjuvant	14:12 - 14:30
	Sudhir Kasturi (Emory University, United States)	

Symposium
13:00 - 14:30

Bristol

SY09 Choosing to Use: What People Want from HIV Prevention

HIV prevention products currently in use were introduced after successful clinical trials for efficacy with little consideration of user preference. Results from completed efficacy trials consistently show evidence of low product use among adolescent and young women. This session will explore strategies for adherence support, risk perception, social marketing and end-user engagement strategies during product development.

Chairs:

Sinead Delany-Moretlwe (University of the Witwatersrand, South Africa)
Andrew Mujugira (Infectious Diseases Institute, Uganda)

SY09.01	Defining and Supporting Prevention Adherence	13:00 - 13:22
	Jessica Haberer (Massachusetts General Hospital/Harvard Medical School, United States)	
SY09.02	Risk Perception and End-users' Perspective: Insights From Research of MPTs and HIV Prevention Products	13:22 - 13:44
	Ariane van der Straten (RTI International, United States)	
SY09.03	Creating Demand for HIV Prevention Products, Programs and Services	13:44 - 14:06
	Wanjiru Mukoma (LVCT Health, Kenya)	
SY09.04	Preference and Habits: How Do Users Decide and How Do We Find Out?	14:06 - 14:28
	Ram Prasad (Final Mile, United States)	

Symposium
13:00 - 14:30

Oxford

SY10 Mucosal Environment: Barriers and Facilitators of Transmission

This session will review how mucosal environments influence the likelihood that HIV transmission occurs following viral exposure. This includes a review of mucosal factors such as microbes and host responses that influence sexual transmission, and immunological mechanisms that dictate the integrity of the mucosal barrier and availability of HIV target cells.

Chairs:

William Kilembe (Zambia Emory HIV Research Project, Zambia)
Lyle McKinnon (University of Manitoba, Canada)

SY10.01	Microbiota and HIV Transmission	13:00 - 13:22
	Heather Jaspan (University of Cape Town/ Seattle Children's Research Institute, South Africa)	

Download Program (PDF)

SY10.02	High Prevalence of Bacterial STIs in HIV-positive Persons: Transmission Implications & Potential Interventions Connie Celum (University of Washington, United States)	13:22 - 13:44
SY10.03	The Rectal Mucosa in At-risk Men who Have Sex With Men: HIV Target Cells and the Inflammatory Response to Condomless Receptive Anal Intercourse Colleen Kelley (Emory University School of Medicine, United States)	13:44 - 14:06
SY10.04	How Do Different Components of the Mucosal Microenvironment Interact to Influence HIV Susceptibility? Cara Wilson (University of Colorado, United States)	14:06 - 14:28

Roundtable
13:00 - 14:30

Marsella, Burdeos & Estrasburgo

RT02 Getting to U: Undetectable = Untransmittable

People living with HIV who are durably virally suppressed are not able to transmit sexually. This roundtable will explore the psychological and behavioral components in deciding to start and stay on treatment, evaluate population impact of viral suppression, explore whether U=U holds for breastfeeding, describe what is known about clinical cohorts of persons being treated and their level of viral suppression, and discuss how to get the word out about U=U within communities.

Chairs:

Judith Auerbach (University of California, San Francisco, United States)
Ntando Yola (Desmond Tutu HIV Foundation, South Africa)

RT02.01	Starting and Staying on ARVs Robert H. Remien (NY State Psychiatric Institute and Columbia University, United States)	13:00 - 13:10
RT02.02	What Are the Population Level Studies Teaching Us about U=U? Nelly Mugo (Kenya Medical Research Institute (KEMRI), Kenya)	13:10 - 13:20
RT02.03	What Does U=U Mean for Breastfeeding? Lena Serghides (University Health Network and University of Toronto, Canada)	13:20 - 13:30
RT02.04	How Do You Know You're "U"? John Brooks (Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention, United States)	13:30 - 13:40
RT02.05	U=U: Unpacking the Message and the Movement Bruce Richman (U=U, United States)	13:40 - 13:50
	Panel Discussion	13:50 - 14:30

Download Program (PDF)

Closing Plenary
15:00 - 16:30

Auditorium

PL04 Putting It Together: Strategies to End the Epidemic

Plenary 4 looks ahead to the potential impact of implementing multiple prevention strategies, and challenges researchers and advocates from every community and prevention field to pool our knowledge, share our experiences and move forward together to help end the epidemic.

Chairs:

Jose Alcamí (Instituto de Salud Carlos III, Spain)
Susan Buchbinder (San Francisco Department of Public Health, United States)
Mike Chirenje (University of Zimbabwe, Zimbabwe)
Georgia Tomaras (Duke University, United States)

PL04.01	Multi-disease Approaches to Combination Prevention - Insights from Rural East Africa Diane Havlir (University of California at San Francisco, United States)	15:00 - 15:20
PL04.02	Implementing a Multi-disciplinary Prevention Revolution Maureen Luba (Centre for the Development of People (CEDEP), Malawi)	15:20 - 15:35
PL04.03	The Impact of Prevention Strategies on HIV Incidence in a Community Center Michael Meulbroek (BCN Checkpoint, Spain)	15:35 - 15:50
PL04.04	A Path Forward for HIV Vaccines John Mascola (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, United States)	15:50 - 16:10
	Panel Discussion with Closing Plenary Speakers	16:10 - 16:25
	Closing Remarks and Handover to 2020 Susan Buchbinder (San Francisco Department of Public Health, United States)	16:25 - 16:30